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ABSTRACT 
Blackleg disease, caused by the fungus Leptosphaeria maculans/Phoma lingam, is one 
of the most economically important diseases of canola and rapeseed. Detoxification of 
canola chemical defenses (phytoalexins and others) is an important mechanism used by 
the blackleg fungus to overcome the plant’s natural defenses. Phytoalexins are anti-
microbial defense metabolites produced de novo by plants in response to pathogen 
attack and other forms of stress. L. maculans is successful in detoxifying several 
cruciferous phytoalexins to different products. For example, brassinin, a key 
phytoalexin from crucifers, is transformed to indole-3-carboxaldehyde. This thesis 
includes investigation of phytoalexin metabolism by L. maculans and related work: (i) 
transformation pathways of cruciferous phytoalexins and analogs; (ii) design and 
synthesis of potential inhibitors of brassinin detoxification.  
In continuation of previous work, homologues, analogs and structural relatives of 
brassinin were analysed for metabolism by L. maculans. Products of metabolism of 
these compounds were identified and the overall metabolic pathways were established. 
It was concluded that structural relatives of brassinin metabolized differently from 
brassinin. Antifungal bioassays of the products suggested that all these transformations 
were detoxification reactions. Among the phytoalexins, rapalexin A was not 
metabolized whereas, erucalexin was metabolized. Results of these metabolism studies 
using L. maculans along with the syntheses and antifungal activities of the metabolites 
will be presented.  
In the second part of this thesis, inhibition of the detoxification of brassinin by L. 
maculans using quinolines and isoquinolines was investigated. These compounds 
resulted from replacement of indolyl containing structures with quinoline and 
isoquinoline moieties, and various substitutions such as phenyl, thiazolyl, bromo, 
chloro, hydroxyl and methoxy groups. All these compounds were tested for their effect 
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on brassinin detoxification and antifungal activity. Overall, a significant effect on the 
rate of brassinin detoxification in cultures of L. maculans was detected in the presence 
of compounds 6-bromo-2-phenylquinoline, 2-phenylquinoline, 3-phenylquinoline and 
1-thiazolylisoquinoline. 6-Bromo-2-phenylquinoline was the most effective compound 
in slowing down the metabolism of brassinin and also was a weak inhibitor of the 
growth of L. maculans (virulent on canola). Results of the syntheses and evaluation of 
the compounds are discussed.  
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Chapter 1: Introduction 
 
1.1 General objectives 
Phytoalexins are secondary metabolites synthesized de novo by plants in response to 
external stress such as pathogen invasion. So far, about 44 cruciferous phytoalexins 
have been isolated from Brassicaceae. Pedras and co-workers investigated the 
detoxification of several cruciferous phytoalexins by their pathogens and determined 
the pathways of phytoalexin metabolism (Pedras, Yaya et al., 2011c). My research 
work explores the detoxification of cruciferous phytoalexins by the phytopathogenic 
fungus of canola Leptosphaeria maculans (Desm.) Ces. et de Not., asexual stage 
Phoma lingam (Tode ex Fr) Desm. and the effects of quinoline and isoquinoline 
derivatives on the brassinin detoxification. The specific objectives are to: 
 Determine the products of transformation of the cruciferous phytoalexins 
rapalexin A (22), erucalexin (29) and brussalexin (36) by Leptosphaeria 
maculans (isolates virulent on canola); 
 Determine the products of transformation of synthetic compounds related to 
brassinin (96, 111, 153, 320, 325, 327, 331 and 333) by L. maculans (isolates 
virulent on canola);   
 Determine antifungal activity of the phytoalexins 17, 22, 29, 36 and compounds 
96, 111, 153, 320, 325, 327, 331 and 333 against L. maculans (isolates virulent 
on canola);  
 Design, synthesize and determine the antifungal activity of potential inhibitors 
(350-366) of brassinin detoxification based on quinoline and isoquinoline 
moieties; 
 Determine the effect of compounds 350-366 on the rate of brassinin 
detoxification by L. maculans (isolates virulent on canola). 
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1.2 Cruciferous plants and fungal pathogens 
Blackleg of cruciferous oilseeds and vegetables is an economically important disease 
and is a serious concern in view of the yield losses that are associated with the disease 
(Gugel and Petrie, 1992). Blackleg disease is caused by L. maculans and L. biglobosa. 
L. biglobosa is less virulent on canola than L. maculans, but could be more damaging 
to Brassica juncea (Rimmer, Shattuck et al., 2007). 
Canola is defined by the Canola Council of Canada (http://www.canola-council.org) as 
seeds of Brassica genus (B. napus, B. rapa or B. juncea ) whose oils contain < 2% 
erucic acid and seed meal contains < 30 µmol of aliphatic glucosinolates (any one or 
any mixture of 3-butenyl glucosinolate, 4-pentenyl glucosinolate, 2-hydroxy-3-butenyl 
glucosinolate and 2-hydroxy-4-pentenyl glucosinolate) per gram of the air-dry, oil-free 
solid (http://www.canola-council.org/ind_definition.aspx). Canola is the second largest 
grown crop in Saskatchewan. In 2007, four million tonnes of canola was produced in 
Saskatchewan, which amounted to 45% of Canada’s total production (Source: 
http://www.agriculture.gov.sk.ca/Saskatchewan_Picture). Blackleg disease is a major 
concern in canola growing areas all over the world. However, disease management 
practices such as  the use of disease resistant cultivars, crop rotation, management of 
infested stubble, use of disease-free seeds has proved to be effective (Gugel and Petrie, 
1992; Rimmer, Shattuck et al., 2007).  
Seeds are the major source of spread of blackleg as L. maculans can survive in seeds 
for long time. Hence, disease-free seeds obtained by fungicidal treatment were found 
effective for controlling blackleg disease (Gugel and Petrie, 1992). In Canada, 
carbathin, thiram and iprodione are registered fungicides used in seed treatments (West, 
Kharbanda et al., 2001). Besides, azoxystrobin, fludloxanil, metalaxyl and other 
fungicidal mixtures are recommended for the purpose (Source: www.ag.ndsu.edu). 
Despite the measures taken, statistics from the Canadian plant disease survey of 2010 
showed that blackleg infections were found in 55% of the tested canola fields and that 
the mean incidence of the disease has not decreased in Saskatchewan over last 10 years 
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(Dokken-Bouchard, Anderson et al., 2011). These statistics suggest that better practices 
are required for the control of blackleg disease.         
 
1.3 Secondary metabolites of cruciferous plants and blackleg 
fungi in attack and defense 
 
Interactions among plants and pathogens are complex and involve attack and 
counterattack mechanisms (Hahlbrock, Bednarek et al., 2011). Secondary metabolites 
of fungi and plants play a major role in these interactions (Berger, Sinha et al., 2007). 
In general, fungal invasion of the plant involves production of toxins and other 
metabolites by the pathogen, which damages the plant cells irreversibly. During the 
infection process, some of the plant receptor sites can recognize fungal metabolites 
(elicitors) that induce defense responses such as production of antifungal compounds 
(Pedras, 2011; Berger, Sinha et al., 2007). Besides, both plants and pathogens produce 
enzymes to detoxify the toxic chemicals produced by the opponent. Thus, there exists a 
continuous arms race between plants and fungal pathogens (Pedras, 2011). It is 
important to understand the chemistry and biochemistry involved in these interactions 
to find better ways to protect plants.    
 
1.3.1 Fungal metabolites 
Crucifer pathogens produce structurally diverse metabolites. Some of them are known 
to be host-selective phytotoxins, which cause disease symptoms only on the plants that 
host the fungal species (Pedras and Yu, 2009). The actual role of these phytotoxins/ 
metabolites in fungal defense is not well understood. However, some of the metabolites 
are characteristic of a particular fungal species (Pedras, Chumala et al., 2007a). 
Metabolites produced by various fungal pathogens of crucifer crops were reported for 
Alternaria brassicicola (Pedras, Chumala et al., 2009a), Rhizoctinia solani (Pedras, Yu 
et al., 2005a) and Sclerotinia sclerotiorum (Pedras and Ahiahonu, 2004). Metabolite 
production by L. maculans was extensively studied and has been reviewed (Pedras and 
Yu, 2009; Pedras, 2001). The blackleg disease is caused by two species L. maculans 
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and L. biglobosa.  L. maculans has several sub groups known to produce quite different 
metabolites. Isolates of L. maculans virulent on canola (Pedras and Yu, 2009) and 
mustard (Pedras, Chumala et al., 2004b; Pedras and Yu, 2009) produce several 
metabolites and phytotoxins.  
 
 
Figure 1.1 Selected structures of phytotoxins: sirodesmins 1-5, phomalirazine (6), 
phomalide (7), maculansins 8a and 8b produced by Leptosphaeria maculans (virulent 
on canola) (Pedras and Yu, 2009; Pedras, Chumala et al., 2007a). 
 
Sirodesmin PL (1) and deacetylsirodesmin PL (2) were the first phytotoxins isolated 
from L. maculans (virulent on canola) (Ferezou, Riche et al., 1977). Since then, other 
phytotoxins such as sirodesmin H (3), sirodesmins J (4) and K (5) belonging to this 
family have been isolated from cultures of L. maculans (virulent on canola) grown in 
minimal medium (MM) (Pedras, Seguinswartz et al., 1990). All these sirodesmins, 
which are polythiodioxopiperazines, cause yellow necrotic lesions on leaves of 
different plants, including crucifers (Pedras, Chumala et al., 2007a). Phomalirazine (6) 
was also produced by isolates of L. maculans virulent on canola. Compound 6 caused 
nectrotic lesions on both susceptible and resistant plants (Pedras, Abrams et al., 1989). 
Phomalirazine (6) was a proposed intermediate in the biosynthesis of sirodesmin PL (1) 
(Pedras, Abrams et al., 1989). Phomalide (7) is the first host-selective phytotoxin 
isolated from cultures of L. maculans (virulent on canola) grown in MM (Pedras, 
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Taylor et al., 1993). Compound 7 caused necrotic lesions on canola leaves but not on 
those of brown mustard (Pedras and Yu, 2009; Pedras and Biesenthal, 1998). The 
biosynthesis of phomalide (7) was inhibited in the presence of sirodesmin PL (1) 
(Pedras and Biesenthal, 1998). Maculansin A (8a) was identified as major metabolite 
from cultures of L. maculans (isolates virulent on canola) grown in PDB medium 
(Pedras and Yu, 2008).  Compound 8a caused lesions on both susceptible and resistant 
plants (Pedras and Yu, 2008; Pedras, 2011). The phytotoxins produced by L. maculans 
(isolates virulent on canola) are shown in figure 1.1.  
Depsilardin (9) is a host-selective toxin produced by isolates of L. maculans (virulent 
on mustard). Compound 9 caused nectrotic lesions when sprayed on leaves of brown 
mustard but not canola (Pedras, Chumala et al., 2004b). The total synthesis of 
compound 9 was recently accomplished (Ward and Pardeshi, 2010). Polanrazines B 
(10) and C (11) were identified as phytotoxic among the group of structurally similar 
compounds produced by Polish type isolates of L. maculans (Pedras and Biesenthal, 
2001). Phomalairdenol A (12) and phomalairdenones A (13) and D (14) were also 
isolated from isolates of L. maculans (virulent on mustard) (Figure 1.2) (Pedras, Erosa-
Lopez et al., 1999a). 
 
Figure 1.2 Selected structures of phytotoxins 9-14 produced by Leptosphaeria 
maculans (virulent on mustard) (Pedras and Yu, 2009) . 
 
There is another group of fungal metabolites known as elicitors. Elicitors bind to 
receptor sites in plant tissues and induce production of phytoalexins (Hahn, 1996).  
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Phytoalexins are antimicrobial plant metabolites produced de novo upon exposure to 
biotic and abiotic stresses (Bailey and Mansfield, 1982). A mixture of cerebrosides C 
(15) and D (16) are the only known specific elicitors isolated from L. maculans 
(virulent on canola) (Figure 1.3). In addition, sirodesmin PL (1) and deacetylsirodesmin 
PL (2) were identified as non-specific elicitors (Pedras and Yu, 2009). 
 
Figure 1.3 Elicitors 15 and 16 produced by Leptosphaeria maculans (virulent on 
canola) (Pedras and Yu, 2009) . 
 
1.3.2 Cruciferous plant metabolites 
Phytoalexins (inducible) (Bailey and Mansfield, 1982) and phytoanticipins 
(constitutive) (Vanetten, Mansfield et al., 1994) play important ecological roles in 
defense against pathogens (Hammond-Kosack and Jones, 1996). Phytoanticipins are 
constitutive plant defenses, whose concentrations increase under stress conditions 
(Vanetten, Mansfield et al., 1994). The developments in cruciferous phytoalexin 
research have been reviewed recently (Pedras, Yaya et al., 2011c; Pedras and Yaya, 
2010; Pedras, 2008; Pedras, Zheng et al., 2007e; Pedras and Ahiahonu, 2005; Pedras, 
Jha et al., 2003b; Pedras, Okanga et al., 2000).   
Phytoalexins 
Recently, Pedras et al., published a comprehensive review dealing with cruciferous 
phytoalexins (Pedras, Yaya et al., 2011c). For this reason, only work of immediate 
interest to this thesis will be reviewed here. Phytoalexins are generally found at the site 
of infection at inhibitory concentrations. Localization studies carried out on several 
species infected with the pathogens illustrated that phytoalexins have specific roles in 
defense (Hammerschmidt, 1999).   
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Figure 1.4 Structures of selected cruciferous phytoalexins: brassinin (17), 1-
methoxybrassinin (18), cyclobrassinin (19), 1-methoxycyclobrassinin (20), rutalexin 
(21), rapalexin A (22), rapalexin B (23), caulilexin B (24), wasalexins A (25) and  B 
(26), spirobrassinin (27), 1-methoxyspirobrassinin (28), erucalexin (29), brassilexin 
(30), sinalexin (31), camalexin (32), 6-methoxycamalexin (33), brassicanal A (34), 
brassicanate A (35) and brussalexin (36) (Pedras, Yaya et al., 2011c). 
 
The phytoalexins brassinin (17) and 1-methoxybrassinin (18) were isolated from 
Chinese cabbage by Takasugi and coworkers in 1986 and these compounds were the 
first phytoalexins reported from Brassicaceae (Takasugi, Katsui et al., 1986). Since 
then, 44 cruciferous phytoalexins have been isolated and their structures have been 
elucidated (Pedras, Yaya et al., 2011c). Crucifers belong to the only plant family 
known to date to produce sulfur-containing phytoalexins. Phytoalexins such as 
brassinins 17 and 18 contain a dithiocarbamate group. The dithiocarbamate group was 
present in several fungicides used in 20
th
 century (Atkinson, 1970). Wasalexins 25, 26 
and camalexins 32 and 33 were isolated from wild crucifers (Pedras, Yaya et al., 
2011c). Selected structures of cruciferous phytoalexins 17-36 are shown in figure 1.4. 
Cruciferous phytoalexins are also known to exhibit broad spectrum of antifungal 
activities against several pathogens (Pedras, Yaya et al., 2011c). The phytoalexin 
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brassinin (17) is a strong inhibitor of the growth of L. maculans, S. sclerotiorum and B. 
cinerea. Brassinins 17 and 18 are considered crucial metabolites among the cruciferous 
phytoalexins, because they are precursors of several other phytoalexins. Scheme 1.1 
summarizes the biosynthetic relationships among the various cruciferous phytoalexins 
(Pedras, Yaya et al., 2011c). 
 
 
Scheme 1.1 Biosynthetic relationship among brassinins 17 and 18, and other 
phytoalexins cyclobrassinin (19), 1-methoxycyclobrassinin (20), rutalexin (21), 
spirobrassinin (27), erucalexin (29), brassilexin (30), brassicanal A (34), brassicanate A 
(35) (Pedras, Yaya et al., 2011c). 
 
Phytoanticipins  
Phytoanticipins are constitutive plant metabolites whose concentrations increase after 
the stress conditions are applied (Vanetten, Mansfield et al., 1994). The distinction 
between phytoalexins and phytoanticipins is sometimes ambiguous, as the same 
compound can be a phytoanticipin in one species and be inducible (phytoalexin) in 
others. For example, arvelexin (39) was isolated from the wild crucifer Thlapsi arvense 
as a phytoalexin (Pedras, Chumala et al., 2003a), while compound 39 was isolated as 
phytoanticipin from canola treated with Plasmodiophora brassicae (Pedras, Zheng et 
al., 2008b). Methyl 1-methoxyindole-3-carboxylate (41) was first isolated as a 
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phytoalexin from wasabi (Pedras, Sorensen et al., 1999b), whereas the same compound 
was isolated as a phytoanticipin in Arabidopsis  thaliana (Pedras and Adio, 2008). 
Compounds 38-40 and 42 are phytoanticipins detected in A. thaliana (Pedras and Adio, 
2008). Phytoanticipins 43 and 44 were isolated from oilseed canola infected with P. 
brassicae (Pedras, Zheng et al., 2008b). Besides, ascorbigen (45), neoascorbigen (46), 
dihydroascorbigens 47, 48 and indole glucosinolates 49-51 were the other 
phytoanticipins isolated (Figure 1.5) (Pedras and Adio, 2008). 
 
Figure 1.5 Structures of phytoanticipins: indole-3-acetonitriles 37-39, compounds 40-
44, ascorbigens 45-48 and glucobrassicins 49-51, produced by cultivated crucifers  
(Pedras, Zheng et al., 2008b) and wild crucifers (Pedras and Adio, 2008). 
 
Several phytoanticipins of Brassicaceae are indole glucosinolates 49-51 and their 
degradation products 37-39. Glucosinolates are derived from aminoacids and are 
produced by several plant families. Grouping of 120 cruciferous glucosinolates into 10 
(A-J) groups by Fahey and co-workers (Fahey, Zalcmann et al., 2002) was recently 
revised by Clarke. Clarke compiled a list of 200 glucosinolates into 13 (A-M) groups 
(Clarke, 2010).  
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1.4 Biotransformation of cruciferous phytoalexins and related 
structures by phytopathogenic fungi 
Fungal pathogens produce detoxifying enzymes, which metabolize plant defense 
compounds such as phytoalexins to less toxic products (Pedras, Yaya et al., 2011c; 
Pedras and Yaya, 2010; Pedras, 2008; Pedras and Ahiahonu, 2005). The metabolism of 
crucifer phytoalexins by several pathogens such as L. maculans, L. biglobosa, A. 
brassicicola, S. sclerotiorum and R. solani were reviewed (Pedras, Yaya et al., 2011c; 
Pedras, 2008; Pedras and Ahiahonu, 2005; Pedras, Okanga et al., 2000). However, the 
metabolism of the compounds related to phytoalexins has not been covered in these 
reviews. Thus, the synthesis and metabolism of compounds related to brassinin (17), 
brassilexin (30) and camalexin (32) by pathogens such as L. maculans (virulent on 
canola), L. biglobosa, A. brassicicola, S. sclerotiorum and R. solani will be reviewed in 
this section. 
 
1.4.1 Syntheses of phytoalexin-related structures 
In this section, general routes used in the synthesis of analogs and related structures of 
brassinin (17), brassilexin (30) and camalexin (32) will be discussed. Compounds 
related to brassinin (17) with changes in the aryl moiety and functional group were 
prepared to test as inhibitors of brassinin detoxification (Pedras and Jha 2006). Similar 
to brassinin, their syntheses were initiated with oximation of aldehydes of general 
structure 52 in presence of NH2OH.HCl to yield oximes of general structure 53, which 
were reduced to the corresponding amines of general structure 54. Treatment of these 
amines 54 with different reagents (iii-vi) as shown in scheme 1.2 afforded the 
compounds of general structure 55, which included dithiocarbamates, ureas, thioureas 
and carbamates (Pedras and Jha, 2006).  
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Scheme 1.2 Synthesis of brassinin analogs of general structure 55. Reagents and 
conditions: (i) NH2OH.HCl, Na2CO3, EtOH; (ii) NiCl2.6H2O, NaBH4, MeOH; (iii) CS2, 
Pyr, Et3N, alkyliodide; (iv) Et3N, alkyl/aryl isocyanate; (v) Et3N, alkyl/aryl 
isothiocyanate; (vi) Et3N, alkylchloroformate (Pedras and Jha, 2006). 
 
 
A general procedure by Ayer and co-workers (Ayer, Craw et al., 1992) was used to 
synthesize substituted camalexins of general structure 57. Solutions of 2-bromothiazole 
in benzene were added to indoles of general structure 56 and MeMgI, and refluxed to 
afford camalexins 57 (Pedras and Ahiahonu, 2002; Pedras and Liu, 2004). Similarly, 
Fischer indole synthesis was used to synthesize the substituted 3-phenylindoles of 
general structure 61 (Scheme 1.3) (Robinson, 1963). Substituted phenyl hydrazines of 
general structure 58 and phenyl acetaldehydes of general structure 59 were heated to 
give the hydrazine intermediates of general structure 60, which were heated  in EtOH 
in presence of ZnCl2 to afford the substituted 3-phenylindoles 61 (Pedras and Hossain, 
2007).    
 
 
Scheme 1.3 Synthesis of camalexin analogs of general structure 57 and 61. Reagents 
and conditions: (i) MeMgI, Et2O; (ii) 2-bromothiazole, benzene (Ayer and Craw et al., 
1992; Pedras and Ahiahonu, 2002; Pedras and Liu, 2004); (iii) heat; (iv) ZnCl2, EtOH, 
heat (Pedras and Hossain, 2007). 
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Some of the analogs of brassilexin (30) reported in the literature have various 
substituents on the indole ring. Synthesis of brassilexins of general structure 64 was 
carried out using an optimized procedure (Pedras and Jha, 2005). Indoline-2-thiones of 
general structure 63 obtained from thionation of various substituted oxindoles of 
general structure 62 were subjected to Vilsmeier formylation followed by aqueous 
ammonia work-up to afford the substituted brassilexins 64. Other brassilexin related 
compounds of general structure 67 with isothiazolyl moieties in their structure were 
synthesized according to the general procedure (Pedras and Suchy, 2006) (Scheme 1.4). 
Aryl acetic acids of general structure 65 were converted to substituted aryl 
acrylaldehydes of general structure 66, which in presence of NH4SCN were cyclized to 
isothiazoles 67. 
 
 
Scheme 1.4 Synthesis of brassilexin analogs of general structure 64 and 67. Reagents 
and conditions: (i) P4S10, NaHCO3, THF; (ii) POCl3, DMF, NH4OH; (iii) I2, Pyr,  
(Pedras and Jha, 2005); (iv) POCl3, DMF; (v) NaOH, EtOH/H2O; (vi) SOCl2, DCM; 
(vii) NH4SCN, DMF, (Pedras and Suchy, 2006). 
 
 
1.4.2 Biotransformations in fungal cultures  
Detoxification is a general strategy used by organisms to convert toxic compounds to 
less toxic products. Detoxification processes involve chemical modifications or 
degradation of the compound.  In general, the first step in the metabolism is the 
detoxification process. The range of transformations of phytoalexins by crucifer 
pathogens is very broad as shown in several reviews (Pedras, Yaya et al., 2011c; 
Pedras, 2008; Pedras and Ahiahonu, 2005; Pedras, Okanga et al., 2000). Besides 
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phytoalexins, several related compounds have been probed for metabolism by crucifer 
pathogens. In this section, first the transformations of compounds closely related to 
brassinin (17) are reviewed. Then, examples highlighting the metabolic transformations 
carried out by fungal pathogens of crucifers are illustrated using analogs of brassilexin 
(30) and camalexin (32). 
Brassinin (17) is antifungal against L. maculans, B. cinerea and S. sclerotiorum, and 
more importantly, compound 17 is a biosynthetic precursor of other phytoalexins 
(Scheme 1.1) (Pedras, Yaya et al., 2011c). Thus, brassinin (17) is considered as an 
important compound among crucifer defenses. Metabolism of brassinin (17) has been 
extensively studied in crucifer pathogens and these studies led to the isolation of four 
brassinin detoxifying enzymes BOLm (Pedras, Minic et al., 2008a), BHLmL2 (Pedras, 
Minic et al., 2009b), BHAb (Pedras, Minic et al., 2009c) and SsBGT1 (recombinant) 
(Sexton, Minic et al., 2009). In fact, the metabolism of compound 17 to indole-3-
carboxaldehyde (74) by L. maculans was the first detoxification of phytoalexins 
identified in cruciferous pathogenic fungi (Pedras and Taylor, 1991). Later, several 
analogs of compound 17 have been probed for the metabolism by L. maculans. These 
compounds were designed by modifying the structure of brassinin (17): i) replacement 
of the indolyl ring in structure 17 with other aromatic moieties; ii) isosteric replacement 
of the hetero atoms in dithiocarbamate side chain (-N-C(S)-SMe) in the structure 17 to 
incorporate thiourea, carbamate, carbonate, ester and thiocarbamate analogs (Pedras 
and Jha, 2006). Based on these results, structural features required for metabolism of 
brassinin-related compounds by L. maculans were highlighted (Pedras, Jha et al., 
2007c). For brassinin-like structures to be metabolized through oxidative degradation 
by L. maculans, the compounds were required to have at least a methylene bridge 
separating the aromatic moiety and the dithiocarbamate side chain. Compounds 68-73 
were metabolized in a similar manner to compound 17 (Scheme 1.5). However, 
brassinin (17) was metabolized differently by L. maculans (virulent on mustard) 
(Pedras, Gadagi et al., 2007b). 
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Scheme 1.5 Biotransformation of brassinin (17) and analogs 68-73 by (i) 
Leptosphaeria maculans (virulent on canola) (Pedras and Jha, 2006; Pedras, Jha et al., 
2007c); (ii) Leptosphaeria maculans (virulent on mustard) (Pedras, Gadagi et al., 
2007b; Pedras, Minic et al., 2009b). 
 
Isolates of L. biglobosa and L. maculans (virulent on mustard) metabolized brassinin 
(17) to 3-indolylmethanamine (76) followed by Nb-acetyl-3-indolylmethanamine (77)  
(Pedras, Gadagi et al., 2007b). Similar to brassinin (17), compounds 68-73 were 
metabolized giving the respective acetylated amines 77 or 78 (Scheme 1.5) (Pedras, 
Gadagi et al., 2007b; Pedras, Minic et al., 2009c). 
 Compounds 79-84 were metabolized to the corresponding acids 85-89 in cultures of L. 
maculans (Scheme 1.6) (Pedras and Jha, 2006; Pedras, Khan et al., 1997). The 
corresponding aldehydes were not detected in fungal cultures, unlike with the 
metabolism of compound 17 (Pedras and Jha, 2006; Pedras, Khan et al., 1997).  
 
However, transformations of the non-indolyl dithiocarbamates such as compounds 79, 
81 and compound 17 were found to be similar in L. maculans (virulent on mustard). 
Compounds 79 and 81 were metabolized to respective products of dithiocarbamate 
hydrolysis followed by acetylation to yield the final products 90 and 91 (Scheme 1.6) 
(Pedras, Khan et al., 1997).  
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Scheme 1.6  Biotransformation of dithiocarbamate analogs 79-84 by (i) Leptosphaeria 
maculans (virulent on canola) (Pedras and Jha, 2006; Pedras, Khan et al., 1997); (ii) 
Leptosphaeria biglobosa (Pedras, Khan et al., 1997). 
 
Both virulent and avirulent isolates of L. maculans metabolized compound 92 in 
identical manner. Compounds 93 and 94 were also hydrolyzed to indolyl-3-propanoic 
acid (95) in cultures of L. maculans (virulent on canola) (Scheme 1.7).  
 
Scheme 1.7 Biotransformation of brassinin analogs 92-94 by (i) Leptosphaeria 
maculans (virulent on canola) (Pedras and Jha, 2006; Pedras, Jha et al., 2007c); (ii) 
Leptosphaeria maculans (virulent on mustard) (Pedras, Gadagi et al., 2007b). 
 
 
Metabolic detoxification of brassinin (17) in S. sclerotiorum was first reported in 2004 
(Pedras, Ahiahonu et al., 2004a). Brassinin (17) and its analog 96 were metabolized 
similarly to products 97 and 98, adding glycosyl moiety at N-1 in both the compounds 
(Scheme 1.8) (Pedras, Ahiahonu et al., 2004a). S. sclerotiorum carried out the 
glycosylation of S-methyl 1-methyltryptamine dithiocarbamate (99) at C-7 of indole, 
since position C-1 of indole was protected with a –CH3 group. Compound 101 was the 
final product of the transformation of 99 by S. sclerotiorum (Ahiahonu, Ph. D. Thesis, 
2004). Similar transformation of compound 100 to compound 102 was observed in 
cultures of S. sclerotiorum incubated with 100, which has the N atom replaced by S at 
position 1 of indole (Pedras and Hossain, 2007). When S in compound 100 at position 
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1 was replaced by O, the resultant compound 103 was resistant to degradation by S. 
sclerotiorum (Scheme 1.9) (Pedras and Hossain, 2007).  
 
Metabolism of compound 84 in S. sclerotiorum yielded compound 104 as a result of 
glycosylation at position 5 of the naphthyl ring (Scheme 1.10) (Pedras, Ahiahonu et al., 
2004a). Examples in schemes 1.9 through 1.11 suggest that glycosylation of 
phytoalexins or analogs is the main transformation carried out by S. sclerotiorum for 
detoxification.   
 
Scheme 1.8 Metabolism of brassinin (17) and analog 96 by Sclerotinia sclerotiorum 
(Pedras, Ahiahonu et al., 2004a). 
 
 
Scheme 1.9 Metabolism of compounds 99 and 100 by Sclerotinia sclerotiorum (Pedras 
and Hossain, 2007). 
 
 
Scheme 1.10 Detoxification of methyl 2-naphthylmethyl dithiocarbamate (84) by 
Sclerotinia sclerotiorum (Pedras, Ahiahonu et al., 2004a). 
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Scheme 1.11 Metabolism of spirobrassinins 27, 28 and 105 by Sclerotinia sclerotiorum 
(Pedras and Hossain, 2006). 
 
No glycosylation was observed in detoxifications of spirobrassinin (27) and analogs 1-
methoxyspirobrassinin (28) and 1-methylspirobrassinin (105), compounds with lower 
inhibition effect against S. sclerotiorum (Scheme 1.11) (Pedras and Hossain, 2006). 
Spirobrassinins 27 and 28 were metabolized to corresponding spirothiazolidinones 106 
and 107 by S. sclerotiorum. Besides, a minor metabolite 108 was detected from 
metabolism of compound 28 by S. sclerotiorum (Pedras and Hossain, 2006). On the 
other hand, compound 105 was first metabolized to its demethylated product 27 
through the intermediate 109, which underwent loss of the hydroxymethyl group at N-1 
to give compound 27. In addition metabolite 110 was also detected from metabolism of 
compound 105 by S. sclerotiorum (Pedras and Hossain, 2006).  S. sclerotiorum carried 
out both glycosylation and non-glycosylation modes of transformation in the case of a 
compound 111, wherein the compound was hydroxylated at C-3 and glycosylated at N-
1 to yield compound 112 (Scheme 1.12) (Pedras and Hossain, 2007).  
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Scheme 1.12 Metabolism of isobrassinin (111) by Sclerotinia sclerotiorum (Pedras and 
Hossain, 2007). 
 
The metabolism of camalexin (32) by several cruciferous fungi was investigated. 
Compound 32 was found to be metabolized by R. solani (Pedras and Khan, 1997), S. 
sclerotiorum (Pedras and Ahiahonu, 2002) and B. cinerea (Pedras, Hossain et al., 
2011a). In addition, analogs of camalexin were screened for metabolism by S. 
sclerotiorum (Pedras and Ahiahonu, 2002) and R. solani (Pedras and Liu, 2004). These 
compounds were derivatives of camalexin (32) in which the indolyl hydrogens were 
replaced with atoms such as F, Me, OMe etc., or the thiazolyl ring was replaced with a 
phenyl ring (Pedras and Ahiahonu, 2002; Pedras and Liu, 2004; Pedras and Hossain, 
2007). Camalexin (32) was metabolized by S. sclerotiorum to 6-oxy-(O-β-
glucopyranosyl)camalexin (116) via 6-hydroxycamalexin (115) (Pedras and Ahiahonu, 
2002). If C-6 of camalexin was blocked with OMe group, as in compound 33, S. 
sclerotiorum metabolized compound 33 in the same manner to compound 32 via an 
oxidative demethylated intermediate 6-hydroxycamalexin (115). In addition, compound 
33 was transformed to a minor metabolite 117 (Pedras and Ahiahonu, 2002).   
However, if C-6 of camalexin was blocked with F, the compound 113 was metabolized 
to N-glucosylated product 118 by S. sclerotiorum (Pedras and Ahiahonu, 2002). On the 
other hand, if C-6 and N-1 of camalexin analogs were blocked, as in compound 114, 
the fungus glycosylated the compound 114 at C-7 (Scheme 1.13). Compound 114 was 
transformed to metabolite 119 by S. sclerotiorum.  In addition, compound 114 was also 
converted to compound 120 by S. sclerotiorum (Pedras and Ahiahonu, 2002). In 
general, O-glycosidation and N-glycosidation, but not C-glycosidation was observed 
among the detoxification reactions by S. sclerotiorum. In compounds where there are 
no NH/OH functionalities available for glycosylation, oxidation preceded the 
glycosylation.  
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Scheme 1.13 Pathways of metabolism of camalexin (32) and analogs 33, 113 and 114 
by Sclerotinia sclerotiorum (Pedras and Ahiahonu, 2002). 
 
 
3-Phenylindole (121) was metabolized to the N-glycosylated compound 125  whereas, 
the analogs 122 and 123 were not metabolized by S. sclerotiorum (Pedras and Hossain, 
2007).  In addition, 3-phenylbenzofuran (124) in contrast to 3-phenylindole (121) was 
not metabolized by S. sclerotiorum (Scheme 1.14) (Pedras and Hossain, 2007). 
 
Scheme 1.14 Transformation of 3-phenylindole (121) and other compounds 122-124 
by Sclerotinia sclerotiorum (Pedras and Hossain, 2007). 
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Camalexin analogs were metabolized by R. solani through various pathways (Pedras 
and Khan, 1997, 2000; Pedras and Liu, 2004). Oxidation of the indole ring is the 
predominant step in metabolism of compounds 32 and 126. Camalexin (32) was 
metabolized to compound 129 through hydroxylation of C-5 (Pedras and Khan, 2000) 
whereas, compound 126, with a Me group at position C-5 was metabolized to the 
hydroxymethyl compound 132. Compound 129 was further metabolized to compounds 
130 and 131 (Pedras and Liu, 2004). Compound 126 was metabolized by R. solani to 
the products 133 and 134 (Pedras and Liu, 2004). Compound 127 was metabolized to 
products 135-137 (Pedras and Liu, 2004) whereas, compound 128 was metabolized to 
products 138-140 (Pedras and Liu, 2004). Nitriles 135 and 138 were found to be the 
major metabolites in these transformations of compounds 127 and 128 by R. solani 
(Scheme 1.15). These examples demonstrated that C-5 of the indole ring is the 
preferred site of transformation by R. solani. However, the site of transformation was 
switched to the thiazole ring if C-5 was blocked by F (Pedras and Liu, 2004). 
 
Scheme 1.15 Metabolism of camalexin (32) and analogs 126-128 by Rhizoctinia solani 
(Pedras and Khan, 2000; Pedras and Liu, 2004). 
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Brassilexin (30) was transformed by isolates of L. maculans virulent on canola (Pedras 
and Suchy, 2005) and mustard (Pedras and Snitynsky, 2010), and by S. sclerotiorum 
(Pedras and Hossain, 2006). The isothiazolyl ring was found to be the preferred site for 
transformation of brassilexin and its analogs by L. maculans (virulent on canola). 
Compound 30 was metabolized to 3-aminomethylene-indoline-2-thione (143)   by L. 
maculans (virulent on canola) (Pedras and Suchy, 2005). Similarly, brassilexin 
derivatives 141 and 142 were metabolized to products 144 and 145 respectively. 
However, analog 146 and others 147-149, in which the isothiazole ring system was 
fused with quinoline, phenyl or benzothiophene moieties were not metabolized by L. 
maculans (virulent on canola) (Scheme 1.16) (Pedras and Suchy, 2006).  
 
Scheme 1.16 Metabolism of brassilexin (30) and other compounds 141, 142 and 146-
149 by Leptosphaeria maculans (virulent on canola) (Pedras and Suchy, 2006). 
 
Brassilexin (30) was metabolized to compound 150 by S. sclerotiorum through 
glycosylation at N-1, whereas compound 141 was first oxidized at the N-Me group and 
then glycosylated to product 151 (Scheme 1.17) (Pedras and Hossain, 2006). Many 
phytoalexin analogs and related compounds were resistant to metabolism by 
cruciferous fungi (Appendix).  
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Scheme 1.17 Metabolism of brassilexin (30) and analog 141 by Sclerotinia 
sclerotiorum (Pedras and Hossain, 2006). 
 
1.4.3  Enzymes and inhibitors of brassinin transformation by 
Leptosphaeria maculans   
 
Four enzymes involved the detoxification of phytoalexin brassinin (17) were isolated 
from four fungal species (Pedras, Minic et al., 2008a; Pedras, Minic et al., 2009b; 
Sexton, Minic et al., 2009). Brassinin oxidase (BOLm) was the first cruciferous 
phytoalexin detoxifying enzyme isolated from L. maculans (virulent on canola) 
(Pedras, Minic et al., 2008a). BOLm has a molecular mass of 57 kDa and was found to 
be glycosylated up to 20% (Pedras, Minic et al., 2008a). BOLm catalyzed the 
transformation of brassinin (17) to indole-3-carboxaldehyde (74) through a potential 
intermediate 152. Several analogs of brassinin were used to probe for substrate 
specificity of BOLm (Pedras, Jha et al., 2007c). Only compounds 17 and 68-73 acted as 
the substrates of BOLm (Scheme 1.18). Based on these results, structural features 
essential for metabolism by BOLm were indicated (Pedras, Jha et al., 2007c). Key 
structural features identified for metabolism among the substrates were: the presence of 
methylene group bridging the 3-indolyl moiety with the side chain functional group 
containing the atoms X=O/S and Y=N/O/S; or presence of a free NH as part of the side 
chain functional groups such as carbonate, mono/dithiocarbamates; small alkyl groups 
such as methyl and ethyl (R=Me, Et) as part of the side chain (Pedras, Jha et al., 
2007c). 
 
Brassinin hydrolases BHLmL2 and BHAb were isolated from L. maculans (virulent on 
mustard) (Pedras, Minic et al., 2009b) and A. brassicicola (Pedras, Minic et al., 2009b), 
respectively. Both the enzymes transformed brassinin (17) to indolyl-3-methanamine 
(76). BHLmL2 was a tetrameric protein with a mass of 220 kDa, while BHAb was a 
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dimeric protein with a mass of 120 kDa. Both BHLmL2 and BHAb belonged to the 
family of amidases (Pedras, Minic et al., 2009b). Several analogs of brassinin were 
tested as probes for specificity and it was found that both BHs show high degree of 
substrate specificity. Only compounds 73, 96 and 153 were metabolized by BHs in 
vitro (Scheme 1.19) (Pedras, Minic et al., 2009b).   
 
Scheme 1.18 Transformation of brassinin (17) and compounds 68-73 by brassinin 
oxidase (BOLm) from Leptosphaeria maculans (virulent on canola) (Pedras, Jha et al., 
2007c). 
 
 
Scheme 1.19 Transformation of brassinin (17) and compounds 73, 96 and 153 by 
brassinin hydrolases from Leptosphaeria maculans (virulent on mustard) and 
Alternaria brassicicola (Pedras, Minic et al., 2009b). 
 
Another enzyme involved in the detoxification of brassinin (17) by S. sclerotiorum 
SsBGT1 was expressed in Saccharomyces cerevisiae and purified (Sexton, Minic et al., 
2009). SsBGT1 converted brassinin (17) to 1-β-D-glucopyranosylbrassinin (97) 
(Scheme 1.20). Two phytoalexins cyclobrassinin (19) and 6-methoxycamalexin (33), 
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and 3-phenylindole (121) were substrates of SsBGT1, but to a less extent relative to 
brassinin (17) (Sexton, Minic et al., 2009). 
 
Scheme 1.20 Transformation of brassinin (17) by SsBGT1 cloned and expressed in 
Saccharomyces cerevisiae (Sexton, Minic et al., 2009). 
 
L. maculans can effectively metabolize some cruciferous phytoalexins. As a result, 
infected plants are depleted of their chemical defenses and consequently, become more 
succeptible to the pathogens (Pedras, Yaya et al., 2011c; Pedras, 2008). On the 
contrary, if phytoalexins are resistant to fungal metabolism, they can protect plants 
from fungal attacks. In this context, brassinin (17) is of great importance because it is 
antifungal against L. maculans and is a precursor of other phytoalexins (Scheme 1.1). 
However, compound 17 is rapidly metabolized by L. maculans and other pathogens 
(Appendix) through enzymatic transformations. Considering the advantages of the 
presence of brassinin (17) in infected plants, it was proposed that BOLm would be a 
reasonable metabolic target to control L. maculans (Pedras, 2011). Inhibition of crucial 
phytoalexin detoxification pathways in the crucifer pathogens may be an attractive 
strategy to control fungal diseases (Pedras, Jha et al., 2003). Pedras and co-workers 
introduced a concept of phytoalexin detoxification inhibitors (PALDOXINS) for 
disease control of specific fungal pathogens (Pedras, Jha et al., 2003). Paldoxins are 
desired to have low antifungal and cytotoxic activities to minimize their effects on 
cultivated ecosystems (Pedras, Minic et al., 2009c). Most importantly, paldoxins could 
enable plants to improve their own defense against pathogens.  
 
Early work was directed towards the design and synthesis of substrate analog 
inhibitors. Isosteric replacement of the atoms N, C, S of the dithiocarbamate of 
   
25 
 
brassinin (17), and replacement of the indolyl moiety with phenyl and naphthyl 
moieties provided access to a library of about 80 compounds (Pedras and Jha, 2006). 
However, some of those compounds (Appendix) were metabolized when tested in 
fungal cultures of L. maculans and with purified BO (Scheme 1.19). Compounds which 
resisted the metabolism were co-incubated with brassinin (17) in fungal cultures of 
which compounds 153 and 157-159 showed effect on the rates of brassinin 
detoxification in fungal cultures (Figure 1.6) (Pedras and Jha, 2006). 
 
Figure 1.6 Structures of compounds 153, and 157-159 that decreased the rate of 
brassinin transformation by Leptosphaeria maculans (virulent on canola) (Pedras and 
Jha, 2006). 
 
 
After isolation of BOLm systematic enzymatic in vitro screening and evaluation of the 
inhibitors was carried out (Pedras, Jha et al., 2007c; Pedras, Minic et al., 2008a). 
However, none of the compounds designed based on the structure of brassinin (17) 
showed inhibition of BOLm activity (Pedras, Jha et al., 2007c). Early lead compounds 
of BOLm inhibitors were identified from a library of phytoalexins and synthetic 
compounds (Pedras, Jha et al., 2007c; Pedras, Minic et al., 2008a). Among the 
phytoalexins, cyclobrassinin (19, 37% at 0.30 mM), wasalexins (25 and 26, 14% at 
0.30 mM), spirobrassinin (27, 34% at 0.30 mM), brassilexin (30, 16% at 0.30 mM) and 
camalexin (32, 53% at 0.30 mM) were identified as inhibitors of BOLm (Pedras, Jha et 
al., 2007c; Pedras, Minic et al., 2008a). Among the synthetic compounds, isobrassinin 
(111, 23% at 0.30 mM) and thiabendazole (160, 25% at 0.30 mM), a commercial 
fungicide, were also identified as inhibitors of BOLm (Figure 1.7) (Pedras, Minic et al., 
2008a). 
   
26 
 
 
Figure 1.7 BOLm inhibitors: Phytoalexins 19, 25-27, 30, 32 and synthetic compounds 
111 and 160 (Pedras, Jha et al., 2007c; Pedras, Minic et al., 2008a). 
 
Optimization studies of lead compounds 25, 26, 30 and 32 afforded better inhibitors of 
BOLm (Pedras, Minic et al., 2009c; Pedras, Minic et al., 2010a). Among the 
derivatives of brassilexin (30), 6-chlorobrassilexin (162, 93% at 0.30 mM) was 
discovered as the best inhibitor of BOLm to date (Pedras, Minic et al., 2010a). Other 
compounds from the series 161-166 showed significant inhibition. In general, 6-
substituted brassilexins 162, 164 and 166 were more inhibitory than their 5-substituted 
counterparts 161, 163 and 165 (Pedras, Minic et al., 2010a). 5-Methoxycamalexin (167, 
72% at 0.30 mM) was identified as the most active inhibitor of BOLm based on the 
structure of camalexin (32) (Pedras, Minic et al., 2009c). In general, 5-substituted 
camalexins 128 and 167 inhibited BOLm to a larger extent than their 6-substituted 
counterparts 33 and 113 (Pedras, Minic et al., 2009c). However, analogs of wasalexins, 
e.g. compound 172, were no better than compounds 25 and 26 (Pedras, Minic et al., 
2010a). Among the other compounds, 6-fluoro-3-phenylindole (123) and 
naphthylisothiazoles 168 and 170  were identified as inhibitors of BOLm (Figure 1.8) 
(Pedras, Minic et al., 2009c). All the compounds that were screened for inhibition of 
BOLm along with their antifungal activities against L. maculans are summarized in the 
appendix section (Appendix A1D). 
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Figure 1.8 Phytoalexins 25, 26, 30-33 and related compounds 113, 121, 123, 128 and 
161-172 tested as inhibitors of BOLm (Pedras, Minic et al., 2009d; Pedras, Minic et al., 
2010a). 
 
Since BOLm activity was detected in leaves of blackleg-infected canola (Pedras, Minic 
et al., 2008a), it is expected that application of paldoxin-like compounds on the infected 
plants would control the infection of  L. maculans. However, the utility of such 
compounds in the control of L. maculans is yet to be demonstrated.  
 
The enzymatic targets of paldoxins are associated with secondary metabolic processes 
of fungal pathogens such as phytoalexin detoxification. By contrast, the traditional 
compounds used in crop protection (fungicides) target enzymes involved in fungal 
primary metabolism. In the following section, fungal enzyme inhibitors that are 
important in the control of fungal diseases fungicides, will be covered.         
 
     
1.5   Crop protectants against pathogenic fungi 
 
The first chemical used as plant protectant was copper sulfate. In 1807, Prevost used 
copper sulfate solutions to control the bunt of wheat crop (Russell, 2005; Klittich, 
2008). Later in 1885, the Bordeaux mixture, a mixture of copper sulfate and lime, was 
invented as first foliar fungicide to treat downy mildew on grapevines and others 
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(McCallan, 1939; Russell, 2005; Klittich, 2008). In the 1930s, dithiocarbamates came 
into light as broad spectrum fungicides and they were effective in the treatments of 
blight and leaf spot diseases of vegetables and fruits (Houeto, Bindoula et al., 1995; 
Russell, 2005). Examples of dithiocarbamate fungicides include thiram (173), maneb 
(174), zineb (175) and mancozeb (176) (Gullino, Tinivella et al., 2010).  Mancozeb 
(176), a 1:10 mixture of compounds 174 and 175 was developed in 1961 and is still a 
widely used fungicide (Russell, 2005; Gullino, Tinivella et al., 2010). Discovery of the 
systemic fungicide carboxin (177) for cereal seed treatments and later, benomyl (178) 
as broad spectrum foliar fungicides (Figure 1.9) opened a new era in the chemical 
control of fungal diseases in the 1970s (Russell, 2005). Research from many 
agrochemical industries like Bayer, Syngenta and Dupont led to significant 
advancements and now there are several commercial fungicides available as plant 
protectants (Russell, 2005; Klittich, 2008). Further studies on the mode of action of 
fungicides and the development of resistance against these compounds in various 
organisms effectively accelerated research in this area. Currently, a team of experts 
from FRAC (Fungicide Resistance Action Committee) guides and monitors all the 
commercial fungicidal crop protectants (Source: www.frac.info). 
      
 
Figure 1.9 Selected early fungicides used in the treatment of fungal diseases 
dithiocarbamates 173-176, carboxin (177) and benomyl (178) (Russell, 2005; Klittich, 
2008; Gullino, Tinivella et al., 2010). 
 
 
Some of the modern fungicides are inhibitors of metabolic processes occurring in 
fungi, including those involved in production of energy (e.g. fungal respiration) and 
biosynthesis of key metabolites (ergosterol, nucleic acids, methionine, melanin etc.) 
(Sisler, 1969; Leroux, 2003; Yamaguchi and Fujimura, 2005) (Source: www.frac.info). 
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Of these, fungicides acting on ergosterol biosynthesis and on the electron transport 
chain in mitochondria constitute the major portion of the fungicide sales (Casida, 
2009).  In this section, commercial fungicides that are known to inhibit specific fungal 
enzymes and compounds that are inhibitors of fungal enzymes and potential crop 
protectants against fungal diseases will be discussed.  
 
1.5.1   Inhibitors of fungal respiration 
 
In eucaryotes, respiration occurs in mitochondria of the cell. At this site, electrons are 
transferred from NADH to molecular oxygen.  This redox process is compensated by 
proton translocation across the inner membrane of mitochondria and eventually, the 
proton gradient drives ATP synthesis and other processes (Saraste, 1999). This 
complex respiratory chain involves four membrane-bound respiratory enzyme 
complexes I-IV and electron carriers such as cytochrome b, c and ubiquinone (Saraste, 
1999; Yamaguchi and Fujimura, 2005). 
The four enzyme complexes are located sequencially within the inner membrane of 
mitochondria. At complex I (NADH:ubiquinone oxidoreductase), electrons are 
transferred from NADH to ubiquinone (Saraste, 1999). At complex III (cytochrome 
bc1), electrons are transferred from ubiquinol to cytochrome c and finally, at complex 
IV electrons are transferred from cytochrome c to molecular oxygen (Saraste, 1999; 
Yamaguchi and Fujimura, 2005). Complexes I, III and IV are directly associated with 
electron transfer, whereas, complex II assists the process by pumping two electrons into 
the ubiquinone pool (Avenot and Michailides, 2010; Omura and Shiomi, 2007).  
 
Many of the fungicidal compounds work by inhibiting respiratory chain enzymes. Due 
to the importance of this process in fungal metabolism, fungicides that inhibit enzymes 
involved in respiration are abundant. Especially, inhibitors of complex III found major 
applications in fungicide development (Knight, Anthony et al., 1997; Sauter, Steglich 
et al., 1999).  
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1.5.1.1  Complex I inhibitors 
Inhibitors of complex I with fungicidal activity are few. By far, diflumetorim (179), a 
pyridinamine, introduced by Yamanaka and co-workers, is the only commercial 
fungicide which is an inhibitor of complex I (Source: www.frac.info). However, this 
target has been of interest for several agrochemical industries. Recently, a series of 
novel aryloxylepidin analogs of general structures 182 and 183 were synthesized and 
used in lead-optimization studies. These compounds were designed as hybrid structures 
of fungicides fenazaquin (180) and quinoxyfen (181), an inhibitor of complex I and 
moderately active fungicide (Figure 1.10) (Kirby, Daeuble et al., 2001). Among the 
series of aryloxylepidines 182 and 183, only 8-halo (F, Cl) substituted compounds 
showed moderate inhibition of complex I and moderate fungicidal activities against 
Ustilago maydis (Kirby, Daeuble et al., 2001).   
 
Besides, natural products such as ajudazol (184), myxalamid (185), aurachin (186), 
phenoxan (187), pyrrolnitrin (188) and thiangazole (189) isolated from myxobacteria 
are known to be antifungal and inhibit fungal respiratory enzymes of complex I (Figure 
1.11) (Degli Esposti, 1994, 1998; Weissman and Mueller, 2010). Based on the analysis 
of inhibitors of complex I, it was determined that inhibitors could bind to three 
different sites in the complex I. But all of the sites shared a major common portion for 
binding (Okun, Lummen et al., 1999). 
 
 
Figure 1.10 Inhibitors of complex I; diflumetorim (179), fenazaquin (180), quinoxyfen 
(181), and aryloxylepidines 182 and 183 used in SAR studies (Kirby, Daeuble et al., 
2001). 
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Figure 1.11 Inhibitors of complex I, natural products 184-191 (Degli Esposti, 1998; 
Hollingworth, Ahammadsahib et al., 1994; Weissman and Mueller, 2010). 
 
Many of the complex I inhibitors do not possess fungicidal or antifungal activities. 
Inhibitors of mitochondrial electron transport complex I have additional biological 
activities (Degli Esposti, 1998). For example, rotenone (190) and pyridaben (191) have 
displayed insecticidal and acaricidal activity (Hollingworth, Ahammadsahib et al., 
1994).      
 
1.5.1.2  Complex II inhibitors 
 
Complex II is a family associated with two integral membrane proteins succinate 
dehydrogenase and succinate:ubiquinone oxidoreductase (Saraste, 1999; Horsefield, 
Yankovskaya et al., 2006). The natural products harzianopyridone (192), isolated from 
culture broth of Trichoderma harzianum, and atpenins A4 (193), A5 (194) from broth 
of Pencillium sp. are known to inhibit succinate:ubiquinone reductase (complex II) 
(Figure 1.12) (Miyadera, Shiomi et al., 2003; Omura and Shiomi, 2007). Inhibition by 
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these compounds is known to be specific to complex II, but not complex I (Miyadera, 
Shiomi et al., 2003).  IC50 values of complex II inhibition by atpenin A5 (194) was 300 
fold lower than that of carboxin (177), a commercial fungicide (Omura and Shiomi, 
2007). However, compounds 192-194 showed low fungicidal activity compared to that 
of the fungicide carboxin (177). On the other hand, natural products ubiquinone (195), 
dinitrophenol (196) and 2-theonyltrifluoroacetate (197) inhibited complex II activity 
but did not possess any fungicidal properties (Horsefield, Yankovskaya et al., 2006).  
 
Figure 1.12  Inhibitors of complex II, natural products 192-197 (Horsefield, 
Yankovskaya et al., 2006; Miyadera, Shiomi et al., 2003; Omura and Shiomi, 2007). 
 
Several classes of compounds have been synthesized and studied for inhibition of 
complex II activity. Important findings of structure-activity relationship (SAR) studies 
came from White et al., based on the lead structure carboxin (177) (White, 1971, 1987, 
1988, 1989, White and Georgopoulos, 1986; White, Phillips et al., 1986; White and 
Thorn, 1975, 1980; White, Thorn et al., 1978). Carboxin (177) was first identified as a 
systemic fungicide against Ureomycis phaseoli, Ustilago nuda and R. solani 
(Vonschme.B and Kulka, 1966). White and co-workers identified the basic structure 
required for the enzyme inhibition activity (White, 1988) and exploited the toxophore 
in the synthesis of classes of compounds such as oxathiin carboxamides of general 
structure 198 (White, 1971), thiophene carboxamides of general structure 199 (White 
and Georgopoulos, 1986), pyrazole carboxanilides of general structure 200 (White, 
Phillips et al., 1986), substituted benzanilides of general structure 201 (White, 1987) 
and furan carboxamides of general structure 202 (Figure 1.13) (White, 1988).  
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Figure 1.13 Complex II inhibitors designed based on structure of lead carboxin (177); 
oxathiin carboxamides 198, thiophene carboxamides 199, pyrazole carboxanilides 200, 
substituted benzanilides 201, furan carboxamides 202 (White, 1971, 1987, 1988, 1989, 
White and Georgopoulos, 1986; White, Phillips et al., 1986; White and Thorn, 1975, 
1980; White, Thorn et al., 1978). 
 
Selby, Hughes et al. (2010) designed and synthesized inhibitors of general structures 
203 and 204 based on the lead natural product atpenin A (193) (Figure 1.14). 
Pyridones, analogs with general structure 203, were found to be moderate inhibitors of 
complex II, while dihyropyridines, analogs with general structure 204, were more 
potent complex II inhibitors compared to atpenin A (300). Especially, compounds 
resulting from substitution of methyl-t-butyl side chain in the structure 311 inhibited 
complex II better than atpenin A (193) (Selby, Hughes et al., 2010).  
 
 
Figure 1.14  Complex II inhibitors 203 and 204 designed based on the lead structure 
atpenin A (193) (Selby, Hughes et al., 2010). 
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1.5.1.3  Complex III inhibitors 
Complex III catalyzes the electron transfer from ubiquinol to cytochrome c. This 
process is coupled to translocation of the protons through the Q-cycle at two 
ubiquinone redox sites Qi and Q0 (Saraste, 1999). Complex III inhibitors include 
strobilurins, which are derivatives of the natural compounds strobilurin A (205) and 
oudemansin A (215) isolated from fungi (Bartlett, Clogh et al., 2001). Strobilurin A 
(205) was first isolated from basidiomycete Strobilurus tenacellus by Anke and co-
workers (Anke, Oberwinkler et al., 1977). Oudemansin A (215) was first identified by 
Anke and co-workers in 1978 (Anke, Hecht et al., 1979), and later many other 
strobilurins 206-214 have been isolated (Figure 1.15) (Sauter, Steglich et al., 1999). 
Strobilurin fungicides bind to the Q0 site of cytochrome b and block the supply of 
electrons to cytochrome c. This blockage in turn affects the production of ATP (Degli 
Esposti, Crimi et al., 1994).  
 
 
Figure 1.15 Complex III inhibitors, natural products strobilurin A (205), oudemansin A 
(215) and others 206-214 (Bartlett, Clogh et al., 2001; Sauter, Steglich et al., 1999). 
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Figure 1.16  Complex III inhibitors, other natural products 216-222 (Rich, 1996; 
Rieske, 1980). 
 
 
Other natural product inhibitors of complex III are shown in figure 1.16. Compounds 
antimycin A (216), funiculosin (217) and 4-hydroxy-quinoline-N-oxide (HQNO, 218) 
are known to bind to the Qi site (Rieske, 1980). Crocacins 219 and 220 were found to 
be inhibitors of complex III and recently analogs of crocacins were prepared for 
optimizing the complex III inhibition of the natural products (Crowley, Berry et al., 
2008). The natural products of microbial origin myxothiazole (221) (Weissman and 
Mueller, 2010) and stigmatellin (222) (Vonjagow and Ohnishi, 1985) bind to Qo site of 
cytochrome bc1 complex.  
 
Research in the area of fungicidal development was revolutionized with the invention 
of the strobilurin fungicides (Nising, Hillebrand et al., 2011). The natural strobilurins 
were unstable under sunlight and thus, were not effective for crop disease treatments. 
Many agrochemical industries like Syngenta and BASF were interested in the 
development of these compounds because of their novel mode of action. In these 
studies, the optimized structure 223 obtained from natural products 205 and 215 was 
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used (Nising, Hillebrand et al., 2011). This enol ether compound 223 contained three 
potential parts for further modification, i.e. (a) the toxophore group: methyl (E)-3-
methoxy-2-(5-phenylpenta-2,4-dienyl) acrylate, (b) a bridge and (c) a side chain 
(Sauter, Steglich et al., 1999). Attempts to modify part A led to Kresoxym methyl 
(224), which was a basis for later development of other strobilurins 227-231. These 
synthetic strobilurins had the toxophore derived from oximino acetate moiety and 
included changes in the side chain part C (Sauter, Steglich et al., 1999). Modification of 
general structure 223 by changing the sidechain, but not the toxophore and the bridge, 
led to the discovery of the fungicides 225-226 (Bartlett, Clogh et al., 2002; Sauter and 
Steglich et al., 1999).  Several thousands of compounds were synthesized and were 
tested for the fungicidal activities. The major modifications and the gradual evolution 
of strobilurins is shown in figure 1.17.  
 
Figure 1.17 Evolution of strobilurin fungicides 223-231 (Bartlett, Clogh et al., 2002; 
Nising, Hillebrand et al., 2011; Sauter, Steglich et al., 1999). 
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On the other hand, researchers at DuPont developed oxazolidinone fungicides based on 
lead structure 232 from Geffken’s lab. SAR studies based on the lead structure 232 led 
to identification of the fungicide famoxadone (233) (Sternberg, Geffken et al., 2001). 
About seven hundred ring analogs falling into general structures 234-238 were 
prepared (Figure 1.18) from the lead structure 232, of which several fungicidal 
compounds were identified. Eventually, famoxadone (233) was launched as the first 
potent fungicide among this class of compounds (Sternberg, Geffken et al., 2001). 
Wang et al. recently synthesized more analogs of general structures 239 and 240 based 
on the structure of famoxadone (233) and identified a more potent inhibitor from the 
compounds of general structure 240 (Wang, Li et al., 2011). Later, fenamidone (241) 
was identified to be active against Plasmophora viticola (Genix, Guesnet et al., 2003) 
and developed as a fungicide. Compound 241 has structural features similar to the ring 
analogs of general structure 237. Optimization of the activities of compound 241 was 
attempted by Genix. Several ring analogs resembling the general structures 234-238 
were prepared. It was found that compound 241 but not its analogs inhibited complex 
III (Genix and Villier, 2003). In particular, only S- but not the R-enantiomer of 
compound 241 inhibited the enzymatic activity (Genix and Villier, 2003). 
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Figure 1.18 Inhibitors of complex III, azolones 232-241 (Genix, Guesnet et al., 2003; 
Sternberg, Geffken et al., 2001; Wang, Li et al., 2011). 
 
Strobilurins display very poor specificity towards inhibition of bc1 complex among 
different species. Inhibition activitiy tests carried out in mitochondrial preparations of 
different species such as yeast, Botrytis, maize, house fly and rat with the help of 14 
strobilurin analogs along with myxothiazole suggested similar activity patterns (Roehl 
and Sauter, 1994).  
 
1.5.2   Inhibitors of ergosterol biosynthesis 
Sterols are important components of cell membranes of fungi. The major sterol found 
among fungi is ergosterol. Mercer (1984, 1981) described the ergosterol biosynthesis in 
two parts namely, pre-epoxysqualene and post-squalene stages. The enzymatic steps in 
the pre-squalene stage are common for sterol synthesis in animals, higher plants and 
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fungi. In order to maintain the selectivity in inhibition of only ergosterol biosynthesis, 
researchers were interested in the enzymes involved in the post-squalene stage (Mercer, 
1991). The steps involved in the synthesis of ergosterol (253) starting from squalene 
(242) via important intermediates 243-252 and the relevant enzymes are summarized in 
scheme 1.21 (Leroux, Fritz et al., 2002; Mercer, 1991). 
 
Scheme 1.21 Post-squalene pathway of ergosterol (253) biosynthesis; enzymes used in 
the description: SE (squalene epoxidase), C14 DM (C14 demethylase), C14 reductase, 
3 KR (3 keto reductase) and isomerase (Leroux, Fritz et al., 2002; Mercer, 1991). 
 
Many of the fungicides interfere with ergosterol biosynthesis by inhibiting the key 
enzymes involved in the biosynthesis (Mercer, 1991; Leroux, 2003; Casida, 2009).  
Based on the target enzyme inhibition, sterol biosynthesis inhibitors could be of 
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different types: C14 demethylase inhibitors (C14 DMI; azoles), C14 reductase 
inhibitors, 3-keto reductase inhibitors (3-KR), ∆8 - ∆7 isomerase inhibitors 
(morpholines) and squalene epoxidase inhibitors (Mercer, 1991).  
 
1.5.2.1  Inhibitors of demethylase (DMI) 
A series of imidazoles, triazoles (collectively called azoles), pyridines, pyrimidines and 
piperazines are known to inhibit demethylation of the substrate dihydrolanosterol (245) 
(Baldwin, 1983). This conversion is catalyzed by the enzyme 14α-demethylase 
(Scheme 1.21) (Mercer, 1984). During the 1970’s the fungicides prochloraz (254), 
imizalil (255), propiconazole (256), prothioconazole (257) and triadimefon (258) were 
introduced. These compounds showed a broad spectrum of fungicidal activity on many 
pathogens of cereals, fruits, peanuts and coffee (Baldwin, 1983). Yanosaka et al. 
synthesized the novel carboxylate derivatives of imidazoles 259-261 shown in figure 
1.19 (Yanosaka, Imai et al., 1991). Compounds 260 and 261 with methoxy and ethoxy 
substituents inhibited the growth of B. cinerea which was reflected in the amount of 
ergosterol synthesized. These compounds also showed potent inhibition of 14α-
demethylase activity (Yanosaka, Imai et al., 1991). Recently, Arnoldi et al. synthesized 
novel compounds of general structures 263 and 264 with fungicidal activity based on 
tetraconazole (262). However, these compounds did not have improved activities but 
had comparable fungicidal activities with respect to tetraconazole (262). All the 
compounds acted as inhibtors of 14α-demethylase (Arnoldi, Carzaniga et al., 2000). 
Triforin (265), another systemic fungicide with mode of action of 14α-demethylase 
inhibition belongs to piperazine group of compounds (Figure 1.19). Compound 265 
was found to be active on Aspergillus fumigatus (Sherald and Sisler, 1975).   
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Figure 1.19 Structures of inhibitors of ergosterol C-14 demethylase 254-265 (Baldwin, 
1983; Yanosaka, Imai et al., 1991; Arnoldi, Carzaniga et al., 2000).  
 
1.5.2.2  Inhibitors of squalene epoxidase 
 
Squalene epoxidase inhibitors inhibit the enzyme involved in the epoxidation of 
squalene (242) to form compound 243 (Scheme 1.21). Allyl amines are an important 
class of compounds among squalene epoxidase inhibitors (Petranyi, Ryder et al., 1984). 
Naftifine (266) was one of the early allyl amine inhibitors of squalene epoxidase and an 
effective antimycotic (Georgopoulos, Petranyi et al., 1981). Structural modification of 
compound 266 led to development of the potent antifungal compound terbinafine 
(267). Compound 267 was determined as a specific inhibitor of fungal squalene 
epoxidase (Petranyi, Ryder et al., 1984). Terbinafine (267) is known to have potent 
fungicidal activities against many pathogens because of its inhibition of squalene 
epoxidase. It was found out experimentally that fungi fed with compound 267 
accumulated squalene (242), and failed to biosynthesize ergosterol (253). Tolnafthate 
(268) and tolciclate (269) were later identified as inhibitors of ergosterol biosynthesis 
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(Figure 1.20) (Ryder, Frank et al., 1986). These thiocarbamate compounds inhibited the 
squalene epoxidase activity from Candida albicans (Ryder, Frank et al., 1986). A good 
correlation between ergosterol biosynthesis inhibition by compounds 268 and 269 and 
their antifungal activity against C. albicans was observed (Ryder, Frank et al., 1986).   
 
 
Figure 1.20 Inhibitors of squalene epoxidase  266-269 (Georgopoulos, Petranyi et al., 
1981; Petranyi, Ryder et al., 1984; Ryder, Frank et al., 1986). 
 
1.5.2.3   Inhibitors of ∆14 reductase and ∆8 - ∆7 isomerase 
 
∆14 - Reductase catalyzes the conversion of compound 246 to 247 and ∆8 - ∆7 
isomerase converts compound 250 to 251 in the biosynthetic pathway leading to 
ergosterol (253) (Scheme 1.21). Morpholines, 3-phenylpropylamines and 
spiroketalamines are important classes of fungicides known to inhibit these two 
enzymes (Leroux, Fritz et al., 2002).  
 
Morpholines with potent fungicidal properties were identified in 1960s (Konig, 
Pommer et al., 1965). Substitution of the N-atom of general structure 270 with an 
aliphatic carbon chain with 10-12 carbon atoms resulted in improved fungicidal 
activities as in tridemorph (271) (Konig, Pommer et al., 1965). It is also known that 
morpholines and their structural analogs inhibit sterol biosynthesis in higher plants 
(Rahier, Schmitt et al., 1986). Further optimization of morpholine-based analogs with 
general structure 270 led to the identification of the more potent fungicides 
fenpropiomorph (272) and fenpropidin (273). Compound 272 contains a phenylpropyl 
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unit attached to morpholine and in the other compound 273, the morpholine ring was 
replaced with piperidine ring (Figure 1.21). Both the compounds 272 and 273 showed 
fungicidal properties against powdery mildews (Himmele and Pommer, 1980). 
However, the in vitro assays using enzymes isolated from S. cerevisiae demonstrated 
that tridemorph (271) was a strong inhibitor of ∆8 - ∆7 isomerase, whereas compounds 
272 and 273 showed inhibition of both ∆14 reductase and ∆8 - ∆7 isomerase (Baloch 
and Mercer, 1987). Compounds 272 and 273 also were active against Microdochium 
nivale and also inhibited ∆8 - ∆7 isomerase activity in cell free assays (Debieu, Bach et 
al., 2000).   
 
 
Figure 1.21 Inhibitors of sterol biosynthesis: morpholines 270 and related fungicides 
271-273 and spiroxamines 274-276 (Baloch and Mercer, 1987; Kraemer, Berg et al., 
1999; Debieu, Bach et al., 2000). 
 
 
Later, a class of compounds representing the general structure of spiroketalamine 274 
was developed. Spiroxamine or KWG 4168 (274), the most active fungicide from this 
class, had four isomers, of which compounds 275 and 276 were biologically active 
(Figure 1.21). Compound 274 showed inhibition of ∆14 reductase (Kraemer, Berg et 
al., 1999) and was very effective, with a broad spectrum of activity.  It showed good 
activity against cereal rusts and leaf blotch pathogens (Dutzmann, 1997).    
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1.5.2.4  Inhibitors of ergosterol 3-ketoreductase 
 
Figure 1.22 Inhibitors of ergosterol 3-ketoreductase 277 and 278 (Kruger, Etzel et al., 
1999; Debieu, Bach et al., 2001). 
 
In 1999, Bayer introduced a new fungicide fenhexamid (278) optimized from 
compounds with a general structure 277. Compounds having the cycloalkyl substituent 
instead of the ‘Y’ group, a dihalosubstituted phenyl ring, and a free ‘NH’ group in the 
general structure 277 exhibited fungicidal activity against B. cinerea (Figure 1.22) 
(Kruger, Etzel et al., 1999). Later Debieu, Bach et al. (2001) showed that fenhexamid 
(278) inhibits sterol biosynthesis by a totally different mode as compared to other 
known fungicides. It was reported that compound 278 inhibited 3-keto reductase 
involved in the C-4 demethylation of compound 247 in ergosterol biosynthesis 
(Scheme 1.21) (Debieu, Bach et al., 2001). 
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1.5.3 Inhibitors of melanin biosynthesis 
 
Scheme 1.22 Selected steps in fungal melanin biosynthetic pathway carried out with 
the help of 1,3,6,8-tetrahydroxy naphthalene reductase (1,3,6,8-THNR), 1,3,6,8-
trihydroxy naphthalene reductase (1,3,8-THNR) and scytalone dehydratases (SD) 
(Butler and Day, 1998). 
 
Melanin in mammals is biosynthesized from tyrosine and 3,4-dihydroxyphenylalanine 
(L-DOPA), whereas in fungi melanin derives from acetyl and malonyl CoA through 
polyketide biosynthesis (Butler and Day, 1998). 1,3,6,8-Tetrahydroxynaphthalene 
(279), scytalone (280), 1,3,8-trihydroxynaphthalene (281), vermelone (282) and 1,8-
dihydroxynaphthalene (283) are important intermediates in the fungal biosynthesis of 
melanin (Scheme 1.22). Most of  the enzymes involved in the melanin biosynthesis 
pathway are well characterized (Butler and Day, 1998). Design of melanin biosynthesis 
inhibitors is mainly based on two target enzymes: the reductases 1,3,6,8-
tetrahydroxynaphthalene reductase, 1,3,8-trihydroxynaphthalene reductase (phthalide, 
tricyclazole, pyroquilone) and scytalone dehydratase (carpropamid, dicyclocymet, 
fenoxanil). Besides the inhibitors of the above two enzymes, two natural products 
(Figure 1.23) were identified as potent inhibitors of the polyketide synthase. The first 
one, aflastatin A (284), was a compound isolated from Streptomyces species (Ono, 
Sakuda et al., 1997). Studies of Okamoto et al. revealed that the compound 284 inhibits 
early steps in the melanin biosynthesis (Okamoto, Sakurada et al., 2001). The second 
compound abikoviromycin (285) was isolated from Colletotrichum lagenarium 
(Maruyama, Okamoto et al., 2003). 
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Figure 1.23 Inhibitors of melanin biosynthesis: natural products aflastatin A (284) 
(Okamoto, Sakurada et al., 2001) and abikoviromycin (285) (Maruyama, Okamoto et 
al., 2003).  
 
1.5.3.1  Inhibitors of trihydroxynaphthalene reductases  
Wheeler and Gleenblatt (1988) showed that some of the inhibitors of melanin 
biosynthesis in appressoria of Pyricularia oryzae were as well inhibitors of reductases 
involved in conversion of 1,3,6,8-tetrahydroxynaphthalene (279) and 1,3,8-
trihydroxynaphthalene (281) to scytalone (280) and vermelone (282), respectively 
(Wheeler and Greenblatt, 1988). However, these compounds did not inhibit enzymatic 
reactions that dehydrate scytalone (280) and vermelone (282). This suggested that these 
compounds were inhibitors of only the reductases and not of dehydratases in the 
melanin biosynthetic pathway (Wheeler and Greenblatt, 1988). Among these 
compounds, three of the strongest inhibitors of trihydroxynaphthalene reductase 
activity, namely tricyclazole (286), phthalide (287) and pyroquillon (288), are used as 
commercial fungicides to treat rice blast disease (Figure 1.24) (Liao, Basarab et al., 
2001). Binding of the inhibitors phthalide (287) and pyroquilone (288) to the active site 
was explained using X-ray crystal structures of the inhibitors bound to 1,3,6,8-
tetrahydroxynaphthalene reductase (Liao, Basarab et al., 2001).   
 
Jordan and co-workers used a computational program and developed a docking model 
to design and score several compounds as potential inhibitors of 1,3,8-
trihydroxynaphthalene reductase. The shape of the active site, lipophilicity and 
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hydrogen bond donation were the important properties that were explored in the design 
process. Functional groups that append to the planar, lipophilic core were chosen 
(Jordan, Basarab et al., 2001). Based on these criteria several analogs were designed 
which exhibited a range of Ki values including nano molar potencies. A good 
correlation was observed in case of a few inhibitors between the predicted and 
observed inhibition of trihydroxynaphthalene reductase values. The most potent 
inhibitors of this class were compounds 290-294 (Figure 1.24) (Jordan, Basarab et al., 
2001). 
 
 
Figure 1.24 Inhibitors of trihydroxynaphthalene reductase 286-289 (Liao, Basarab et 
al., 2001) and 290-294 (Jordan, Basarab et al., 2001). 
 
Recently, Brunskole and co-workers used a series of compounds and identified a few 
structurally diverse inhibitors 295-299 of trihydroxynaphthalene reductase (Figure 
1.25) from Curvularia lunata, a known plant pathogen. Inhibitor activities in these 
studies were explored by homology modeling of the active site of C. lunata (Brunskole, 
Stefane et al., 2008). 
 
Figure 1.25 Inhibitors of trihydroxynaphthalene reductase 295-299 (Brunskole, Stefane 
et al., 2008). 
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1.5.3.2  Inhibitors of scytalone dehydratase 
Scytalone dehydratases catalyze the conversion of scytalone (280) and vermalone (282) 
to compounds 281 and 283, respectively, in the fungal melanin biosynthetic pathways 
(Scheme 1.22). Scytalone dehydratase (SD) is an important agrochemical target from 
the Magnaporthe grisea, which causes blast disease of rice. It was found that M. grisea 
mutants devoid of scytalone dehydratase were unable to infect the rice plants (Chumley 
and Valent, 1990).  
The first inhibitor of scytalone dehydratase, a salicylamide 300, was designed based on 
the structure of substrate 280 and the probable enzymatic mechanism (Hodge and 
Pierce, 1993). Peryhydroxy carbonyl moiety involved in H-bonding was important for 
activity. SAR studies suggested that the compounds resulted from replacement of the 
hydroxyl group in compound 300 with F, Cl or OMe groups resulted in loss of activity 
by two folds (Hodge and Pierce, 1993). Replacement of a cyclic hydrogen bond array 
in compound 300 with a phenazine ring made compound 304 an equally potent 
(nanomolar) inhibitor of SD. Inhibitor design in this work was guided through the 
isosteric replacement of the active chemical ingredient such as the peryhydroxybenzoyl 
group with a quinazoline moiety (Hodge and Pierce, 1993). 4-aminoquinazoline as the 
bioisostere of the salicylamide moiety was exploited by Chen and co-workers, who 
tried several replacements of heterocyclics in structure 300 (Chen, Xu et al., 1998). 
Compounds 303a and 304a effectively inhibited SD among the compounds 302a-305a 
that were obtained with heterocyclic replacement in compound 300 with quinolines, 
isoquinolines, quinazolines and benzotriazines (Figure 1.26). Further, a more potent 
lead inhibitor of SD, 301 was used in optimization studies (Jennings, Wawrzak et al., 
1999).  
Replacement of the side chain in compound 301 by the 3,3-diphenylpropyl moiety 
resulted in an increase of activity in compounds 304c and 305c. Modification of 
structure 304c by substitution of the nitrile group, as in compound 306, further 
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improved the SD inhibitory activity (Chen, Xu et al., 1998). Chen, Xu et al. (1998) 
observed a similar effect with compound 307 that was optimized from triazine structure 
305c (Figure 1.26). The increased activity was due to displacement of a water molecule 
in the active site with a nitrile group, which was evident from the crystal structure 
(Chen, Xu et al., 1998; Walter, 2002).  
 
Figure 1.26 Design of inhibitors of scytalone dehydratase 302-307 based on the 
structure of compounds 300 and 301 (Chen, Xu et al., 1998; Hodge and Pierce, 1993; 
Walter, 2002). 
 
Jennings and co-workers retained the amide functional group among their newly 
designed inhibitor compounds since the amide group was important in hydrogen 
bonding (Jennings, Wawrzak et al., 1999). Using the combinatorial chemistry of 
amines from the previous lead compounds and several acids, a picomolar potent 
inhibitor of SD 308 was identified (Jennings, Wawrzak et al., 1999). During these 
studies various amides, synthesized from coupling of (R)-α-methyl-4-
bromobenzylamine and other amines with several acids, were initially screened as 
mixtures, and then more potent compounds were screened separately (Jennings, 
Wawrzak et al., 1999). Basarab noted that compound 309 was a potent inhibitor (47 
pM) of SD but, that it was detoxified by M. grisea (Basarab, Jordan et al., 1999; Jordan, 
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Lessen et al., 1999). However, when the substitutuent on the amide moiety in 309 was 
replaced by a phenoxypropyl group, a stable and more potent inhibitor 310 was 
resulted. Further, two phenoxypropylsalicylamides 313 and 314 were designed based 
on the structures of known fungicides dicyclomet (311) and carpropamid (312) (Jordan, 
Lessen et al., 1999). Especially, compound 314, a structural relative of dicyclomet 
(311), was a very effective inhibitor of SD. Further, based on the structure of 
compound 314, and thorough analysis of binding interactions of potent inhibitors with 
SD, replacement of the t-butyl group by smaller groups and modification of the amide 
substituent by introducing additional phenyl substituents were considered (Figure 
1.27). This strategy resulted in the series of norephedrine analogs with more potent 
inhibitors such as 315 and 316 (Basarab, Jordan et al., 1999).  
 
 
Figure 1.27 Inhibitors of scytalone dehydratase 308-316 (Basarab, Jordan et al., 1999; 
Jennings, Wawrzak et al., 1999; Jordan, Lessen et al., 1999). 
 
1.5.4   Impact of fungicidal usage 
Fungicides are benificial to improve the quality and yield of crops that are prone to 
fungal diseases. Thus, with the growing demand for food, production of fungicides is 
equally important. Kleffman reported that fungicidal usage on oilseed rape increased by 
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16% in the UK between 2009 and 2011 (Kelffmann, 2009). However, the negative 
impact of fungicide use has been recognized (Dewaard, Georgopoulos et al., 1993; 
Russell, 2005; Yang, Hamel et al., 2011). Fungicides such as 
ethylenebisdithiocarbamates 174-176 are known to be metabolized to ethylenethiourea, 
which is carcinogenic (Yang, Hamel et al., 2011). Residues of these fungicides have 
been found in several food samples and harvested crops, which is of great concern 
(Caldas, Conceicao et al., 2001). Excessive use of fungicides might lead to 
development of fungicide resistant fungal strains (Dewaard, Georgopoulos et al., 1993).  
Although there are fungicides against important targets, there is a continuous necessity 
for identification of new fungicides because of the pathogens’ possible resistance 
mechanisms. Possible mechanisms of fungicide restance in fungi are: i) alteration of 
enzyme target sites; ii) synthesis of alternative enzymes to substitute the fungicide 
target enzyme; iii) overproduction of fungicide target; iv) reduced uptake of the 
fungicide; and v) metabolic breakdown (Ma and Michailides, 2005). For example, 
resistance to inhibitors of respiratory complexes is known among some pathogenic 
fungi (Leroux, Gredt et al., 2010). Similarly, carboxin derivatives acting as inhibitors 
of succinate dehydrogenase (complex II) were also metabolized with the help of 
hydroxylation of aromatic hydrogens and methyl and methylene hydrogens. Resistance 
against scytalone dehydratase inhibitors is also known (Source: www.frac.info). In 
addition the use of fungicides could have an effect on the non-target soil 
microorganisms that indirectly help the crop production (Yang, Hamel et al., 2011).  
European scientists showed that massive usage of farm fungicides may be linked with 
negative effects of human resistance to pathogens (Enserink, 2009).  
The availability of “omics” technology will be of help in identifying novel fungicidal 
targets (Fernandez Acero, Carbu et al., 2011). It is possible that the chances of 
developing resistance to the inhibitors of primary metabolism in pathogens is higher 
when compared to inhibitors of fungal secondary metabolism such as detoxification of 
phytoalexins. In that way paldoxins may be more beneficial than conventional 
fungicides.  
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1.6 Conclusions 
 
 
Chemistry and Biochemistry aspects involved in plant-pathogen interactions are very 
complex, and a thorough understanding of those would be helpful in implementing 
measures for controlling plant pathogens. Enzymatic detoxification of plant defense 
metabolites such as phytoalexins is an important strategy adopted among several 
crucifer pathogens. As a consequence, plants are deprived of their natural defenses and 
would depend on the unnatural defenses. Although, there are different modes of 
blackleg disease treatments, chemical and non-chemical both, available to treat L. 
maculans, these methods are not sustainable. Especially, despite the effectiveness of 
the fungicides in controlling fungal diseases, several pathogens acquire resistance to 
these chemicals, making them less viable. In this regard, paldoxins might serve as 
better crop protecting agents, provided the phytoalexin detoxification inhibitors are 
designed and optimized as per the desired properties including low antifungal and 
cytotoxic activities.  
 This thesis presents investigations of the Chemistry involved in metabolism of 
phytoalexins and related compounds by L. maculans (virulent on canola) and the 
effects of quinoline and isoquinoline derivatives on phytoalexin detoxification. 
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Chapter 2: Results and discussion 
 
 
2.1 Phytoalexins and analogs 
 
2.1.1  Synthesis  
2.1.1.1  Phytoalexins 
 
To study the biological activities of phytoalexins, it is essential to have these 
compounds available in sufficient quantities. Synthetic routes for all the published 
cruciferous phytoalexins have been established and the work has been reviewed 
(Pedras, Yaya et al., 2011c; Pedras, Zheng et al., 2007e). In my current work, 
phytoalexins were synthesized based on the best available published procedures. 
Syntheses of brassinin (17) (Kutschy, Dzurilla et al., 1998; Pedras, Borgmann et al., 
1992), rapalexin A (22) (Pedras, Zheng et al., 2007d), and erucalexin (29) (Pedras, 
Suchy et al., 2006) were carried out as shown in experimental procedures according to 
the published procedures. Brussalexin (36) was synthesized by a modification of the 
previously reported synthetic procedure (Pedras, Zheng et al., 2007f). The modified 
route includes the synthesis of brussalexin (36) through the indolyl-3-methanethiol 
(319) intermediate as shown in the scheme 2.1. First, thioacetate 318 was prepared 
starting from grammine (317) according to a published procedure (Benghait, Crooks, 
1983).  Next, the crucial step involved the hydrolysis of unprotected thioacetate 318 
using hydrazine hydrate (Tomlison, Grey et al., 2002), whereas the previous procedure 
had involved the hydrolysis of N-Boc protected 318. Thus, in the absence of protection 
and deprotection steps, the new procedure uses a shorter route to access compound 36. 
Synthesis of compound 319 is reported here for the first time following a 
transformation similar to that reported for the –SAc group (Tomlinson, Grey et al., 
2002). Compound 319 is a potential intermediate which gives access to several indolyl-
3-methanethiol derivatives, including brussalexin (36).  
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Scheme 2.1 Synthesis of brussalexin (36). Reagents and conditions: (i) Me2SO4, H2O; 
(ii) CH3COSH, KOH, 70 °C, 66% (Benghait and Crooks, 1983); (iii) NH2NH2.H2O, 
THF, 80 °C, 84%; (iv) Et3N, allyl isocyanate, DCM, 86%. 
 
2.1.1.2 Phytoalexin analogs  
 
Syntheses of the phytoalexin analogs, dithiocarbamates 96 (Pedras and Okanga, 2000), 
111 and 342 (Pedras, Suchy et al., 2006), 325 (Gaspari, Banerjee et al., 2006), 327, 331 
and dithiocarbonates 153 (Pedras and Jha, 2006), 333 included common reaction 
conditions in the final step. They involved the treatment of the corresponding amines 
155, 324, 326, 330, 339 and 343 or alcohols 156 and 332 with a base (Pyr, Et3N or 
NaH) followed by reaction with CS2 and MeI. The amines 324, 330, 339 (Pedras, 
Suchy et al., 2006), 343 (Pedras, Suchy et al., 2006) and alcohol 332 were prepared 
according to the procedures described in the experimental section, whereas compounds 
156 and 326 were purchased from commercial sources. Compounds 96 (Pedras and 
Okanga, 2000), 111 and 342 (Pedras, Suchy et al., 2006) were synthesized as 
previously reported. Methyl indolyl-3-methylcarbamodithioate (320) was synthesized 
starting from compound 319 in the presence of triethylamine and methyl isothiocyanate 
in 76% yield (Scheme 2.2). Compound 325 was synthesized according to a general 
procedure used in the case of dithiocarbamate synthesis (Pedras, Yaya et al., 2011c). 
Oximes 323 were prepared starting from acid 95 in three steps according to a published 
procedure (Pedras, Minic et al., 2010b). Amine 324 was prepared by reduction of the 
oximes 323 using a NiCl2/NaBH4 system (Kutschy, Dzurilla et al., 1998), a procedure 
different from the reductive amination procedure used by Gaspari et al., in the synthesis 
of compound 324 (Gaspari, Banerjee et al., 2006). Finally, compound 325 was 
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prepared starting from amine 324 according to a general final step in the synthesis of 
dithiocarbamates, recently used by Gaspari et al. (Gaspari, Banerjee et al., 2006) 
(Scheme 2.3).  
 
Scheme 2.2 Synthesis of methyl indolyl-3-methylcarbamodithioate (320). Reagents 
and conditions: (i) Et3N, MeNCS, DCM, 76%. 
 
 
Scheme 2.3 Synthesis of methyl 3-(3-indolyl)propyldithiocarbamate (325). Reagents 
and conditions: (i) EtOH, H2SO4, 115°C, 96%; (ii) DiBAl-H, toluene, -78 °C, 90%; (iii) 
NH2OH.HCl, Na2CO3, EtOH/H2O, 97% (Pedras and Minic et al., 2010b); (iv) NaBH4, 
NiCl2.6H2O, MeOH; (v) Pyr, Et3N, CS2, CH3I, 43% (Gaspari, Banerjee et al., 2006). 
 
In addition to homologues of brassinin (17), non-indolyl dithiocarbamates such as 
compounds 327 and 331 were synthesized using known methodology (Pedras, Jha et 
al., 2003b; Pedras and Jha, 2006; Pedras, Zheng et al., 2007e; Pedras, Yaya et al., 
2011c). Methyl benzimidazolyldithiocarbamate (327) was synthesized starting from 
commercially available benzimidazole (326) in 72% yield (Scheme 2.4). An alternative 
route for the synthesis of compound 327 was recently published, starting from 
compound 326 using NaOH as base, and a combination of CS2 and dimethyl sulfate in 
DMSO in comparable yields (Devmurari, Shivanand et al., 2010). Methyl 4-
biphenyldithiocarbamate (331) was synthesized using the same reagents as in the case 
of brassinin (Section 4.3.1.1), starting from 4-biphenylcarboxaldehyde (328) instead of 
indolyl-3-carboxaldehyde (74) in 64% yield (Scheme 2.5). It was found that yields of 
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non-indolyl dithiocarbamates were higher than those of indolyl dithiocarbamates. 
Further, the analogs of brassinin 153 and 333, with ethyl and propyl chains connecting 
the dithiocarbonate to 3-indolyl moieties were synthesized. Compound 153 was 
synthesized as previously reported in 90% yield (Pedras and Jha, 2006), whereas 
compound 333 was prepared starting from compound 321 in 69% yield (Scheme 2.6). 
First, ester 321 (Pedras, Minic et al., 2010b) was reduced using LiAlH4 to alcohol 332, 
which was converted to dithiocarbonate 333 in the presence of NaH, CS2 and MeI.    
 
 
Scheme 2.4 Synthesis of methyl (benzimidazolyl)dithiocarbamate (327). Reagents and 
conditions: (i) NaH, THF, 0 °C; (ii) CS2, CH3I, 72%. 
 
 
 
Scheme 2.5 Synthesis of methyl 4-biphenyldithiocarbamate (331). Reagents and 
conditions: (i) NH2OH.HCl, Na2CO3, EtOH/H2O, 97%; (ii) NaBH4, NiCl2.6H2O, 
MeOH, 91%; (iii) Pyr, Et3N, CS2, CH3I, 72%. 
 
 
Scheme 2.6 Synthesis of methyl indolyl-3-propyldithiocarbonate (333).  Reagents and 
conditions: (i) LiAlH4, THF, 0 °C, 95%; (iii) NaH, THF, 0 °C; (iv) CS2, CH3I, 73%. 
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2.1.2 Antifungal activity 
 
The choice of concentration of the compounds to be used in metabolism studies was 
made based on the antifungal activity of each compound. Phytoalexins and analogs 
were tested for antifungal activity against L. maculans at 0.50, 0.20 and 0.10 mM 
concentrations using a mycelial radial growth assay (Pedras and Jha, 2006). Solutions 
of each compound in ACN/DMSO (0.50 mM) were used to prepare assay solutions by 
serial dilution in PDA (potato dextrose agar), and control solutions were prepared with 
1% ACN/DMSO in PDA. Further, the compound solutions and control solutions in 
PDA media were added to wells of 6-well sterile plates (35 mm well diameter, 2 
ml/well). Mycelial plugs (4 mm) of L. maculans (virulent isolate UAMH 9410) grown 
on V8 juice-agar media for 7 days were inoculated upside down in the centre of wells. 
After incubation of the plates under constant light for 7 days the growth of mycelia in 
each well was measured and used in the calculation of antifungal activities as described 
in the experimental section 4.5. The antifungal activities of compounds 17, 22, 29, 36, 
96, 111, 153, 320, 325, 327, 331, 333 and 342 that were tested for metabolism in L. 
maculans are summarized in table 2.1.    
Brassinin (17) is considered a key compound among crucifer phytoalexins (Pedras, 
Yaya et al., 2011c). The structure of compound 17 contains a dithiocarbamate group 
linked to an indolyl moiety by a methylene unit. Some of the pesticides designed in 20
th
 
century were dithiocarbamate analogs. However, the antifungal activity of brassinin 
(17) cannot be attributed only to the dithiocarbamate functional group because 
methyldithiocarbamate itself does not possess antifungal activity against L. maculans 
(Pedras, Minic et al., 2011b). It is worth noting that the commercial fungicide 
mancozeb (176), which is ethylene bisdithiocarbamate, functions by a mode of action 
associated with multi-site activity (Gullino, Tinivella et al., 2010). The mode of action 
of compound 17 on crucifer pathogens remains to be established.  
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Table 2.1 Percentage of growth inhibition
a
 of Leptosphaeria maculans incubated with 
phytoalexins 17, 22, 29, 36 and analogs 96, 111, 153, 320, 325, 327, 331, 333 and 342. 
 
Compound Inhibition ± SD (%)
a
 
0.50 mM 0.20 mM 0.10 mM 
Brassinin (17) 55 ± 3 21 ± 4 10 ± 4 
Rapalexin-A (22) c.i. 53 ± 6 21 ± 6 
Erucalexin (29) 40 ± 4 17 ± 4 6 ± 2 
Brussalexin (36) 43 ± 3 25 ± 2 7 ± 4 
Tryptaminedithiocarbamate (96) c.i. 71 ± 4 43 ± 2 
Isobrassinin (111) 44 ± 4 23 ± 4 13 ± 3 
Tryptophol dithiocarbonate (153) 30 ± 3 18 ± 2 6 ± 3 
Methyl indolyl-3-methylcarbamodithioate (320) 61 ± 5 35 ± 3 17 ± 3 
Methyl 3-(3-indolyl)propyldithiocarbamate (325) 67 ± 3 46 ± 5 21 ± 5 
Methyl benzimidazolyl dithiocarbamate (327) c.i. 45 ± 4 32 ± 7 
Methyl 4-biphenyl dithiocarbamate (331) 46 ± 4 32 ± 4 14 ± 4 
Methyl 3-(3-indolyl)propyldithiocarbonate (333) 32 ± 4 15 ± 2 7 ± 3 
1-Methoxyisobrassinin (342) 34 ± 3 15 ± 3 7 ± 3 
a
 The percentage of inhibition was calculated using the formula: % inhibition = 100 – [(growth on 
amended/growth in control) × 100];  c.i. = complete inhibition. 
 
Results of antifungal bioassays showed that the phytoalexins erucalexin (29) and 
brussalexin (36) were less potent inhibiting the fungal growth than brassinin (17), while 
rapalexin A (22) displayed higher inhibition than brassinin. Among the brassinin 
homologues, both 96 and 325 were more inhibitory against the fungal growth than 
brassinin (17). Methyl tryptaminedithiocarbamate (96) showed complete inhibition of 
the fungal growth at 0.50 mM, while compound 325 showed about 70% growth 
inhibition at 0.50 mM. Dithiocarbamate 327 showed complete inhibition of fungal 
growth at 0.50 mM, whereas compounds 343, 320, 111, 153, 331 and 333 were less 
potent than brassinin (17) at similar concentrations. The antifungal activities of 
compounds 17, 22, 29, 36 and analogs 96, 111, 153, 320, 325, 327, 331, 333 are 
summarized in table 2.1. 
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2.1.3 Metabolism  
2.1.3.1 Metabolism of phytoalexins 
 
Rapalexin A (22) is a phytoalexin isolated from B. rapa (canola) upon elicitation with 
A. candida (Pedras, Zheng et al., 2007d). The antifungal bioassays determined that 
compound 22 was growth-inhibitory against L. maculans at 0.50 - 0.20 mM (isolates 
virulent on canola). Rapalexin A (22) was added to the fungal cultures of L. maculans 
and also to the uninoculated (control) medium at 0.10 mM. HPLC analysis of neutral, 
basic and acidic extracts revealed that compound 22 was extracted under neutral 
conditions and that no new metabolites were detected. Also, recovery of rapalexin A 
(22) from cultures and from the control samples was comparable (Figure 2.1). These 
results indicated that rapalexin A (22) was not metabolized by L. maculans. So far, 
compound 22 is the third crucifer phytoalexin known to resist transformation by L. 
maculans, after spirobrassinin (27) (Pedras, Jha et al., 2005b) and camalexin (32) 
(Pedras, Jha et al., 2005b). Accumulation of these special phytoalexins in crucifer 
plants might offer additional protection against L. maculans. For this reason, it is 
important to further explore the defence metabolite profiles of crucifers infected with 
the blackleg fungus and identify the metabolites that resist transformation. 
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Figure 2.1 Curves representing the recovery of rapalexin A (22, 0.10 mM) in cultures 
of Leptosphaeria maculans in minimal medium and in control medium.  
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Erucalexin (29), a phytoalexin first isolated from Erucastrum gallicum (Pedras, Suchy 
et al., 2006), contains a spirocylic dithiocarbamate moiety attached to the indolyl 
derived unit at C-2. This compound 29 is a regio isomer of 1-methoxyspirobrassinin 
(28). Erucalexin (29) is known to be antifungal against R. solani and S. sclerotiorum 
(Pedras, Suchy et al., 2006), but compound 29 showed less antifungal activity against 
L. maculans than brassinin (17).  To determine if erucalexin (29) was transformed by L. 
maculans, this compound was incubated with fungal cultures of L. maculans (BJ-125). 
HPLC analyses of the broth extracts of cultures incubated with erucalexin (29) 
collected at different time intervals indicated it to be completely metabolized within 48 
h; two new peaks were detected at tR = 10.0 and 8.5 min. The compound with tR = 10.0 
was identified as demethoxyerucalexin (335) and the compound with tR = 8.5 min as 
dihydroerucalexin (334). Compound 335 appeared to be formed earlier than compound 
334 and in larger amount in cultures of L. maculans in minimal media; however, in 
cultures of L. maculans in water, compound 334 was detected as the major metabolite 
and compound 335 was present in negligible quantities. Attempts to recover compound 
334 from fungal cultures in minimal media resulted in its degradation to 
demethoxyerucalexin (335). Compound 334 could only be recovered from fungal 
cultures in water after freeze drying the broth. Finally, results from biotransformation 
experiments using mycelia of L. maculans in water incubated with erucalexin (29) 
demonstrated that compound 29 was metabolized to compound 334, and that 
compound 335 resulted from its decomposition. 
Confirmation of the structures of metabolites with tR = 10.0 and 9.2 min was carried out 
using spectroscopic data. HPLC-ESI-MS analysis of the samples indicated that the 
metabolite at tR = 10.0 min had a mass of 250.0 Da, which is 30 mass units less than 
erucalexin (29). 
1
H NMR analysis of the broth extract indicated the presence of one 
methyl group and an intact spirocyclic system, as in compound 29. Overall, the 
1
H 
NMR spectral pattern of the compound with tR = 10.0 min was similar to that of 
compound 29 except for the absence of the signal due to N-OMe. Thus, 
demethoxylated product of 29 seemed a probable structure. Upon comparison with a 
synthetic sample of demethoxyerucalexin (335), the unknown metabolite with tR = 10.0 
min was identified as compound 335.  
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HPLC-ESI-MS analysis indicated that the metabolite with tR = 9.2 min had a base peak 
corresponding to 250 Da and a weak fragment at 282 Da. Adequate quantities of this 
metabolite (tR = 9.2 min) were not formed when fungal cultures in minimal media were 
incubated with compound 29. Moreover, demethoxyerucalexin (335) was formed in 
larger amounts before the metabolite with tR = 9.2 min was detected in the cultures. 
Overall, it seemed that erucalexin (29) was transformed to compound with tR = 9.2 min 
via demethoxyerucalexin (335).  However, no formation of demethoxyerucalexin (335) 
was detected when it was incubated in fungal cultures in minimal media. When 
compound 29 was incubated in fungal cultures in water, compound with tR = 9.2 min 
was detected as the major metabolite, with negligible amounts of demethoxyerucalexin 
(335). 
1
H NMR spectrum of freeze-dried extract of the 48 h samples indicated a 
complex mixture of sirodesmins and a distinct spirocyclic system similar to erucalexin 
(29). Attempts to purify the unknown metabolite by FCC on silica gel or alumina were 
unsuccessful, resulting in decomposition of the compound with tR = 9.2 min to 
demethoxyerucalexin (335). Finally, compound with tR = 9.2 min was purified by FCC 
using a reversed phase silica gel column. 
The 
1
H NMR spectrum of the purified metabolite with tR = 9.2 min showed a –SMe 
group, a -OMe group and a spirocyclic system as in compound 29. However, this 
compound showed, relative to the 
1
H NMR spectrum of erucalexin (29), two additional 
peaks at 4.94 and 4.09 ppm, with the peak at 4.09 ppm due to an exchangeable proton. 
HRMS-EI analysis indicated that the unknown metabolite had a molecular formula 
C12H14N2O2S2 which was two mass units higher than erucalexin (29). The probable 
structure of the unknown metabolite was identified as dihydroerucalexin (334) which 
was further confirmed by synthesis. Thus, compound 334 was identified as the product 
of erucalexin (29) reduction by L. maculans. 
Synthesis of dihydroerucalexin (334) using NaBH4 reduction of racemic erucalexin 
(29) resulted in the formation of compounds 334a and 334b as a mixture of 
diastereomers in 3:1 ratio. The major isomer could be isolated in pure form, while the 
minor isomer was purified only up to a 1:1 mixture of diastereomers. Further, it was 
important to determine the stereoselectivity of the reduction of erucalexin (29) in 
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fungal cultures. The 
1
H NMR spectrum of freeze-dried crude extract of the fungal 
cultures incubated with erucalexin (29) indicated two sets of proton signals 
corresponding to the major and minor diastereomers in 2:1 ratio. It was observed that 
the same major product was formed in both chemical and enzymatic reductions of 
racemic erucalexin (29).      
Further, the relative stereochemistry in each diastereomer 334a and 334b was 
established based on the results of nuclear Overhauser effect (NOE) experiments and 3-
D modeling of compound 334 (Figure 2.2). NOE difference experiments were carried 
out using a 3:1 mixture of diastereomers 334a and 334b. When the methine proton of 
the major diastereomer at 4.95 ppm was irradiated, the signal intensity (0.3%) of the 
methylene proton at 4.26 ppm was increased (Part C). Likewise, when the methylene 
proton of the major diastereomer at 4.26 ppm was irradiated, the signal intensity 
(0.05%) of the methine proton at 4.95 ppm was increased (Part D). On the other hand, 
when the methine proton at 5.24 ppm of the minor isomer was irradiated no NOE was 
observed on any of the methylene protons (Part B). Further, atomic distances between 
corresponding methine (Ha/Hb) and methylene protons (HR/HS) in the possible 
diastereomers (2S,3S)-3-dihydroerucalexin (334a) and (2S,3R)-3-dihydroerucalexin 
(334b) revealed that only in compound 334a (and its enantiomer) the two hydrogen 
atoms, i.e. Ha and HS are in proximity (< 3.5 Å)  to experience the NOE (Figure 2.2). 
Consequently, the relative stereochemistry in the major diastereomer was assigned to 
be as in compound (2S,3S)-3-dihydroerucalexin (334a) or its enantiomer, in which Ha 
shares a cis relationship with HS. On the other hand, in the minor isomer (2S,3R)-3-
dihydroerucalexin (334b) (or its enantiomer) the two hydrogens, i.e. Hb and HS, shared 
a trans geometry. The reason for preferential formation of one of the diastereomers 
over the other is not clear.        
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Figure 2.2 Relative stereochemistry in major and minor isomers of compound 334 
determined based on 1-D NOE difference experiments and 3-D models of 
diastereomers (2R,3R)-3-dihydroerucalexin (334a) and (2R,3S)-3-dihydroerucalexin 
(334b). (A) Expansion of the 
1
H NMR spectrum of 334a and 334b;  (B) Irradiation of 
Hb of 334b; (C) Irradiation of Ha of 334a; (D) Irradiation of HS of 334a;  (E) Analysis 
of NOE correlations based on the atomic distances in the models 334a and 334b. 
 
E 
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Time-course metabolism studies revealed that erucalexin (29) was completely 
metabolized within 48 h while dihydroerucalexin (334) remained in the cultures 
(Figure 2.3) and no further metabolite was detected (Scheme 2.7). As described in 
section 1.4, L. maculans (virulent on canola) is capable of producing several 
detoxifying enzymes, although there is no reported example of reduction of any 
cruciferous phytoalexins. Thus, reduction of erucalexin (29) is the first enzymatic 
transformation of its kind observed for L. maculans (virulent on canola).  
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Figure 2.3 Progress curves of the transformation of erucalexin (29, 0.10 mM), 
formation of dihydroerucalexin (334) in mycelial cultures of Leptosphaeria maculans 
in water, and control erucalexin (29) in water. 
Besides, it was not clear if in fungal cultures grown in minimal media, erucalexin (29) 
was transformed to compound 334 and demethoxyerucalexin (335) via two different 
pathways. The degradation of dihydroerucalexin (334) to demethoxyerucalexin (335) 
during its isolation from fungal cultures in minimal media suggested that compound 
334 might be less stable in culture media. To further clarify this issue, control cultures 
of identical concentrations of 334 (0.20 mM) in minimal media and water were 
analyzed by HPLC. Analysis of the samples directly injected suggested that stability of 
compound 334 was similar in minimal media and in water. Next, control cultures of 
dihydroerucalexin (334) in minimal media and water at identical concentrations (0.20 
mM) were extracted with EtOAc and the extract was analyzed by HPLC. Comparison 
of the HPLC chromatograms of the extracts indicated a lower recovery of compound 
(29) 
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334 from minimal media than from water (Figure 2.4). That is, the HPLC 
chromatograms of the extracts showed formation of higher amounts of 
demethoxyerucalexin (335) in minimal media than in water. This might suggest that 
components of the minimal media, e.g. metal ions, could catalyze the decomposition of 
dihydroerucalexin (334). Overall, these results demonstrated that demethoxyerucalexin 
(335) was not a product of erucalexin (29) metabolism by L. maculans (Scheme 2.7). 
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Figure 2.4 Progress curves of the recovery of dihydroerucalexin (334, 0.20 mM) in 
water and minimal media (MM). HPLC analysis was carried out by injecting the 
solutions of compound 334 in water and MM (DI: Direct Injection) or their ethylacetate 
extracts (EtOAc ext).  
 
 
 
Scheme 2.7 (i) Biotransformation of erucalexin (29) by Leptosphaeria maculans and 
(ii) its non-enzymatic conversion. 
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Brussalexin (36), another phytoalexin isolated recently from Brussel sprouts, is known 
to be antifungal against several crucifer pathogens (Pedras, Zheng et al., 2007f) 
including L. maculans. So far, compound 36 is the only cruciferous phytoalexin 
derived from 3-indolylmethanethiol (319). Culture medium incubated with 36 revealed 
that the compound was not stable and was degraded to undetermined products. Further, 
stability studies performed in water determined that brussalexin (36) upon standing in 
aqueous solution decomposed to 3-indolylmethanol (337) via likely intermediate 336, 
over a period of 72 h (t1/2 = 24 h) (Scheme 2.8). Although, under in vitro culture 
conditions compound 36 is not stable, 36 is stable in the infected plant which is 
evidenced by its isolation in reasonable amounts (Pedras, Zheng et al., 2007f). On the 
contrary, if part of the induced brussalexin (36) is degraded to compound 337, further 
conversion of compound 337 to ascorbigen (45) and indole oligomers is expected 
(Agerbirk, Olsen et al., 1998). In this regard, compound 337 was tested for stability in 
water and MM. It was noted that compound 337 was not stable in MM and degraded to 
3,3′-diindolylmethane (<6 h) (338), while transformed in water in very low quantities 
(t1/2>72 h). Hence, the compound 337 was incubated with mycelia of L. maculans in 
water and it was observed that indole-3-carboxaldehyde (74) was also detected besides 
3,3′-diindolylmethane (338), although in trace quantities (<2%). This suggested that 
aldehyde 74 was the enzymatic product of the metabolism of compound 337 by L. 
maculans (Scheme 2.9).   
 
Scheme 2.8 Transformation of brussalexin (36) to 3-indolylmethanol (337). 
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Scheme 2.9 (i) Decomposition of compound 337; (ii) metabolism (traces) of compound 
337 by Leptosphaeria maculans. 
 
2.1.3.2  Metabolism of phytoalexin analogs 
 
 
It is important to explore the compounds that resist metabolism by L. maculans. From 
the examples summarized in section 1.4.2, it is clear that L. maculans can carry out a 
wide range of transformations. In continuation of previous work (Pedras and Okanga, 
2000), dithiocarbamates 96, 111, 320, 325, 327, 331, 342 and dithiocarbonates 153, 
333 bearing 2-indolyl, 3-indolyl, 4-biphenyl, and benzimidazolyl related moieties were 
investigated to determine their metabolism by L. maculans (BJ-125). 
Firstly, the brassinin analog methyl indolyl-3-methylcarbamodithioate (320) having a 
dithiocarbamate group attached to the 3-indolyl moiety was used in the study. This 
compound, being a derivative of 3-indolylmethanethiol (319), is also an analog of 
brussalexin (36). More importantly, compound 320 shares a structural resemblance 
with brassinin (17).  Compound 320 was not stable in aqueous media and degraded to 
3-indolylmethanol (337) (t1/2 = 20 h) (Scheme 2.10).  
 
 
Scheme 2.10 Degradation of compound 320 to 3-indolylmethanol (337). 
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Next, metabolism of isobrassinin (111) in cultures of L. maculans (BJ-125) was 
investigated. Isobrassinin (111) is a regioisomer of brassinin (17) with an attachment of 
the dithiocarbamate side chain to a 2-indolylmethyl moiety. Isobrassinin (111, 0.10 
mM) was completely metabolized within 48 h after incubation (Figure 2.5) in cultures 
of L. maculans (BJ-125). HPLC chromatograms of extracts of samples collected at 24 h 
indicated the presence of a metabolite (tR= 4.6 min) that was transformed to another 
compound (tR = 2.2 min) in 48-72 h. To establish the structures of these metabolites, 
larger scale cultures of L. maculans (isolate BJ-125) incubated with compound 111 
were extracted and the extract was purified by FCC, followed by preparative thin layer 
chromatography (PTLC). Further, metabolites were identified and the pathway of 
biotransformation was established (Scheme 2.11 and scheme 2.12). 
 
 
Scheme 2.11 Biotransformation of isobrassinin (111) by Leptosphaeria maculans. 
 
 
 
 
Scheme 2.12 Biotransformation of 1-methoxyisobrassinin (342) by Leptosphaeria 
maculans. 
 
The structure of the metabolite with tR = 4.5 min was determined by analysis of its 
spectroscopic data. The HRMS-EI spectral data indicated the molecular formula 
C10H8N2O2. 
1
H NMR spectrum indicated the intact 2-substituted indole moiety 
accounting for the structure of Nb-acetyl-2-indolylmethanamine (340). Finally, the 
structure of the metabolite (tR = 4.5 min) was confirmed by comparing with a synthetic 
sample. The metabolite with tR = 2.2 min was identified as indole-2-carboxylic acid 
(341) based on 
1
H NMR spectroscopy and HPLC-DAD comparison with an authentic 
sample. The potential intermediate and the first product of the metabolism of 
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isobrassinin (111) in cultures of L. maculans was proposed  to be 2-
indolylmethanamine (339), However, since compound 339 was not detected in the 
neutral extracts from cultures of  L. maculans incubated with isobrassinin (111), 
samples were basified using 33% NH4OH (pH~11) and extracted in 5% DCM/MeOH. 
The HPLC analysis of the basic extract indicated a peak at tR  = 3.1 min that was 
confirmed to be indole-2-methanamine (339) by comparison with a synthetic sample 
(Pedras, Suchy et al., 2006). HPLC analysis for the transformation of compound 111 to 
339 and 340 showed that the amine 339 was not detected after 48 h and that the acetyl 
amine 340 was not detected after 96 h. Compound 111 was completely metabolized in 
48 h (Figure 2.5). 
Further, to establish the pathway of transformation of isobrassinin (111), 2-
indolylmethanamine (339) and Nb-acetyl-2-indolylmethanamine (340) were separately 
fed to cultures of L. maculans (BJ-125). HPLC chromatograms indicated that amine 
339 was converted to acetamide 340 in 15-24 h.  Compound 340 was completely 
converted to indole-2-carboxylic acid (341) after 96 h. Results of the metabolism of 
isobrassinin (111) indicated that it was metabolized at slower rate than brassinin (48 h 
vs 18 h). It is interesting to note that in cultures of L. maculans (BJ-125), compound 17 
is metabolized to compound 74 through oxidation while its regioisomer 111 is 
transformed to amine 339, through hydrolysis. It was shown that brassinin (17) was 
transformed to 3-indolylmethanamine (76) by a similar transformation in isolates of L. 
maculans (virulent on mustard). The enzyme involved, brassinin hydrolase (BH), has 
been isolated and characterized (Pedras, Minic et al., 2009b). The antifungal activities 
of the products formed during the metabolism of compound 111 by L. maculans 
(virulent on canola) are described in the following section.   
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Figure 2.5 Progress curves of the metabolism of isobrassinin (111, 0.10 mM); 
formation of 2-indolylmethanamine (339) and Nb-acetyl-2-indolylmethanamine (340) 
in cultures of Leptosphaeria maculans grown in minimal media. 
 
Next, 1-methoxyisobrassinin (342) was incubated in cultures of L. maculans (BJ-125). 
HPLC chromatograms of the neutral and basic extracts of the fungal cultures incubated 
with compound 342 were analyzed up to 72 h. HPLC-ESI-MS chromatograms of the 
extract of neutral samples revealed two peaks with tR  = 21.5 min (compound 342) and 
tR  = 8.9 min. The molecular mass of the metabolite with tR  = 8.9 min was 218 Da, 
which suggested the structure of 1-methoxy-Nb-acetyl-2-indolylmethanamine (344). 
HPLC analysis of the basic extracts of the samples indicated the presence of 1-
methoxy-2-indolylmethanamine (343). It was also observed that acetamide 344 
accumulated in fungal cultures incubated with 1-methoxyisobrassinin (342) and no new 
metabolite was observed. To clarify if compound 344 is the final biotransformation 
product of 342 in L. maculans, it was incubated with fungal cultures and HPLC 
analysis of samples up to 72 h was conducted. These experiments revealed that 
compound 344 was not transformed. Thus, the pathway of biotransformation of 
compound 342 resembles that of compound 111 except for the final step (Scheme 2.11 
and scheme 2.12). The progress curves representing the metabolism of compound 342 
and its metabolites are depicted in figure 2.6.  These transformations support the earlier 
observations that L. maculans does not transform aromatic rings. 
 
Time (h) 
C
o
n
c 
(m
M
) 
(111) 
(339) 
(340) 
   
71 
 
0
0.02
0.04
0.06
0.08
0.1
0 12 24 36 48 60 72
1-Methoxyisobrassinin
1-Methoxy Nb-acetyl-2-indolylmethanamine
1-Methoxy-2-indolylmethanamine
 
 
Figure 2.6 Progress curves of the metabolism of 1-methoxyisobrassinin (342, 0.10 
mM); formation of 1-methoxy-2-indolylmethanamine (343) and 1-methoxy-Nb-acetyl-
2-indolylmethanamine (344) in cultures of Leptosphaeria maculans grown in minimal 
media. 
 
Previous studies (Pedras and Okanga, 2000) had shown that methyl 
tryptaminedithiocarbamate (96) was metabolized in cultures of L. maculans in a 
pathway different from that of brassinin (17). The sequence of steps involved in the 
detoxification of compound 96 was established; however, a time-course study of the 
metabolism of the compound 96 had not been published. Since such studies are 
important for comparison of the rates of metabolism among different phytoalexin 
analogs, compound 96 was incubated with cultures of L. maculans (BJ-125). Neutral, 
acidic and basic extracts of the samples collected at different time intervals were 
analyzed by HPLC and the metabolites 155, 345-347 were detected and quantified 
(Figure 2.7). The Results confirmed the previous observations that methyl 
tryptaminedithiocarbamate (96) is metabolized via two different pathways (Scheme 
2.13). Compound 345 was found to be a major product of metabolism, while compound 
346 was also detected in reasonable amounts in cultures of L. maculans (BJ-125) 
incubated with compound 96.  
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Scheme 2.13 Biotransformation of methyl tryptaminedithiocarbamate (96) by 
Leptosphaeria maculans (Pedras and Okanga, 2000). 
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Figure 2.7 Progress curves of the metabolism of methyl tryptaminedithiocarbamate 
(96, 0.10 mM); formation of tryptamine (155), methyl 3a-hydroxy-3,3a,8,8a-
tetrahydropyrrolo[2,3-b]indol-1(2H)-yl carbodithioate (345) and Nb-acetyltryptamine 
(346) in cultures of Leptosphaeria maculans grown in minimal media. 
 
Next, methyl 3-(3-indolyl)propyldithiocarbamate (325) was added to cultures of L. 
maculans. Compound 325 is a homologue of brassinin (17) with two additional 
methylene units. Analysis of the HPLC and ESI-MS chromatograms of the neutral, 
acidic and basic extracts of the samples indicated that the products of transformation 
are compounds 95, 324 and 348. Unlike the homologue of brassinin, i.e. compound 96, 
there was only one pathway detected in fungal cultures incubated with compound 325 
(Scheme 2.14). Compound 325 was completely metabolized in 72 h (Figure 2.8). 
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Comparison of the metabolism rates of homologues of brassinin 96 and 325 in cultures 
of L. maculans (BJ-125) indicated that compound 96 was metabolized more slowly 
than compound 325. It is likely that 96, being highly antifungal against L. maculans, 
this compound induces multiple enzymes for faster detoxification of the same 
compound. This allows the fungus to be in contact with the antifungal compound for a 
minimum time.     
 
 
Scheme 2.14 Biotransformation pathway of methyl 3-(3-indolyl)propyldithiocarbamate 
(325) by Leptosphaeria maculans. 
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Figure 2.8 Progress curves of the metabolism of methyl 3-(3-
indolyl)propyldithiocarbamate (325, 0.10 mM); formation of 3-indolylpropanamine 
(324) and Nb-acetyl-3-indolylpropanamine (348) in cultures of Leptosphaeria maculans 
grown in minimal media. 
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In addition to the indolyl analogs, dithiocarbamates bearing non-indolyl moieties were 
also analyzed for metabolism in L. maculans. Compound 327 has the dithiocarbamate 
functional group as part of the benzimidazole ring system. The compound showed very 
high antifungal activity against L. maculans (BJ-125) at the concentrations (0.50, 0.20, 
0.10 mM) tested, and is more antifungal than brassinin (17). Compound 327 was 
incubated with cultures of L. maculans and samples were withdrawn up to 96 h. HPLC 
chromatograms of EtOAc extract of each sample indicated a new metabolite at tR 4.2 
min. Comparison with an authentic sample confirmed that the metabolite was 
benzimidazole (326), which was not metabolized (Scheme 2.15) [confirmed by analysis 
of fungal cultures incubated with benzimidazole (326)]. In contrast to the primary 
amines 155, 324, 339 and 343 which are first products of dithiocarbamate metabolism, 
benzimidazole (326) is a secondary amine part of the aromatic system. It is likely that 
the fungal enzyme responsible for acetylation is ineffective in transforming compound 
326. Compound 327 was not detected in cultures of L. maculans (BJ-125) 72 h after the 
incubation, while 326 accumulated in the cultures up to 72 h (Figure 2.9). These results 
suggest that enzymatic acetylation of amines takes place only in substrates fulfilling 
specific structural requirements.  
 
Scheme 2.15 Biotransformation pathway of methyl benzimidazolyldithiocarbamate 
(327) by Leptosphaeria maculans in minimal media. 
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 Figure 2.9 Progress curves of the metabolism of methyl 
benzimidazolyldithiocarbamate (327, 0.10 mM) and formation of benzimidazole (326) 
in cultures of Leptosphaeria maculans grown in minimal media. 
 
 
 
 
Scheme 2.16 Biotransformation pathway of methyl 4-biphenyldithiocarbamate (331) 
by Leptosphaeria maculans. 
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Figure 2.10 Progress curves of the metabolism of methyl 4-biphenyldithiocarbamate 
(331, 0.10 mM) and formation of N-acetyl-4-biphenylmethanamine (349) in cultures of 
Leptosphaeria maculans grown in minimal media. 
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Finally, methyl 4-biphenyldithiocarbamate (331) was incubated with cultures of L. 
maculans (BJ-125) and samples were withdrawn at different time intervals and 
analyzed by HPLC. HPLC chromatograms of the neutral, acidic and basic extracts of 
samples indicated a major metabolite with tR = 18.3 min. HPLC-ESI-MS analysis of 
the metabolite followed by comparison with an authentic sample obtained by synthesis 
indicated that the metabolite was N-acetylbiphenylmethanamine (349). However, the 
first product of metabolism of 4-biphenylmethanamine (330) was not detected, 
probably due to its immediate conversion to compound 349. Moreover, N-
acetylbiphenylmethanamine (349) was not metabolized to any other product. The 
pathway of metabolism of compound 331 in L. maculans is shown in scheme 2.16. 
Compound 331 was rapidly metabolized within 48 h, although it was detected in 
cultures in very low quantities up to 96 h. Accumulation of compound 349 was 
observed after 24 h period (Figure 2.10).  Results of the metabolism of indolyl and 
nonindolyl dithiocarbamates 111, 320, 325, 327, 331 and 342 suggested that the crucial 
first step in their detoxification process involves a hydrolysis reaction catalyzed by a 
hydrolase(s).       
Next, indolyldithiocarbonates 153 and 333 were tested. Previous studies had suggested 
that methyl tryptopholdithiocarbonate (153) was metabolized to tryptophol (156) in 
cultures of L. maculans (Pedras and Jha, 2006). To further compare this transformation 
with compound 17, compound 153 was incubated with cultures of L. maculans and 
EtOAc extracts of the samples collected at different time periods were analyzed by 
HPLC. HPLC chromatograms indicated that compound 153 was not detected after 48 h 
and tryptophol (156) accumulated in the cultures up to 96 h (Figure 2.11). To verify if 
compound 156 is the final product in the pathway of tryptopholdithiocarbonate (153) 
metabolism, tryptophol was incubated with the cultures of L. maculans (BJ-125). Time 
course studies indicated that tryptophol (156) is further converted to indole-3-acetic 
acid (347), but at a very slow rate (Scheme 2.17). More than 50% of tryptophol (156) 
was detected in cultures of L. maculans at 72 h after incubation. 
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Scheme 2.17 Biotransformation of methyl tryptopholdithiocarbonate (153) by 
Leptosphaeria maculans. 
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Figure 2.11 Progress curves of the metabolism of tryptophol dithiocarbonate (153, 
0.05 mM) and formation of tryptophol (156) in cultures of Leptosphaeria maculans 
grown in minimal media. 
 
Next, indolyldithiocarbonate 333 was incubated with cultures of L. maculans. 
Compound 333 is a homologue of compound 153 with one additional methylene unit. 
HPLC chromatograms of the neutral extract samples up to 72 h indicated the presence 
of a new metabolite with tR = 7.2 min. Comparison of this metabolite with a standard 
sample indicated that it was 3-(3-indolyl)-1-propanol (332), which was metabolized to 
indole-3-propanoic acid (95). The sequence of steps involved in the metabolism of 
compound 333 by L. maculans is shown in scheme 2.18. However, compound 333 was 
metabolized faster in cultures of L. maculans than compound 153 (24 h vs 72 h, figure 
2.11 and figure 2.12). Comparison of the detoxification pathways of the compounds 
153 and 333 (Scheme 2.17 and scheme 2.18) showed that hydrolysis is the key reaction 
in the metabolism of indolyldithiocarbonates.  
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 Figure 2.12 Progress curves of the metabolism of methyl 3-(3-
indolyl)propyldithiocarbonate (333, 0.05 mM); formation of 3-(3-indolyl)propanoic 
acid (95) and 3-(3-indolyl)-1-propanol (332) in cultures of Leptosphaeria maculans 
grown in minimal media. 
 
 
 
Scheme 2.18 Biotransformation of methyl 3-(3-indolyl)propyldithiocarbonate (334) by 
Leptosphaeria maculans. 
 
2.1.4 Synthesis and antifungal activity of metabolites 
2.1.4.1 Synthesis  
 
Dihydroerucalexin (334) is a product of erucalexin (29) metabolism in L. maculans. 
The structure of the metabolite was confirmed after comparison of the analytical data 
with a synthetic sample. Compound 334 was synthesized by reduction of erucalexin 
(29) in presence of NaBH4 in methanol in 60% yield (Scheme 2.19) as a 3:1 mixture of 
diastereomers. Compound 334 was purified on reversed phase column (C18), as it was 
unstable on silica gel and neutral alumina.  
Synthesis of the tricyclic compound 345 was carried out as previously reported (Pedras 
and Okanga, 2000). 3-(3-Indolyl)propanol (332) was synthesized starting from indolyl-
3-propanoic acid (95) as shown in the scheme 2.10. Amines 324, 330, 339 and 343 are 
Time (h) 
C
o
n
c 
(m
M
) 
(333) 
(332) 
(95) 
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synthetic precursors to dithiocarbamates and their preparation procedures are as 
described in the experimental section. Nb-Acetyltryptamine (346) was synthesized as 
previously reported (Pedras and Okanga, 2000) in 91% yield. Other acetylamines 340, 
344, 348 and 349 were prepared according to the general procedure (Scheme 2.20) by 
simple acetylation of amines using Pyr / Ac2O in 74-90% yields.  
 
 
 
Scheme 2.19 Synthesis of dihydroerucalexin (334).  Reagents and conditions: (i) 
NaBH4, MeOH, 0 °C, 60%; 
 
 
 
Scheme 2.20 Synthesis of acetamides 340, 344, 348 and 349.  Reagents and conditions: 
(i) Pyr, Ac2O, DCM, 0 °C, 74-90%. 
 
 
2.1.4.2 Antifungal activity  
To determine if compounds 29, 96, 111, 153, 320, 325, 327, 331, 333 and 342 were 
metabolized by L. maculans through detoxification pathways, the antifungal activities 
of metabolites 95, 155, 156, 324, 326, 330, 334, 339-341, 343, 344 and 346-349 against 
L. maculans were determined using the mycelia radial growth bioassay reported in the 
experimental (Pedras and Jha, 2006). The results are averages of experiments 
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conducted in triplicates, at least twice. As seen from several examples in section 2.1.3.1 
and 2.1.3.2, L. maculans is capable of metabolizing many of the antifungal compounds.     
Comparison of the antifungal activities suggested that compound 29 (0.50 mM) showed 
about 40% inhibition of fungal growth, while compound 334 (0.50 mM) showed only 
about 23% inhibition. Thus, metabolism of compound 29 (Scheme 2.7) was identified 
as a detoxification process in L. maculans. It is worth highlighting that compound 29 is 
known to inhibit BO, a detoxifying enzyme involved in detoxification of brassinin (17) 
(Pedras, Minic et al., 2008a).          
Further, antifungal activities of compound 111 and metabolites 339 and 340 against L. 
maculans (BJ-125) were compared. The results established that the inhibitory activity 
decreased as follows: 111 > 339 > 340 (Table 2.1). Since the metabolites 339 and 340 
were less antifungal than compound 111, metabolism of compound 111 by L. maculans 
(BJ-125) was a detoxification process. A metabolic detoxification of compound 111 
was earlier reported in S. sclerotiorum (Pedras and Hossain, 2006), although to a 
different product. Similarly, antifungal assays of compound 342 and metabolites 343 
and 344 against L. maculans (BJ-125) established the decreasing order of inhibitory 
activity as follows: 342 > 343 > 344 (Table 2.1). Thus, metabolism of compound 342 
by L. maculans (BJ-125) (Scheme 2.12) was also determined to be a detoxification 
process. Further, the antifungal activity of compound 96 with those of metabolites 155 
and 345-347 was compared. The higher antifungal activity of compound 96 compared 
to its products 155 and 345-347 confirmed that its metabolism is a detoxification 
process, as reported earlier (Pedras and Okanga, 2000).  Next, the products of 325 
metabolism by L. maculans, 95, 324 and 348 displayed their antifungal activities in the 
following order: 95 < 348 < 324, suggesting a detoxification process. Further, the 
antifungal activities of the nonindolyl dithiocarbamates and their metabolic products 
followed a similar trend as above, indicating their detoxification by L. maculans. This 
was evident from the relative antifungal activity of each compound, 327 > 326, and 331 
> 349.  
Finally, the products from the metabolism of dithiocarbonates 153 and 333, 156 and 
332 respectively, displayed lower antifungal activities than the parent compounds. On 
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this basis, it was concluded that the metabolism of indolyldithiocarbonates 153 and 333 
is a detoxification. Antifungal activities of the respective transformation products 95, 
155, 156, 324, 326, 330, 332, 334, 339-341, 343, 344 and 346-349 against L. maculans 
are summarized in table 2.2. 
 
Table 2.2 Percentage of growth inhibition
a
 of Leptosphaeria maculans incubated with 
metabolites 95, 155, 156, 324, 326, 330, 332, 334, 339-341, 343, 344 and 346-349. 
 
Compound Inhibition ± SD (%)
a
 
0.50 mM 0.20 mM 0.10 mM 
3-(3-Indolyl)propanoic acid (95) 78 ± 2 67 ± 4 41 ± 5 
Tryptamine (155) 28 ± 2 15 ± 5 12 ± 3 
Tryptophol (156) 28 ± 5 16 ± 4 n.i. 
3-Indolylpropanamine (324) 27 ± 5 14 ± 4 n.i. 
Benzimidazole (326) 45 ± 7 28 ± 4 15 ± 2 
4-Biphenyl methanamine (330) 
3-(3-Indolyl)-1-propanol (332) 
n.s. 
18 ± 2 
n.s. 
14 ± 3 
n.s. 
7 ± 2 
Dihydroerucalexin (334) 23 ± 2 13 ± 2 7 ± 2 
2-Indolylmethanamine (339) 33 ± 2 19 ± 4 n.i 
Nb-Acetyl-2-indolylmethanamine (340) 33 ± 4 18 ± 2 7 ± 2 
Indole-2-carboxylic acid (341) 19 ± 2 7 ± 2 n.i 
1-Methoxy-2-indolylmethanamine (343) 19 ± 3 8 ± 3 n.i 
Nb-Acetyl-1-methoxy-2-indolylmethanamine 
(344) 
30 ± 3 11 ± 3 4 ± 2 
Nb-Acetyltryptamine (346) 15 ± 3 7 ± 2 n.i 
Indole-3-acetic acid (347) 32 ± 3 17 ± 5 10 ± 3 
Nb-Acetyl-3-3-(3-indolyl)propanamine (348) 24 ± 3 13 ± 4 10 ± 3 
N-Acetyl-4-biphenylmethanamine (349) 30 ± 5 14 ± 4 9 ± 4 
a
 The percentage of inhibition was calculated using the formula: % inhibition = 100 – [(growth on 
amended/growth in control) × 100]; n.i.= no inhibition; n.s.= not soluble. 
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2.1.5 Conclusions 
In summary, the metabolic pathways of brassinin analogs dithiocarbamates 96, 111, 
320, 325, 327, 331, 342 and dithiocarbonates 153, 333 appear to be similar, involving 
hydrolysis as the key step followed by further transformations. Rates of metabolism of 
the compounds 29, 96, 111, 153,  320, 325, 327, 331, 333 and 342 compared to 
compound 17 were different; there was no correlation between the metabolic rates and 
the antifungal activity of the compounds as previously observed in S. sclerotiorum 
(Pedras and Hossain, 2006). Slower metabolic rates of compound 342 relative to 320, 
compound 96 relative to 325, and compound 153 relative to 333 might suggest that the 
hydrolase(s) likely catalyzing these transformations are not very selective and accept a 
wide range of substrates. Metabolites 95, 155, 156, 324, 326, 330, 334, 339-341, 343, 
344 and 346-349 displayed lower antifungal activities against L. maculans compared to 
their respective parent compounds 29, 96, 111, 153,  320, 325, 327, 331, 333 and 342. 
Thus, metabolism of the phytoalexin analogs 96, 111, 153, 320, 325, 327, 331, 333, 
342 and the phytoalexin 29 were identified as detoxification reactions by L. maculans. 
Rapalexin A (22) was found to be resistant to metabolism by L. maculans. Results of 
these biotransformation experiments are summarized below in table 2.3.  
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Table 2.3 Products of metabolism in cultures of Leptosphaeria maculans incubated 
with phytoalexins 17, 22, 29, 36 and analogs 96, 111, 153, 320, 325, 327, 331, 333 and 
342.  
Compound incubated with 
cultures/ Antifungal activity 
(%)
b
 at 0.50 mM 
Recovery 
at 24 h 
Major products of metabolism, molar %
a
 
(time in h) / Antifungal activity (%)
b
 at 
0.50 mM 
Brassinin (17)/ 55 ± 3 < 5% Indole-3-carboxaldehyde (74) 
Rapalexin-A (22)/ c.i. 65% No metabolism 
Erucalexin (29)/ 40 ± 4 n.d. Dihydroerucalexin (334), 33% (48)/ 23 
± 2 
Brussalexin (36)
c
/ 43 ± 3 < 50%
c
 Not stable
d
 
Methyl 
trytaminedithiocarbamate (96)/ 
c.i. 
55% Methyl 3a-hydroxy-3,3a,8,8a-
tetrahydropyrrolo[2,3-b]indol-1(2H)-yl 
carbodithioate (345), 38% (72)/ 5 ± 1 
Nb-Acetyltryptamine (346), 20% (72)/ 
15 ± 3  
Isobrassinin (111)/ 44 ± 4 < 5% Nb-Acetyl-2-indolylmethanamine (340), 
30% (48)/ 33 ± 4  
Tryptophol dithiocarbonate 
(153)/ 30 ± 3 
15% Tryptophol (156), 32% (24)/ 28 ± 5 
Methyl indolyl- 
3-methylcarbamodithioate 
(320)
c
/ 61 ± 5 
~30%
c
 Not stable
d
 
Methyl 3-(3-
indolyl)propyldithiocarbamate 
(325)/ 67 ± 3 
37% Nb-Acetyl-3-(3-indolyl)propanamine 
(348), 6% (24)/ 24 ± 3 
Methyl benzimidazolyl 
dithiocarbamate (327)/ c.i. 
10% Benzimidazole (326), 62% (24)/ 45 ± 7 
Methyl 4-biphenyl 
dithiocarbamate (331)/ 46 ± 4 
< 5% N-Acetyl-4-biphenylmethanamine 
(349), 21% (72)/ 30 ± 5 
Methyl 3-(3-
indolyl)propyldithiocarbonate 
(333)/ 32 ± 4 
n.d. 3-(3-Indolyl)-1-propanol (332), 60% 
(24)/ 18 ± 2 
1-Methoxyisobrassinin (342)/ 
34 ± 3 
47% Nb-Acetyl-1-methoxy-2-
indolylmethanamine (344), 37% (48)/ 
30 ± 3 
a
 Percentages were determined using a calibration curve and are average of experiments conducted in 
triplicates ± standard deviation; 
b
 percentages were determined using the formula: % inhibition = 100 – 
[(growth on amended/growth in control) × 100]; 
c
 compounds were tested in media alone and found not 
stable; 
d
 degraded to 3-indolylmethanol (337); c.i. = complete inhibition; n.d. = not detected. 
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2.2 Brassinin detoxification inhibitors 
 
 
The design of inhibitors of brassinin detoxification is a challenging task. It took a great 
deal of work to identify inhibitors of BOLm. Among 80 compounds tested, analogs of 
brassinin (17) and related compounds (Appendix A1D), none inhibited BOLm activity 
(Pedras, Minic et al., 2008a). Screening of libraries of natural products and additional 
synthetic compounds (Section 1.4.3) led to the identification of the first inhibitors of 
BOLm (Pedras, Jha et al., 2007c). Optimization of the lead structures, especially 
brassilexin (30) (Pedras, Minic et al., 2010a) and camalexin (32) (Pedras, Minic et al., 
2009d) resulted in more potent inhibitors of BOLm (Appendix). Most of the known 
inhibitors of BOLm have indolyl or related moieties with relevant substitution at 
positions 2, 3, 5 and 6. It was shown that compound 168 containing a 2-naphthylyl 
moiety was also a potent inhibitor of BOLm (Pedras, Minic et al., 2009d). Since the 
additional number of compounds of interest that could be synthesized based on the 
indolyl and napthylyl moieties are limited, a replacement of these skeletons was looked 
for. Replacement of the heterocyclic moiety in the lead structure with a different 
hetero-aromatic unit is a general strategy explored in lead-optimization studies 
(Giardina, Artico et al., 1999). As seen in section 1.5, a similar strategy was adopted to 
produce some of the agrochemicals discussed.     
Here, it was thought to explore non-indolyl heteroaromatic systems in lead 
optimization studies. Assuming that indolyl and naphthylyl skeletons have sizes that 
are suitable for entry to the active site of BOLm, a hybrid of these moieties, i.e. a 
quinoline/ isoquinoline was chosen to produce potential inhibitors of BOLm. Two 
groups of potential inhibitiors were designed: (i) the first group of inhibitors containing 
thiazole and phenyl moieties attached to the substituted quinoline skeleton and (ii) the 
second group of inhibitors containing thiazole and phenyl moieties attached to the 
substituted isoquinoline skeleton (Figure 2.13). Compounds 353, 358, 360, 363, 364 
and 366 are new compounds. Next, the synthesis of the compounds 350-366 was 
undertaken, as described below.   
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Figure 2.13 Potential brassinin detoxification inhibitors 350-366. 
 
 
2.2.1 Synthesis 
2.2.1.1  Synthesis of quinoline derivatives 
Synthesis of 350 was carried out according to a published procedure (Dondoni, Dall’ 
Occo et al., 1984) in comparable yield, as reported in the experimental.  
Starting material 368 was prepared according to a reported procedure (Alford and 
Schofield, 1952). Nitration of 3-bromobenzaldehyde (367) with HNO3/H2SO4 afforded 
the required product 368 (Scheme 2.21). Synthesis of the 2-phenylquinolines 351-356 
followed a general procedure (Li, Ahmed et al., 2007).  Substituted 2-
nitrobenzaldehydes 368-373 were reduced in the presence of Fe/HCl and the 
intermediates were treated with acetophenone in presence of KOH to afford the desired 
compounds 351-356 (Scheme 2.21). This reaction can be applied to wide range of 
substrates and is probably a more efficient way to obtain 2-phenylquinolines than the 
alternative routes involing cross-coupling reactions (Vuoti, Autio et al., 2008). 
Synthesis of the 3-phenylquinolines 357-361 followed a general procedure (Li, Ahmed 
et al., 2007). Similarly, substituted 2-nitrobenzaldehydes 369-373 were reduced in the 
presence of Fe/HCl and the intermediates were treated with phenylacetaldehyde in 
presence of KOH to afford the desired compounds 357-361 (Scheme 2.21). Reactions 
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involving the substrate 372 leading to the products 355 and 360 were low yielding, 
whereas similar reactions involving the substrate 373 leading to compounds 356 and 
361 afforded higher yields. Overall, the one-pot reactions yielded the 2- and 3-phenyl 
substituted quinolines in moderate to good yields.    
 
 
Scheme 2.21 Synthesis of compounds 351-361. Reagents and conditions: (i) 
HNO3/H2SO4, 0-5 °C, 68% (Alford and Schofield, 1952); (ii) Fe/HCl, EtOH; (iii) 
KOH, acetophenone, 42-83%; (iv) KOH, PhCH2CHO, 39-80%. 
 
2.2.1.2  Synthesis of isoquinoline derivatives  
 
Intermediates 377 and 378 were prepared by a modification of the Pomeranz-Fritsch 
reaction used for preparation of isoquinolines (Jiang, Duckett et al., 2007). Substituted 
benzaldehydes 367 and 374 were treated with aminoacetaldehyde dimethyl acetal 
(Dean-Stark conditions) and the imine acetal intermediates 375 and 376 were cyclized 
in the presence of H2SO4 and P2O5 to yield substituted isoquinolines 377 and 378. The 
reaction yields over two steps were in the range 10-20% and were lower than those 
reported earlier (Jiang, Duckett et al., 2007; Czako, Kurti et al., 2009). Finally, 
synthesis of compounds 362-364 was carried out starting from compounds 377-379 
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using the same procedure adopted for the synthesis of compound 362 (Dondoni, Dall’ 
Occo et al., 1984) (Scheme 2.22).  
 
 
     
Scheme 2.22 Synthesis of compounds 362-364. Reagents and conditions: (i) 
aminoacetaldehyde dimethyl acetal, toluene, reflux (Dean-Stark); (ii) P2O5, H2SO4, 160 
°C, 15-20% (Czako, Kurti et al., 2009); (iii) ClCO2Et, DCM, 2-trimethylsilylthiazole, 
r.t.; (iv) o-chloranil, toluene, reflux, 15-32%. 
 
Starting material 383 was synthesized according to a reported procedure (Alcock, 
Wirth et al., 1993) and compound 384 was purchased from Alfa Aesar. Syntheses of 1-
phenylisoquinolines 365 and 366 were carried out using modification of a general 
procedure (Korn, Schade et al., 2006). Substituted 1-chloroisoquinolines 383 and 384 
were treated with iodine followed by PhMgCl and Fe powder in THF to afford the 
desired compounds 365 and 366. Addition of iodine to the reaction mixture was an 
extra step towards the modification of the reported procedure, which failed to yield the 
product. Ideal conditions for better yields employed the following stoichiometry of 
chemicals: substituted 1-chloroisoquinoline (1eq), iodine (1 eq), PhMgCl (1.2 eq), and 
Fe powder (2 eq) (Scheme 2.23). On the other hand, 1-phenylisoquinolines can also be 
prepared by cross-coupling reactions (Jin, Gu et al., 2011; Tian, Lenkeit et al., 2010). 
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Scheme 2.23 Synthesis of compounds 365 and 366. Reagents and conditions: (i) I2, 
THF; (ii) PhMgCl, Fe, THF (Korn, Schade et al., 2006). 
 
2.2.2 Antifungal activity  
 
The antifungal activity of compounds 350-366 was determined against L. maculans 
(isolate BJ-125) using a mycelia radial growth bioassay as previously described. The 
results are the averages of experiments carried out in triplicates, at least twice. Results 
showed that compounds 355, 357, 361, 362 and 364 displayed higher antifungal 
activity against L. maculans than brassinin (17). Among these, compounds 357, 361 
and 362 inhibited the blackleg fungal growth completely.  Compounds 350, 351, 361 
and 365 showed antifungal activity similar to that of brassinin (17) at 0.50 mM. 
Compounds 352-354, 356, 358 and 359 showed lower antifungal activity than brassinin 
(17) against L. maculans. There seemed to be no general trend regarding structure-
activity relationship. Among substituted 3-phenylquinolines, compounds 358 and 359 
with Cl substitution at position 5 and 6 of 3-phenylquinoline moiety displayed lower 
antifungal activities than the parent compound 357. The antifungal activity of 
compounds 360 and 361 was higher than brassinin (17), but lower than that of the 
parent unsubstituted compound 357. All the substituted 2-phenylquinolines were less 
inhibitory against L. maculans than the parent unsubstituted compound 351 and 
brassinin (17), except compound 355. Compound 362 displayed higher antifungal 
activity than compound 350. Compounds 363 and 364 with Br substitution at positions 
6 and 7 of the 1-(thiazol-2-yl)isoquinoline (362) moiety displayed lower antifungal 
activities than the parent compound 362, but both the compounds 363 and 364 were 
more inhibitory against L. maculans than brassinin (17). 7-Bromo-1-phenylisoquinoline 
(366) displayed less antifungal activity than compound 365. Antifungal activities of the 
compounds 350-366 are summarized in table 2.4. 
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Table 2.4 Percentage of growth inhibition
a
 of Leptosphaeria maculans incubated with 
potential brassinin (17) detoxification inhibitors 350-366 (5 days, constant light). 
 
Compounds  Inhibition ± SD (%)
a
 
0.50 mM 0.20 mM 0.10 mM 
Brassinin (17) 62 ± 4 25 ± 3 12 ± 4 
2-(Thiazol-2-yl) quinoline (350) 54 ± 3 46 ± 4 8 ± 3 
2-Phenylquinoline (351) 54 ± 2 31 ± 4 16 ± 5 
6-Bromo-2-phenylquinoline (352) 27 ± 4 14 ± 4 n.i. 
5-Chloro-2-phenylquinoline (353) 39 ± 2 18 ± 4 9 ± 2 
6-Chloro-2-phenylquinoline (354) 26 ± 4 18 ± 5 5 ± 2 
6-Hydroxy-2-phenylquinoline (355) 68 ± 5 42 ± 4 32 ± 4 
6-Methoxy-2-phenylquinoline (356) 36 ± 4 20 ± 4 8 ± 2 
3-Phenylquinoline (357) c.i. 77 ± 4 39 ± 7 
5-Chloro-3-phenylquinoline (358)  17 ± 3 11 ± 2 8 ± 4 
6-Chloro-3-phenylquinoline (359) 28 ± 3  17 ± 3 5 ± 2 
6-Hydroxy-3-phenylquinoline (360) 73 ± 5 45 ± 4 30 ± 4 
6-Methoxy-3-phenylquinoline (361) c.i. 68 ± 5 55 ± 5 
1-(Thiazol-2-yl)isoquinoline (362) c.i. c.i. 52±4 
6-Bromo-1-(thiazol-2-yl)isoquinoline (363) 75 ± 6 54 ± 3 15 ± 4 
7-Bromo-1-(thiazol-2-yl)isoquinoline (364) 82 ± 5 63 ± 3 25 ± 6 
1-Phenylisoquinoline (365) 54 ± 5 32 ± 4 30 ± 3 
7-Bromo-1-phenylisoquinoline (366) 47 ± 3 31 ± 4 12 ± 2 
a
 The percentage of inhibition was calculated using the formula: % inhibition = 100 – [(growth on 
amended/growth in control) × 100]; c.i. = complete inhibition; n.i.= no inhibition. 
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2.2.3 Screening for inhibition of brassinin detoxification 
 
Screening of potential inhibitors of brassinin detoxification can be performed using 
fungal cultures or the purified detoxifying enzyme, BOLm. Both studies are necessary 
for preliminary identification of inhibitors of brassinin detoxification. In particular, 
screening of the potential inhibitors in fungal cultures is important because it would 
give information about their effect on brassinin detoxification as well as the stability of 
compounds in vivo.  Thus, results of screening studies in fungal cultures are useful in 
providing the information about interesting compounds that can be used in enzymatic 
screening. In the current thesis, studies related to screening of the potential inhibitors in 
fungal cultures are discussed. 
Previously, brassinin (17) was co-incubated with compounds 153, and 157-159 (0.1 
mM) in 48 h-old cultures of L. maculans (10
6
/ml) (Pedras and Jha, 2006).  It was 
observed that brassinin (17, 0.10 mM) was metabolized at slower rates (> 15 h) in 
presence of compounds 153, and 157-159 than in control cultures (0.10 mM, 15 h). It 
was hypothesized that slower metabolism of brassinin (17) in the presence of tested 
compounds could be due to: (i) inhibition of brassinin detoxification or/ and (ii) 
inhibition of fungal growth. Thus, knowledge of the antifungal activities of the 
potential inhibitors, and effect of these compounds on brassinin metabolism in fungal 
cultures was important for preliminary evaluation. On this basis, compounds 153, 157-
159, that showed low inhibition of the growth of L. maculans but a significant effect in 
inhibition of brassinin detoxification, were considered as compounds of interest for 
paldoxin design (Pedras and Jha, 2006).  Later on, in vitro screening using purified 
BOLm determined that compounds 153 and 157-159 were not inhibitors of BOLm 
(Pedras, Jha et al., 2007c).  
On the other hand, camalexin (32), a phytoalexin which did not inhibit brassinin 
detoxification in fungal cultures (Pedras, Jha et al., 2005b), was determined to be an 
inhibitor of BOLm (Pedras, Jha et al., 2007c). Camalexin (32) was not identified as 
inhibitor of brassinin detoxification from screening studies in fungal cultures because 
compound 32 was both inducer and inhibitor of BOLm (Pedras, Minic et al., 2009c). 
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Because, induction and inhibition of BOLm occurred simultaneously, it was likely that 
the fungal culture conditions in which brassinin (17, 0.10 mM) was quickly 
metabolized (15 h) might not be discriminative. It was thought that slower rates of 
brassinin metabolism (detection up to 48 h instead of 15 h) may be required to detect 
the inhibitory effect of compounds like camalexin (32). Thus, better conditions for the 
screening of potential inhibitors of brassinin detoxification in fungal cultures were 
explored. 
2.2.3.1 Optimization of screening method 
 
Several experiments were carried out to optimize the screening conditions to 
specifically slow down the rate of brassinin metabolism in fungal cultures. Since the 
rate of brassinin metabolism is dependent on the amount of mycelia mass present in 
fungal cultures, conditions that stabilized the mycelia mass were first tried. It was 
predicted that addition of brassinin (17) and other inducers of BOLm to the fungal 
cultures in the exponential growth phase might induce the detoxifying enzyme of L. 
maculans rapidly, leading to faster metabolism of brassinin (17). Supportingly, it was 
observed that the rate of brassinin (17) metabolism was not decreased when 
exponentially growing mycelial cultures were co-incubated with camalexin (32), an 
inducer and inhibitor of BOLm (Pedras, Jha et al., 2005). On the other hand, it was 
observed that growth of the mycelia was inhibited if the toxic potential inhibitors and 
brassinin (17) were added to the fungal cultures in the exponential growth phase 
(Pedras and Jha, 2006). Thus, in order to establish a new screening protocol, culture 
conditions that do not allow rapid growth of the mycelia were employed. 
Minimal media was inoculated with 10
6
/ml spores and incubated for 7 d. After 7 d, 
mycelia were transferred to water and the cultures in water were incubated with 
brassinin (17, 0.1 mM) either immediately or after 24 h. In either case, metabolism of 
brassinin (17, 0.1 mM) was faster than in the original experiments (Pedras and Jha, 
2006) (15 h); i.e. the compound was not detected after 6 h. Further, cultures of L. 
maculans (BJ-125, 10
4
/ml) were grown in minimal media for 5 days and mycelia were 
transferred to water. After 3 days, brassinin (17) was incubated with mycelial cultures 
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in water. Under these conditions (Entry 7, table 2.5), the brassinin (17) metabolism rate 
decreased (detected up to 48 h). Conditions tried towards optimization of the screening 
protocol (Entries 1-7) are summarized in table 2.5.  
 
Table 2.5 Culture conditions for optimization of the screening method to determine the 
effect of potential inhibitors on brassinin detoxification. 
 
Entry Glucose 
g/l 
Spores 
#/ml 
Incubation times (in 
MM) 
Brassinin (0.10 
mM) detection 
1 15 g 10
6
 2 d
 a
  Up to 15 h 
2 15 g 10
6
 7 d → water (0 h)b Up to 6 h 
3 15 g 10
6
 7 d → water (1 d)b Up to 6 h 
4 15 g 10
4
 5 d → water (0 h)b Up to 6 h 
5 15 g 10
4
 5 d → water (1 d)b Up to 6 h 
6 15 g 10
4
 5 d → water (2 d)b Up to 15 h 
7 15 g 10
4
 5 d → water (3 d)b Up to 48 h 
a 
Standard conditions: brassinin was added to 2 d-old mycelial cultures (Pedras and Jha, 
2006); 
b 
mycelia from x d-old cultures (in MM) were transferred to water and incubated 
for additional x d before the addition of brassinin (0.10 mM). 
 
In order to test the new conditions (Entry 7, table 2.5), a camalexin analog, 5-
methoxycamalexin (167, 72% inhibition of BOLm at 0.30 mM) (Pedras, Minic et al., 
2009c) was tested for its inhibitory effect on brassinin detoxification. Mycelia from 5 
d-old cultures in minimal media were transferred to water and, after three additional 
days, compound 167 (0.10 mM) followed by brassinin (17, 0.10 mM) were added and 
incubated up to three days. Samples were withdrawn at different time intervals, 
extracted with EtOAc, and the extracts were analyzed by HPLC-DAD. In the presence 
of compound 167 (0.10 mM), complete metabolism of brassinin (17) was delayed until 
96 h (vs ~48 h in control samples) (Figure 2.14). In control cultures, the time required 
for 50% metabolism (t1/2) of brassinin (17, 0.10 mM) was ~ 15 h and 100% metabolism 
(tBr) of 17 was achieved after ~ 48 h. In the presence of compound 167, values of t1/2 
and tBr increased to 36 h and 96 h respectively, indicating the inhibition of brassinin 
detoxification in fungal cultures. Compound 167, like compound 32, is both an inducer 
and inhibitor of BOLm (Pedras, Minic et al., 2009c) and yet, the current screening 
protocol successfully demonstrated the decrease of brassinin detoxification rates in the 
presence of compound 167. Thus, the new conditions (Entry 7, table 2.5) proved 
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advantageous over previous conditions (Entry 1, table 2.5) and would provide a better 
opportunity to observe the effect of potential inhibitors in decreasing the rate of 
brassinin detoxification over a long period (at least up to 48 h).   
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Figure 2.14 Metabolism of brassinin (17, 0.10 mM) in the presence of 5-
methoxycamalexin (167, 0.10 mM) in cultures of Leptosphaeria maculans (10
4
/ml 
spores). 
 
 
2.2.3.2 Screening of potential inhibitors of brassinin detoxification 
 
Each of the synthetic potential inhibitors was screened for the effect in decreasing the 
rate of brassinin detoxification according to the new screening method. In control 
cultures, time required for 50% metabolism (t1/2) of brassinin (17, 0.10 mM) varied 
between 6-15 h and 100% metabolism (tBr) of 17 was ~ 48 h. Higher values of t1/2 and 
tBr in the cultures of potential inhibitors co-incubated with brassinin (17) in comparison 
with those in controls are indicative of the effect of the tested compounds in decreasing 
the rates of brassinin detoxification. However, in some cases t1/2 of brassinin in the 
presence of potential inhibitor is about the same as in control cultures (~ 6 h), but the 
values of tBr were > 48 h. Among the quinoline derivatives, 2-thiazolylquinoline (350, 
0.10 mM) did not affect the rate of brassinin metabolism (Figure 2.15). In presence of 
compound 350, complete metabolism of brassinin (17) took place in 48 h (tBr) and 50% 
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metabolism of compound 17 in 6 h (t1/2). The values of t1/2 and tBr are similar to that of 
control cultures (incubated with only brassinin). Next, compounds 352, 354 and 359 
were co-incubated with brassinin (17, 0.10 mM). Comparison of the values of t1/2 and 
tBr in the cultures of compounds 352, 354 and 359 co-incubated with brassinin (17, 0.10 
mM) with those in the control cultures (incubated with only 17) demonstrated that 
compound 354 did not affect the brassinin detoxification, while compound 359 
decreaesd the brassinin metabolism rate to a small extent. Importantly, compound 352 
upon co-incubation with brassinin (17) decreased its metabolism to a large extent. The 
value of t1/2 was larger (~ 65 h vs 6 h in control) in the cultures of compound 352 co-
incubated with brassinin (17) than in similar cultures of compounds 354 (~ 6 h vs 6 h in 
control) and 359 (~ 6 h vs 6 h in control). Brassinin metabolism in the presence of 352 
was delayed to 96 h (Figure 2.16). 
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Figure 2.15 Progress curve for the detoxification of brassinin (17, 0.10 mM) in the 
presence of 2-(thiazol-2-yl) quinoline (350, 0.10 mM) in mycelia cultures of 
Leptosphaeria maculans in water. 
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Figure 2.16 Progress curves for the detoxification of brassinin (17, 0.10 mM) in the 
presence of 6-bromo-2-phenylquinoline (352, 0.10 mM), 6-chloro-2-phenylquinoline 
(354, 0.10 mM) and 6-chloro-3-phenylquinoline (359, 0.10 mM) in cultures of 
Leptosphaeria maculans in water. 
 
 
Compounds 353 or 358 (0.10 mM) incubated with brassinin (17) had a moderate effect 
on its metabolic rate. Results indicated that brassinin (17) in the presence of 353 and 
358 was completely metabolized in 72 h (48 h in control cultures, Figure 2.17). The 
values of t1/2 were greater (~ 24 h vs 6 h in control) in cultures incubated with brassinin 
(17) and containing compounds 353 or 358, indicating their moderate effect in 
decreasing the rate of brassinin detoxification. 
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Figure 2.17 Progress curves for the detoxification of brassinin (17, 0.10 mM) in the 
presence of 5-chloro-2-phenylquinoline (353, 0.10 mM) and 5-chloro-3-
phenylquinoline (358, 0.10 mM) in cultures of Leptosphaeria maculans in water. 
 
 
Similarly, when compounds 355, 356, 360 and 361 were co-incubated with brassinin 
(17), all the compounds except 361 showed a small effect in decreasing the rate of 
brassinin detoxification. Brassinin (17, 0.10 mM) was completely metabolized in 
control cultures incubated with only brassinin and in cultures co-incubated with 
compound 361 within 48 h. Metabolism of brassinin was delayed up to 72 h when co-
incubated with compound 356 (Figure 2.18). However, the values of t1/2 in cultures of 
compounds 356 or 361 co-incubated with brassinin (17) were comparable to the t1/2 
value in control cultures. Metabolism of brassinin (17) was delayed up to 72 h when 
co-incubated with compound 355 and 360 (Figure 2.19). However, the values of t1/2 in 
cultures of compounds 355 and 360 co-incubated with brassinin (17) were comparable 
to the t1/2 value in control cultures.  
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Figure 2.18 Progress curves for the detoxification of brassinin (17, 0.10 mM) in the 
presence of 6-methoxy-2-phenylquinoline (356, 0.10 mM) and 6-methoxy-3-
phenylquinoline (361, 0.10 mM) in cultures of Leptosphaeria maculans in water. 
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Figure 2.19 Progress curves for the detoxification of brassinin (17, 0.10 mM) in the 
presence of 6-hydroxy-2-phenylquinoline (355, 0.10 mM) and 6-hydroxy-3-
phenylquinoline (360, 0.10 mM) in cultures of Leptosphaeria maculans in water. 
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Figure 2.20 Progress curves for the detoxification of brassinin (17, 0.10 mM) in the 
presence of 2-phenylquinoline (351, 0.10 mM) and 3-phenylquinoline (357, 0.10 mM) 
in cultures of Leptosphaeria maculans in water. 
 
 
The effect of compounds 351 and 357 (0.10 mM) on the rate of brassinin metabolism is 
shown in figure 2.20. Both the compounds showed a substantial effect in decreasing the 
rates of brassinin metabolism. Complete metabolism of brassinin (17, 0.10 mM) took 
place at 96 h in presence of 351 and 357, whereas in the absence of these compounds 
brassinin (17) was metabolized within 48 h. However, the value of t1/2 in cultures of 
compounds 351 co-incubated with brassinin (17) was comparable to the t1/2 value in 
control cultures. However, the value of t1/2 in cultures of compound 357 co-incubated 
with brassinin (17) was ~ 48 h, suggesting a strong effect of compound 357 in 
decreasing the rate of brassinin detoxification.  
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Figure 2.21 Progress curves for the detoxification of brassinin (17, 0.10 mM) in the 
presence of 1-(thiazol-2-yl)isoquinoline (362, 0.10 mM), 6-bromo-1-(thiazol-2-
yl)isoquinoline (363, 0.10 mM) and 7-bromo-1-(thiazol-2-yl)isoquinoline (364, 0.10 
mM) in cultures of Leptosphaeria maculans in water. 
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Figure 2.22 Progress curves for the detoxification of brassinin (17, 0.10 mM) in the 
presence of 1-phenylisoquinoline (365, 0.10 mM) and 7-bromo-1-phenylisoquinoline 
(366, 0.10 mM) in cultures of Leptosphaeria maculans in water. 
 
Among the isoquinoline analogs 362-366, compounds 363 and 364 did not affect the 
rate of brassinin metabolism when co-incubated with compound 17 in cultures of L. 
Time (h) 
C
o
n
c 
(m
M
) 
Time (h) 
C
o
n
c 
(m
M
) 
(17) 
(366) 
(365) 
(17) 
(363) 
(364) 
(362) 
   
100 
 
maculans (BJ-125). Under these conditions, brassinin (17, 0.10 mM) in presence of 
compounds 363 and 364 was metabolized as in control cultures within 48 h. Even the 
values of t1/2 in cultures of compounds 363 and 364 incubated with brassinin (17) were 
comparable to the t1/2 value in control cultures. Metabolism of brassinin (17) was 
delayed up to 96 h when co-incubated with compound 362 (Figure 2.21). The value of 
t1/2 in cultures of compounds 362 co-incubated with brassinin (17) was greater (45 h vs 
~ 6 h) than the t1/2 value in control cultures. This suggested that compound 362 has a 
significant effect in decreasing the rate of brassinin detoxification. 
 
Compounds 365 and 366 appeared to have significant effect in decreasing the rate of 
brassinin detoxification. When the compounds 365 and 366 were co-incubated with 
brassinin (17), metabolism of 17 was delayed up to 96 h (Figure 2.22). The values of 
t1/2 in cultures of compounds 365 and 366 incubated with brassinin (17) were greater 
than those in control cultures, suggesting an effect of these compounds on the rate of 
brassinin detoxification.  
 
However, in the above screening experiments (Figures 2.15-2.22), from the recovery of 
potential inhibitors 350-366 from fungal cultures (shown as control curves), it was 
difficult to determine if the compounds were stable and not metabolized. Moreover, in 
these plots, compounds 350-366 were quantified based on the calibration curves not 
built at the time of the screening experiments but, at a later stage. On further 
comparison of the calibration curves of brassinin (17) built at the time of screening 
experiments and at a later stage, a discrepancy of approximately 20% was noted. Thus, 
the concentration of the compounds 350-366 from screening experiments shown in the 
graphs (Figures 2.15-2.22) are potentially less than the reported values. It was not clear 
if the low recovery values of compounds 350-366 are due to the metabolism of the 
concerned compounds, especially because there were no metabolites detected in the 
fungal cultures (10
4
 Spores/ ml). However, it would be possible that the compounds 
350-366 might metabolize to metabolites that are not extractable from the fungal 
cultures. For further clarification, investigation of the metabolism of compounds 350-
366 in fungal cultures (10
6
 Spores/ml) was carried out in minimal media.  
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2.2.3.3 Metabolism of compounds 350-366  
 
To establish if any of compounds 350-366 were metabolized by L. maculans, solutions 
in ACN/DMSO (final conc 0.10 mM) were added to fungal cultures in minimal media 
(10
6 
spores/ml of L. maculans, isolates virulent on canola) and samples (2 ml) were 
collected after 0, 6, 24 and 48 h of incubation, extracted with EtOAc and analyzed by 
HPLC. Control experiments were also carried out by incubating compounds 350-366 in 
media alone. 
 
The concentration of compounds 352, 355, 360, 361, 363 and 364 decreased in the 
fungal cultures, indicating that these compounds were rapidly metabolized (Figure 
2.23). Metabolites were detected only in the fungal cultures incubated with 6-hydroxy-
2-phenylquinoline (355, tR = 3.1 min) and 6-hydroxy-3-phenylquinoline (360, tR = 3.3 
min). Compounds 355 and 360 were completely metabolized to unknown metabolites 
within 48 h of incubation with fungal cultures. Compounds 351, 353, 356, 358 and 359 
were metabolized in the fungal cultures (Figure 2.24) at a slow rate, although new 
metabolites were observed only from compounds 351 (tR = 2.9 min) and 358 (tR = 3.9 
min). On the other hand, recoveries of compounds 350, 354, 357, 362, 365 and 366 
from fungal cultures were found to be either very little or not at all changed over a 0-48 
h period or showing large deviations, suggesting that these compounds might not be 
metabolized in fungal cultures (Figure 2.25). 
 
Altogether, comparison of the recoveries of compounds 350-366 in fungal cultures as 
well as in control media led to inconsistent results (Figures 2.23-2.25). Thus, further 
investigation is necessary to confirm the metabolism of these compounds. 
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Figure 2.23 Progress curves representing the recovery of 6-bromo-2-phenylquinoline 
(352, 0.10 mM), 6-hydroxy-2-phenylquinoline (355, 0.10 mM), 6-hydroxy-3-
phenylquinoline (360, 0.10 mM), 6-methoxy-3-phenylquinoline (361, 0.10 mM), 6-
bromo-1-(thiazol-2-yl)isoquinoline (363, 0.10 mM) and 7-bromo-1-(thiazol-2-
yl)isoquinoline (364, 0.10 mM) that seemed to metabolize rapidly in cultures (Cul) of 
Leptosphaeria maculans. 
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Figure 2.24 Progress curves representing the recovery of 2-phenylquinoline (351, 0.10 
mM), 5-chloro-2-phenylquinoline (353, 0.10 mM), 6-methoxy-2-phenylquinoline (356, 
0.10 mM), 5-chloro-3-phenylquinoline (358, 0.10 mM) and 6-chloro-3-phenylquinoline 
(359, 0.10 mM) that seemed to metabolize at a slow rate in cultures (Cul) of 
Leptosphaeria maculans. 
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Figure 2.25  Progress curves representing the recovery of 2-(thiazol-2-yl) quinoline 
(350, 0.10 mM), 6-chloro-2-phenylquinoline (354, 0.10 mM), 3-phenylquinoline (357, 
0.10 mM), 1-(thiazol-2-yl)isoquinoline (362, 0.10 mM), 1-phenylisoquinoline (365, 
0.10 mM) and 7-bromo-1-phenylisoquinoline (366, 0.10 mM) that are not likely 
metabolized in cultures (Cul) of Leptosphaeria maculans. 
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2.2.4 Conclusions 
 
In summary, among the quinoline derivatives screened for their effect on brassinin 
detoxification, compounds 351-353, 355 and 357-360 decreased the rate of brassinin 
metabolism (Figure 2.26). Especially, cultures of compounds 352, 353, 357, 358 and 
360 co-incubated with brassinin (17) demonstrated t1/2 and tBr values greater than the 
respective values in control cultures. These results demonstrated a significant effect of 
compounds 352, 353, 357, 358 and 360 in decreasing the rate of brassinin metabolism. 
Further studies indicated that compounds 351-353, 355 and 358-360 were likely 
metabolized in the cultures of L. maculans (virulent on canola) while compound 357 
was not (Figure 2.26). Among the isoquinoline derivatives, compounds 362, 365 and 
366 slowed down the rate of brassinin metabolism. Values of t1/2 and tBr in the cultures 
of compounds 362, 365 and 366 co-incubated with brassinin (17) were greater than the 
respective values in control cultures. Further studies indicated that compounds 362, 365 
and 366 were not likely metabolized in the cultures of L. maculans (virulent on canola) 
(Figure 2.26). The remaining compounds 350, 354, 356, 361, 363 and 364 did not show 
a detectable effect on the rate of brassinin metabolism in the cultures of L. maculans 
(virulent on canola) (Figure 2.27). Additional experiments indicated that these 
compounds were likely metabolized in the cultures of L. maculans (virulent on canola). 
Among the quinoline compounds 351-353, 355 and 357-360 (Figure 2.26) which 
delayed the metabolism of brassinin (17), compounds 352, 358 and 359 displayed < 
30% inhibition of the growth of L. maculans at 0.50 mM. However, all the three 
compounds 352, 358 and 359 were likely metabolized by L. maculans (virulent on 
canola). Overall, compound 352 (0.10 mM) with a t1/2 value of 65 h and only 27% 
inhibition of L. maculans growth at 0.50 mM appeared to be the most promising 
compound towards lead optimization. However, compound 352 seemed to be 
metabolized rapidly in the cultures of L. maculans (virulent on canola). Among the 
isoquinolines 362, 365 and 366 (Figure 2.26) which delayed the metabolism of 
brassinin (17), none displayed < 30% inhibition of the growth of L. maculans at 0.50 
mM. On the other hand, compound 362 showed complete growth inhibition of L. 
maculans at 0.50 mM, and also a strong effect in decreasing the rate of brassinin (17) 
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metabolism (t1/2 value in screening studies ~ 45 h). However, compound 362 was not 
likely metabolized in the fungal cultures of L. maculans (virulent on canola).  
 
 
 
 
Figure 2.26 Compounds that slowed down the rate of brassinin metabolism in cultures 
of Leptosphaeria maculans (virulent on canola) in water: (A) that are likely 
metabolized 351-353, 355 and 358-360; (B) that are not likely metabolized 357, 362, 
365 and 366.  
 
 
 
Figure 2.27 Compounds 350, 354, 356, 361, 363 and 364 that did not affect the rate of 
brassinin metabolism in cultures of Leptosphaeria maculans in water. 
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Considering the results from antifungal activities, screening for the effect on the 
decrease of brassinin detoxification rates and metabolic stability in cultures, 
compounds 352 and 362 seemed like promising structures. Thus, for a better 
understanding of the utility these compounds, several analogs of 352 and 362 have to 
be synthesized and tested for their antifungal activities, effect on brassinin 
detoxification and metabolic stability in fungal cultures.  
In vitro evaluation of the compounds 352, 362 and others for BOLm inhibition would 
be essential to further exploit the quinoline and isoquinoline based scaffolds in 
optimization studies. The summary of the results of screening, antifungal activities and 
possible metabolic stability of compounds 350-366 in fungal cultures tested towards 
evaluation of paldoxin-like properties is presented in table 2.6. 
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Table 2.6 Concentration of brassinin (17) remaining in cultures of Leptosphaeria 
maculans incubated with compounds 350-366. 
Compound coincubated with brassinin (17)/ 
antifungal activity
 c
 (0.50 mM) 
Recovery (%)
d
 of brassinin 
(17)  
Brassinin (17)/ 62 ± 4 50% (6 h); n.d. (48 h) 
2-(Thiazol-2-yl)quinoline (350)
a
/ 54 ± 3 50% (6 h); 31% (24 h) 
2-Phenylquinoline (351)
b
/ 54 ± 2 50% (18 h); 12% (48 h) 
6-Bromo-2-phenylquinoline (352)
b
/ 27 ± 4 50% (65 h); 39% (72 h) 
5-Chloro-2-phenylquinoline (353)
b
/ 39 ± 2 50% (24 h); 19% (48 h) 
6-Chloro-2-phenylquinoline (354)
a
/ 26 ± 4 50% (6 h); 11% (24 h) 
6-Hydroxy-2-phenylquinoline (355)
b
/ 68 ± 5 50% (15 h); 20% (48 h) 
6-Methoxy-2-phenylquinoline (356)
b
/ 36 ± 4 50% (14 h); n.d. (48 h) 
3-Phenylquinoline (357)
a
/ c.i. 50% (48 h); 29% (72 h) 
5-Chloro-3-phenylquinoline (358)
b
/  ± 3 50% (24 h); 11% (48 h) 
6-Chloro-3-phenylquinoline (359)
b
/ 28 ± 3 50% (6 h); 11% (24 h) 
6-Hydroxy-3-phenylquinoline (360)
b
/ 73 ± 5 50% (19 h); 10% (48 h) 
6-Methoxy-3-phenylquinoline (361)
b
/ c.i. 50% (14 h); n.d. (48 h) 
1-(Thiazol-2-yl)isoquinoline (362)
a
/ c.i. 50% (45 h); 24 (72 h) 
6-Bromo-1-(thiazol-2-yl)isoquinoline (363)
b
/ 75 ± 6 50% (9 h); n.d. (48 h) 
7-Bromo-1-(thiazol-2-yl)isoquinoline (364)
b
/ 82 ± 5 50% (6 h); n.d. (48 h)  
1-Phenylisoquinoline (365)
a
/ 54 ± 5 50% (24 h); 47% (48 h) 
7-Bromo-1-phenylisoquinoline (366)
a
/ 47 ± 5 50% (26 h); 18% (48 h) 
a 
not likely metabolized by L. maculans;
  b 
likely metabolized by L. maculans; 
c 
values were 
calculated using the formula: % inhibition = 100 – [(growth on amended/growth in control) × 100]; d 
molar percentages were determined using a calibration curve and are average of experiments 
conducted in triplicates ± standard deviation; c.i. = complete inhibition; n.d. = not detected. 
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Chapter 3: Conclusions and future work 
 
It was established that rapalexin A (22) can resist transformation by L. maculans. 
Compound 22 is the third example of a phytoalexin, after spirobrassinin (27) and 
camalexin (32), that was not metabolized by the blackleg fungus. On the other hand, 
erucalexin (29) in contrast to its regioisomer 1-methoxyspirobrassinin (28), was found 
to be metabolized by L. maculans (virulent on canola) by reduction. Brassinin (17) and 
its regioisomer isobrassinin (111) were metabolized differently by L. maculans (BJ-
125). During screening of different brassinin related structures, 111, 153, 320, 325, 
327, 331, 333 and 342, it was established that dithiocarbamates 111, 325, 327, 331, 342 
were metabolized differently than brassinin (17). These results are in agreement with 
earlier findings (Pedras, Jha et al., 2007; Pedras, Minic et al., 2008) that compounds 96, 
111, 153, 320, 325, 327, 331, 333 and 342 were not substrates of BOLm. 
Detoxification of dithiocarbamates 111, 325, 327, 331, 342 and dithiocarbonates 153 
and 333 by L. maculans occurred via a hydrolysis reaction. These broad range reactions 
demonstrated that the hydrolase(s) involved in these transformations are not very 
selective.  
 
Replacement of indolyl and naphthylyl moieties in the first generation inhibitors of 
BOLm with quinoline and isoquinoline moieties provided a basis for the design of 
several potential inhibitors of brassinin detoxification by L. maculans. However, most 
of the substituted quinoline and isoquinoline derivatives 353-361 and 366 incorporating 
phenyl substitution at the 2 or 3 positions showed less effects in decreasing the rate of 
brassinin detoxification relative to compounds 351, 357 and 362. There was no SAR 
observed among the compounds in regards to the effects such as decreasing the rate of 
brassinin detoxification and antifungal activity. Overall, compounds 352 and 362 
showed substantial effects in decreasing the rate of brassinin detoxification. However, 
compound 352 but not 362 had low antifungal activity against L. maculans. This 
demonstrated the scope for further investigation of compounds based on the structures 
352, 362 and others as inhibitors of brassinin detoxification. Further studies are 
required to understand the metabolic stability in L. maculans (virulent on canola) and 
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BOLm inhibition activities of compounds 350-366. In addition, compounds derived 
from other potential heterocyclic skeletons need to be explored to probe for their effect 
in decreasing the rate of brassinin detoxification, BOLm inhibition activity and 
antifungal activity against L. maculans (virulent on canola).  
Future work 
 Test compounds 350-366 for inhibition of brassinin transformation using 
purified BOLm. 
 Determine the metabolic stability of compounds 350-366 in cultures of L. 
maculans (virulent on canola). 
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Chapter 4: Experimental 
4.1 General methods 
All reagents and chemicals were purchased either from Aldrich or Alfa Aesar. Solvents 
used in syntheses were dried prior to use according to established procedures (pyridine 
and DMF with 3 Å molecular sieves, THF and Et2O over sodium and benzophenone, 
DCM, CH3CN, and benzene over CaH2) (Leonard, Lygo et al., 1995). 
Analytical thin layer chromatography (TLC) was carried out on alumina sheets (Merck, 
60 F254 5 × 2 cm × 0.2 mm) pre-coated with silica gel. Compounds developed on the 
TLC plates were visualized under UV light (254/366 nm) and/or by dipping in a 
solution of 5% (w/v) aqueous phosphomolybdic acid containing 1% (w/v) ceric sulfate 
and 4% (v/v) H2SO4, followed by charring on a hot plate. 
Flash column chromatography (FCC) was carried out using silica gel grade 60, mesh 
size 230 – 400 Å. Preparative thin layer chromatography (prep TLC) was carried out on 
silica gel plates, Kieselgel 60 F254 (20 × 20 cm × 0.25 mm). 
NMR spectra were obtained on Bruker Avance 500 spectrometers. For 
1
H NMR (500 
MHz), the chemical shift values (δ) are reported in parts per million (ppm) relative to 
tetramethylsilane. The δ values were referenced to CDCl3 (CHCl3 at 7.27 ppm), and 
CD3CN (CHD2CN at 1.94 ppm). First-order behavior was assumed in analysis of 
1
H 
NMR spectra and multiplicities are indicated by the following notations; s = singlet, d 
= doublet, t = triplet, q = quartet, m = multiplet and br = broad.  Spin coupling 
constants (J values) are reported to the nearest 0.5 Hz. 
13
C data were collected on the 
Bruker Avance 500 spectrometers at 125.8 MHz. The 
13
C chemical shift
 (δ values) 
were referenced to CDCl3 (77.2 ppm) and CD3CN (118.7 ppm).  
HPLC analysis was carried out with Agilent high performance liquid chromatography 
instruments equipped with quaternary pump, automatic injector, and diode array 
detector (DAD, wavelength range 190–600 nm), degasser, and a column, having an in-
line filter. Elution methods: method A: column Eclipse XDB-C18 (5 μm particle size 
silica, 4.6 i.d. × 150 mm), mobile phase H2O–MeOH (1:1, v/v) to MeOH, for 25.0 min, 
linear gradient, and at a flow rate 0.75 ml/min; method B (for amines both solvents 
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contain 0.01% propanamine): column Zorbax ODS (3.5 μm particle size silica, 3.0 
i.d. × 100 mm), mobile phase H2O–MeOH (4:6, v/v) to MeOH, for 10.0 min, linear 
gradient, at a flow rate of 0.50 ml/min; method C: column Zorbax ODS (3.5 μm 
particle size silica, 3.0 i.d. × 100 mm), mobile phase H2O–ACN (3:1, v/v) to ACN, for 
40.0 min, linear gradient, at a flow rate of 0.40 ml/min. HPLC–DAD-ESI-MS analysis 
was carried out with an Agilent 1100 series HPLC system equipped with an 
autosampler, binary pump, degasser, and a diode array detector connected directly to a 
mass detector (Agilent G2440A MSD-Trap-XCT ion trap mass spectrometer) with an 
electrospray ionization (ESI) source. 
Fourier transform infrared (FTIR) spectra were recorded on Bio-Rad FTS-40 
spectrometers. Spectra were measured by the diffuse reflectance method on samples 
dispersed in KBr. High resolution mass spectra (HRMS-EI) were obtained on a VG 70 
SE mass spectrometer. 
Minimal medium (MM) contains the following chemicals:  
Solution 1: KNO3 (3.12 g/l, 30.8 mM), K2HPO4 (0.75 g/l, 4.31 mM), KH2PO4 (0.75 g/l, 
5.51 mM), NaCl (0.10 g/l, 1.71 mM), asparagine (0.28 g/l, 2.12 mM);  
Solution 2: CaCl2·2H2O (0.10 g/l, 0.68 mM), MgSO4·7H2O (0.50 g/l, 2.03 mM);  
Solution 3: ZnSO4·7H2O (0.395 mg/l, 1.37 µM), CuSO4·5H2O (0.079 mg/l, 0.32 µM), 
MnSO4·4H2O (0.0405 mg/l, 0.18 µM), MoO3 (85%, 0.05 mg/l, 0.12 µM), ferric citrate 
(0.535 mg/l, 2.16 µM), Na2B4O7·10H2O (0.0375 mg/l, 0.10 µM);  
Solution 4: thiamine (0.1 mg/l, 0.38 µM);  
Glucose: (15 g/l, 83.3 mM). 
Solutions 1 and 3 and glucose were mixed and the pH of the mixed solution was 
adjusted to 6.55 and autoclaved. The autoclaved solution was combined with solutions 
2 and 4 (solutions 2 and 4 were sterilized, separately). Canadian virulent isolates of L. 
maculans (BJ 125) were grown in Erlenmeyer flasks (125 ml) containing MM (50 ml) 
inoculated with fungal spores (5×10
7
/50 ml) and incubated on a shaker at 120 rpm, at 
23 ± 2 °C (Pedras and Biesenthal, 2000). Cultures were grown in triplicate. 
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4.2 Fungal isolates 
Fungal isolates were provided by Agriculture and Agri-Food Canada Research Station, 
Saskatoon and University of Alberta, Edmonton. For spore collection, virulent isolates 
BJ-125 and UAMH 9410 were subcultured on V8 agar under continuous light, at 24 ± 
2 °C for 14 days. Spores were collected by centrifugation of the spore suspension 
(Pedras and Jha, 2006) diluted, counted under a microscope using haemocytometer and 
stored at -20 °C. 
4.3 Phytoalexins and analogs 
4.3.1 Synthesis of phytoalexins  
4.3.1.1  Brassinin (17) 
 
Reagents and conditions: (i) NH2OH.HCl, Na2CO3, 95%; (ii) NiCl2.6H2O, NaBH4, 
MeOH, 70%; (iii) Et3N, pyridine, CS2, 0 °C; (iv) MeI, 5 °C, 73% (Takasugi, Monde et 
al., 1988). 
 
Compound 17 was prepared according to a reported procedure. A solution of 
NH2OH.HCl (957 mg, 13.8 mmol) and Na2CO3 (803 mg, 7.58 mmol) in water (10 ml) 
was added to a solution of indolyl-3-carboxaldehyde (74, 1.0 g, 6.9 mmol) in EtOH (25 
ml) and stirred for 1 h at 80 °C. The reaction mixture was concentrated using rotary 
evaporator and the resulting precipitate was filtered to afford indolyl-3-carboxaldoxime 
(385, 1050 mg, 6.56 mmol) as an off-white solid in 95% yield (Pedras, Borgmann et 
al., 1992).  
NaBH4 (1075 mg, 28.44 mmol) was added to a solution of oximes 385 (700 mg, 4.37 
mmol) and NiCl2.6H2O (1039 mg, 4.37 mmol) in MeOH (10 ml) and stirred at 0 °C for 
10 min. The reaction mixture was then diluted with 2:1 mixture of water and aq. NH3 
(50 ml), filtered and extracted with EtOAc (3 x 100 ml). The combined organic 
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extracts were dried over Na2SO4 and concentrated. The residue was subjected to FCC 
(CHCl3/MeOH/aq.NH3, 80:20:1) to afford 3-indolylmethanamine (76, 450 mg, 3.08 
mmol) in 70% yield as white solid (Kutschy, Dzurilla et al., 1998).  
CS2 (199 l, 3.31 mmol) was added to a solution of amine 76 (440 mg, 3.01 
mmol) and Et3N (837 l, 6.02 mmol) in pyridine (3 ml) cooled to 0˚ C, and stirred at 
same temperature for 10 min. Next, CH3I (282 l, 4.51 mmol) was added and the 
reaction mixture was stirred at r.t. for 30 min. The reaction mixture was poured into 1.5 
M H2SO4 (50 ml) and extracted with EtOAc (2 x 100 ml). The combined organic 
extract was dried over Na2SO4 and concentrated under reduced pressure. The residue 
was subjected to FCC on silica gel (20% EtOAc/Hex) to afford brassinin (17, 521 mg, 
2.20 mmol) as an off-white solid in 73% yield (Pedras, Borgmann et al., 1992). 
HPLC tR = 11.9 min (method A). 
1
H NMR (500 MHz, CD3CN) δ 9.25 (br s, 1H, D2O exchangeable), 8.24 (br s, 1H, D2O 
exchangeable), 7.63 (d, J = 8 Hz, 1H), 7.43 (d, J = 8 Hz, 1H), 7.31 (d, J = 2 Hz, 1H), 
7.16 (dd, J = 8, 8 Hz, 1H), 7.08 (dd, J = 8, 8 Hz, 1H), 5.04 (d, J = 5 Hz, 2H), 2.55 (s, 
3H) and minor signals 4.77 (d) and 2.64 (s) (ca. 1/10 itensity of the major peaks) due to 
a rotamer.  
13
C NMR (125 MHz, CD3CN) δ 199.2, 137.8, 128.2, 126.2, 123.2, 120.7, 120.0, 112.9, 
111.9, 43.6, 18.6.  
HRMS-EI m/z: measured 236.0438 ([M]
 +
, calcd. 236.0442 for C11H12N2S2). MS (EI) 
m/z (% relative int.):  236 (34), 162 (12), 130 (100), 129 (32), 102 (16). 
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4.3.1.2  Rapalexin A (22) 
 
Reagents and conditions: (i) AgNO3, benzoyl chloride, CH3CN, 21%; (ii) Pd/C, AcOH, 
H2; (iii) CSCl2, DCM, 19% over 2 steps (Pedras, Zheng et al., 2007d).  
 
Compound 22 was prepared according to the reported procedure by Pedras et al 
(Pedras, Zheng et al., 2007d). 
Benzoyl chloride (116 μl, 0.84 mmol) was added dropwise to a stirred solution of silver 
nitrate (137 mg, 0.81 mmol) in acetonitrile (1 ml) at 0 °C and further stirred for 10 min. 
This solution was added to a solution of 4-methoxyindole (386, 98 mg, 0.67 mmol) in 
acetonitrile (8 ml) at -20 °C with vigorous stirring. After 1 hr, the reaction mixture was 
brought to room temperature and stirred for additional 2 hrs. The reaction mixture was 
diluted with water (20 ml) and extracted with EtOAc (3×20 ml). The combined organic 
extract was washed with sodium carbonate (10% aqueous solution, 10 ml); dried over 
Na2SO4 and concentrated under reduced pressure. The residue was purified by FCC on 
silica gel (hexane- EtOAc, 10:1) to afford 4-methoxy-3-nitroindole (387, 27 mg, 0.14 
mmol) as a yellow powder in 21 % yield. 
Platinum (IV) oxide (40 mg) was added to a solution of 4-methoxy-3-nitroindole (387, 
75 mg, 0.39 mmol) in 95% EtOH (5 ml) and the mixture was hydrogenated at balloon 
pressure with vigorous stirring. After complete consumption of the starting material 
according to TLC, the reaction mixture was concentrated to 1/3 volume using a rotary 
evaporator, and immediately used in the next step. The reaction mixture in EtOH (1 ml) 
was added dropwise to a stirred mixture of DCM (3 ml) and thiophosgene (38 μl, 0.41 
mmol) at room temperature. After stirring for 10 min, the mixture was diluted with 
water (10 ml) and extracted with DCM. (3×10 ml). The combined organic extract was 
dried over Na2SO4 and concentrated under reduced pressure. The residue was subjected 
to FCC on silica gel (20% EtOAc/Hex) to afford rapalexin A (22, 15 mg, 0.07 mmol) 
in 19% yield as a white solid (Pedras, Zheng et al., 2007d).  
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HPLC tR = 16.0 min (method A). 
1
H NMR (500 MHz, CDCl3): δ 7.97 (brs, NH), 7.17 (t, J = 8 Hz, 1H), 7.08 (d, J = 2 Hz, 
1H), 6.95 (d, J = 8 Hz, 1H), 6.58 (d, J = 8 Hz, 1H), 4.00 (s, 3H).  
13
C NMR (125 MHz, CDCl3): δ 154.1, 135.9, 136.1, 125.1, 118.3, 114.2, 108.1, 104.9, 
101.1, 55.5.  
HRMS-EI m/z: measured 204.0356 ([M]
 +
, calcd. 204.0357 for C10H8N2OS). MS (EI) 
m/z (% relative int.): 204 [M
+
] (100), 189 (57), 173 (11), 161 (30), 149 (13), 101 (22). 
 
4.3.1.3   Erucalexin (29) 
 
 
 
Reagents and conditions: (i) Na2WO4.2H2O, 30% H2O2; (ii) Me2SO4, K2CO3, 55% 
(Kawasaki and Kodama et al., 1991); (iii) t-BuLi, THF, -78 °C; (iv) DMF, 86%; (v) 
NH2OH.HCl, Na2CO3, EtOH/H2O, 93%; (vi) NaBH3(CN), TiCl3, NH4OAc, MeOH; 
(vii) Pyr, Et3N, CS2, CH3I, 51%; (V) CrO3, AcOH/H2O, 32% (Pedras, Suchy et al., 
2006). 
 
Compound 29 was prepared according to a procedure by Pedras et al (Pedras, Suchy et 
al., 2006). A solution of Na2WO4.2H2O (485 mg, 1.47 mmol) in water (5 ml) was 
added to the stirred solution of indoline (388, 1000 mg, 8.4 mmol) in MeOH (40 ml) 
and the reaction mixture was cooled to -15 ºC and stirred for 10 min. Next, a solution 
of 30% H2O2 (10 ml, 72.6 mmol) in MeOH (15 ml) was added slowly to the reaction 
mixture and stirring was continued at -15 ºC. After 30 minutes, solid K2CO3 (9.28 g, 
67.2 mmol) and dimethyl sulphate (2.1 ml, 22.26 mmol) were added with vigorous 
stirring and the reaction mixture was stirred for further 1.5 h at 8-13 ºC. The reaction 
mixture was then poured into water (120 ml) and extracted with Et2O (2×100 ml). The 
combined organic extract was dried over Na2SO4 and concentrated under reduced 
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pressure. The residue was subjected to FCC on silica gel (20% DCM/Hex) to afford 1-
methoxyindole (389, 674 mg, 4.58 mmol) in 55% yield (Kawasaki, Kodama et al., 
1991).  
t-BuLi in pentane (4.3 ml, 4.3 mmol) was added dropwise to a solution of 1-
methoxyindole (389, 420 mg, 2.86 mmol) in dry THF (10 ml, under an Ar atmosphere), 
cooled to −78 °C, and stirred at same temperature. After 15 min, DMF (0.75 ml, 4.8 
mmol) was added and the reaction temperature was gradually raised to r.t under 
continued stirring. After 1 hr, the reaction mixture was cooled to 0 °C, diluted with 1 M 
HCl (30 ml) and extracted with Et2O. The combined organic extract was dried over 
Na2SO4 and concentrated under reduced pressure. The residue was subjected to FCC on 
silica gel (20% EtOAc/Hex) to afford 1-methoxyindolyl-2-carboxaldehyde (390, 435 
mg, 2.48 mmol, 86%) as an off-white solid.  
A solution of NH2OH·HCl (312 mg, 4.52 mmol) and Na2CO3 (209 mg, 1.98 mmol) in 
water (3 ml) was added to 1-methoxyindolyl-2-carboxaldehyde (390, 500 mg, 2.82 
mmol) in EtOH (10 ml) and stirred at room temperature. After 20 min, the reaction 
mixture was diluted with brine (30 ml) and extracted in EtOAc. The combined organic 
extract was dried over Na2SO4 and concentrated under reduced pressure to yield pure 
1-methoxyindolyl-2-carboxaldoxime (391, 497 mg, 93%). AcONH4 (891 mg, 11.57 
mmol) and NaBH3CN (663 mg, 10.53 mmol) were added to a cooled solution of 1-
methoxyindolyl-2-carboxaldoxime (391, 200 mg, 1.05 mmol) in MeOH (10 ml) and 
stirred at 0 °C. After 5 min, a solution of TiCl3 [prepared by mixing commercially 
available 30% TiCl3 in 2 M HCl (4.9 ml) with 1 M NaOH solution (3.2 ml)] was added 
and the mixture was stirred for 20 min at 0 °C. The reaction mixture was then diluted 
with 2:1 mixture of H2O and NH4OH (50 ml) and extracted with EtOAc. The combined 
organic extract was dried over Na2SO4 and concentrated under reduced pressure to 
yield the crude 1-methoxyindolyl-2-methanamine (343), which was taken to next step 
without purification. CS2 (75 μl, 1.26 mmol) was added to a cooled solution of this 
amine 343 (1.05 mmol) and Et3N (219 μl, 1.58 mmol) in pyridine (2 ml) and stirred at 0 
°C for 30 min. Next, CH3I (99 μl, 1.58 mmol) was added and the mixture was stirred at 
same temperature. After 1 h, the reaction mixture was diluted with 1.5 M H2SO4 (20 
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ml) and extracted with Et2O. The combined organic extract was dried over Na2SO4 and 
concentrated under reduced pressure. The residue was purified by FCC on silica gel 
(20% EtOAc/Hex) to afford 1-methoxyisobrassinin (342, 142 mg, 0.53 mmol) as 
colorless oil in 51% yield (Pedras, Suchy et al., 2006).  
A solution of CrO3 (244 mg, 2.43 mmol) in water (0.75 ml) was added to a solution of 
1-methoxyisobrassinin (342, 118 mg, 0.44 mmol) in acetic acid (2.5 ml) and stirred at 
room temperature. After 5 min, the reaction mixture was diluted with brine (20 ml) and 
was extracted using EtOAc. The combined organic extract was washed with 10% 
K2CO3 solution (20 ml), dried over Na2SO4, and concentrated under reduced pressure. 
The residue was purified by FCC (SiO2; hexane–acetone, 5:1) to afford erucalexin (29, 
38 mg, 0.13 mmol) in 32% yield as a brown solid (Pedras, Suchy et al., 2006).  
HPLC tR = 14.9 min (method A). 
1
H NMR (500 MHz, CDCl3): δ 7.68 (d, J = 8 Hz, 1H), 7.63 (ddd, J = 8, 8, 1 Hz, 1H), 
7.22 (d, J = 8 Hz, 1H), 7.12 (dd, J = 8, 8 Hz, 1H), 4.73 (d, J = 16 Hz, 1H), 4.44 (d, J = 
16 Hz, 1H), 3.97 (s, 3H), 2.61 (s, 3H).  
13
C NMR (125 MHz, CDCl3): δ 192.0, 165.8, 159.9, 138.0, 124.5, 123.7, 121.1, 114.0, 
94.2, 71.8, 65.3, 15.7.  
HRMS-EI m/z: measured 280.0337 ([M]
 +
, calcd. 280.0340 for C12H12N2O2S2). MS 
(EI) m/z (% relative int.): 280 [M
+
] (46), 249 (81), 207 (32), 176 (100), 132 967), 105 
(76), 87 (36). 
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4.3.1.4   Brussalexin (36) 
 
Reagents and conditions: (i) Me2SO4, H2O; (ii) CH3COSH, KOH, 70 °C, 66%; (iii) 
NH2NH2.H2O, THF, 80 °C, 84%; (iv) Et3N, allyl isocyanate, DCM, 86%. 
 
Compound 36 was prepared by modification of the procedure by Pedras et al (Pedras, 
Zheng et al., 2007f). Dimethyl sulphate (435 μl, 4.59 mmol) was added dropwise to a 
suspension of grammine (317, 400 mg, 2.3 mmol) in water (5 ml) and stirred till the 
reaction medium turned homogeneous. Next, a solution of potassium thioacetate (5.05 
mmol) [generated by dissolving thiolacetic acid (360 μl) and KOH (283 mg) in water 
(3 ml)] was added and the reaction mixture was heated to 70 °C under stirring.  After 3 
h, the reaction mixture was cooled to r.t. and extracted with Et2O (3 × 50 ml). The 
combined organic extract was dried over Na2SO4 and concentrated under reduced 
pressure. The residue was purified by FCC (SiO2; 20% EtOAc/Hex) to afford indolyl-
3-methylthioacetate (318, 309 mg, 1.50 mmol) as a pale brown oil in 66% yield 
(Benghait and Crooks, 1983). 
Hydrazine hydrate (109 mg, 2.19 mmol) was added to a solution of indolyl-3-
methylthioacetate (318, 150 mg, 0.73 mmol) in THF (4 ml) and refluxed for 45 min. 
The reaction mixture was concentrated, adsorbed on silicagel, and fractionated (5% 
EtOAc/Hex) to afford indolyl-3-methanethiol (319, 100 mg, 0.61 mmol) in 84% yield.  
HPLC tR = 11.2 min (method A). 
1
H NMR (500 MHz, CDCl3): δ 7.89 (br s, NH), 7.68 (d, J = 8 Hz, 1H), 7.30 (d, J = 8 
Hz, 1H), 7.20 (dd, J = 7.5, 7.5 Hz, 1H), 7.14 (dd, J = 7.5, 7.5 Hz, 1H), 7.05 (s, 1H), 
3.95 (d, J = 7 Hz, 2H), 1.82 (t, J = 7 Hz, SH). 
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13
C NMR (125 MHz, CDCl3): δ 136.5, 126.3, 122.6, 122.2, 119.8, 119.1, 115.8, 111.5, 
19.8.  
FTIR (KBr) νmax cm
-1
:  3410, 3054, 2922, 2557, 1618, 1550, 1456, 1350, 1223, 1093, 
742.  
UV (HPLC, CH3OH–H2O) λmax (nm): 220, 276. 
HRMS-EI m/z: measured 163.0453 ([M]
 +
, calcd. 163.0456 for C9H9NS). MS (EI) m/z 
(% relative int.): 163 [M
+
] (20), 130 (100). 
Allyl isocyanate (28 mg, 0.34 mmol) was added to a solution of indolyl-3-methanethiol 
(319, 50 mg, 0.31 mmol) and triethylamine (17 μl, 0.62 mmol) in DCM (2 ml) and 
stirred at r.t., for 20 min. After complete conversion of the starting material, the 
reaction mixture was concentrated and loaded on the column of silica gel and eluted 
with EtOAc-Hex (20:80, v/v) to afford brussalexin (319, 65 mg, 0.26 mmol) in 86% 
yield.  
HPLC tR = 10.4 min (method A). 
 
1
H NMR (500 MHz, CDCl3): δ 8.14 (br s, 1H), 7.68 (d, J = 8 Hz, 1H), 7.35 (d, J = 8 
Hz, 1H), 7.22 (ddd, J = 8, 8, 1 Hz, 1H), 7.18-7.15 (m, 1H), 5.82 (m, 1H), 5.45 (br s, 
1H), 5.20 (d, J = 17 Hz, 1H), 5.15 (dd, J = 10, 1 Hz, 1H), 4.42 (s, 2H), 3.91 (br s, 2H).  
13
C NMR (125 MHz, CDCl3): δ 167.5, 136.5, 133.9, 126.8, 123.7, 122.5, 119.9, 119.1, 
117.0, 112.3, 111.5, 43.8, 25.7.  
HRMS-EI m/z: measured 246.0832 ([M]
 +
, calcd. 246.0827 for C13H14N2OS). MS (EI) 
m/z (% relative int.): 246 [M
+
] (8), 163 (6), 130 (100), 102 (7). 
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4.3.2 Synthesis of phytoalexin analogs    
4.3.2.1 Methyl tryptamine dithiocarbamate (96) 
 
 
Reagents and conditions: (i) Et3N, Pyr, CS2; CH3I, 87%. 
 
Compound 96 was synthesized as previously reported (Pedras and Okanga, 2000).  A 
solution of tryptamine (155, 300 mg, 1.87 mmol) in THF (2 ml) was added to a 
suspension of sodium hydride (54 mg, 2.25 mmol) in THF (3 ml) and stirred at r.t for 5 
min. Next, CS2 (135 μl, 2.246 mmol) followed by MeI (5 μl, 2.81 mmol) were added 
and the reaction mixture was stirred at r.t. After 30 min, the reaction mixture was 
diluted with ice cold water (30 ml) and extracted with EtOAc (2 × 30 ml). The 
combined organic extract was dried over Na2SO4 and concentrated under reduced 
pressure to yield a residue which was separated by FCC (SiO2; 20% EtOAc/Hex) to 
afford methyl tryptaminedithiocarbamate (96, 390 mg, 1.47 mmol) as a yellow solid in 
83% yield (Pedras and Okanga, 2000).  
HPLC tR = 24.6 min (method A). 
1
H NMR (500 MHz, CDCl3): δ 8.10 (br s, NH), 7.64 (d, J = 8 Hz, 1H), 7.39 (d, J = 8 
Hz, 1H), 7.25 (dd, J = 8, 8 Hz 1H), 7.17 (dd, J = 8, 8 Hz 1H), 7.05 (s, 1H), 7.02 (br s, 
NH), 4.10-4.07 (m, 2H), 3.16-3.10 (m, 2H), 2.60 (s, 3H) and minor signals (approx. 
1/3
rd
 the intensity of major ones) due to rotamers at 7.60, 3.77, 2.70.  
13
C NMR (125 MHz, CDCl3): δ 199.0, 136.6, 127.4, 122.6, 122.4, 119.9, 118.9, 112.5, 
111.5, 47.4, 24.8, 18.3 and minor signals (approx. 1/3
rd
 the intensity of major ones) due 
to rotamers at 118.7, 46.3, 24.8, 19.1.  
HRMS-EI m/z: measured 250.0593 ([M]
 +
, calcd. 250.0598 for C12H14N2S2). MS (EI) 
m/z (% relative int.): 250 [M
+
] (6), 202 (16), 143 (63), 130 (100), 115 (7), 103 (6), 77 
(9). 
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4.3.2.2 Isobrassinin (111) 
 
 
Reagents and conditions: (i) EtOH, H2SO4, 115 °C, 87%; (ii) LiAlH4, THF, 0 °C; (iii) 
MnO2, DCM, 80%; (iv) NH2OH.HCl, Na2CO3, EtOH/H2O, 94%; (v) NaBH4, 
NiCl2.6H2O, MeOH; (vi) Pyr, Et3N, CS2, CH3I, 44% (Pedras, Suchy et al., 2006). 
 
Isobrassinin (111) was synthesized as previously reported (Pedras, Suchy et al., 2006). 
H2SO4 (4 drops) was added to a solution of indolyl-2-carboxylic acid (341, 900 mg, 
5.59 mmol) in EtOH (15 ml) and refluxed for 20 hours. The reaction mixture was then 
cooled to room temperature, diluted with water (20 ml) and extracted with DCM (30 
ml). The combined organic extract was washed with 10% Na2CO3 (2 × 20 ml) followed 
by water (30 ml); dried over Na2SO4 and concentrated under reduced pressure to afford 
ethyl indolyl-2-carboxylate (392, 920 mg, 4.87 mmol) in 87% yield.  
LAH (174 mg, 4.6 mmol) was added in small portions to a cooled solution of 
carboxylate 392 (720 mg, 3.83 mmol) in dry THF (17 ml) at 0 °C and stirred at r.t. 
After 1 h, the reaction was quenched with 5 N NaOH (1 ml) and the precipitate was 
filtered over celite. The filtrate was dried over Na2SO4 and concentrated under reduced 
pressure to afford indolyl-2-methanol (393, 546 mg). MnO2 (1.9 g, 22.24 mmol) was 
added to the crude alcohol 393 (545 mg, 3.71 mmol) dissolved in DCM (20 ml) and the 
mixture was stirred at room temperature. After 18 h, MnO2 was filtered off, and the 
filtrate was concentrated under reduced pressure to yield indole-2-carboxaldehyde 
(394, 438 mg, 3.02 mmol) as an off-white solid in 80% yield (Meyer and Kruse, 1984). 
A solution of NH2OH.HCl (624 mg, 8.98 mmol) and Na2CO3 (595 mg, 5.61 mmol) in 
water (5 ml) was added to a solution of indole-2-carboxaldehyde (394, 438 mg, 2.24 
mmol) in EtOH (10 ml) and the reaction mixture was refluxed at 95 °C. After 1 h, 
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EtOH was concentrated under reduced pressure, and the residue was diluted with water 
(5 ml). The resulting precipitate was vacuum filtered to afford E/Z- indole-2-
carboxaldoximes (395, 452 mg, 2.82 mmol) in 94% yield.  
NaBH4 (691 mg, 18.26 mmol) was added to a solution of oximes 395 (450 mg, 2.81 
mmol) and NiCl2.6H2O (668 mg, 2.81 mmol) in MeOH (20 ml) and the mixture was 
stirred at r.t. After 10 min, the reaction mixture was diluted with 2:1 mixture of H2O - 
aqueous NH4OH (35 ml), filtered and extracted with EtOAc (3 x 100 ml). The 
combined organic extract was dried over Na2SO4 and concentrated to afford crude 
indolyl-2-methanamine 339. CS2 (331 l, 5.50 mmol) was added to a solution of crude 
amine (339, 402 mg, 2.75 mmol) and Et3N (142 l, 5.50 mmol) in DCM (1.5 ml), 
cooled to 0 °C, and stirred at same temperature. After 30 min, CH3I (225 l, 3.58 
mmol) was added and the reaction mixture was stirred at r.t., for 1 h. The reaction 
mixture was poured into 1.5 M H2SO4 (50 ml) and extracted with EtOAc (2 x 100 ml). 
The combined organic extract was dried over Na2SO4 and concentrated under reduced 
pressure. The residue was subjected to FCC on silica gel (20% EtOAc/Hex) to afford 
isobrassinin (111, 282 mg, 1.19 mmol) as a pale brown solid in 44% yield (Pedras, 
Suchy et al., 2006).  
HPLC tR = 14.0 min (method A). 
 
1
H NMR (500 MHz, CDCl3):  δ 8.91 (br s, NH), 7.59 (d, J = 8 Hz, 1H), 7.35 (d, J = 8 
Hz, 2H), 7.21 (dd, J = 7.5, 8 Hz, 1H), 7.12 (dd, J = 7.5, 8 Hz, 1H), 6.42 (s, 1H), 5.05 
(d, J = 5.5 Hz, 2H), 2.68 (s, 3H). 
 
13
C NMR (125 MHz, CDCl3): δ 201.3, 136.4, 134.6, 127.6, 122.7, 120.7, 120.2, 111.4, 
102.2, 43.5, 18.7.  
HRMS-EI m/z: measured 236.0450 ([M]
 +
, calcd. 236.0442 for C11H12N2S2). MS (EI) 
m/z (% relative int.): 236 [M
+
] (28), 188 (17), 163 (13), 130 (100), 103 (7), 69 (15). 
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4.3.2.3     Methyl tryptophol dithiocarbonate (153) 
 
Reagents and conditions: (i) NaH, THF, CS2; CH3I, 90% (Pedras and Jha, 2006). 
 
A solution of tryptophol (156, 50 mg, 0.311 mmol) in THF (2 ml) was added to a 
suspension of sodium hydride (15 mg, 0.373 mmol) in THF (1 ml) and stirred at r.t. 
After 5 min, CS2 (22 μl, 0.373 mmol) followed by MeI (40 μl, 0.622 mmol) were added 
and the reaction mixture was stirred at r.t. After 20 min, the reaction mixture was 
diluted with ice-cold water and extracted with EtOAc. The combined organic extract 
was dried over Na2SO4 and concentrated under reduced pressure to yield a residue 
which was purified by FCC (SiO2; 20% EtOAc/Hex) to afford methyl tryptophol 
dithiocarbonate (153, 64 mg, 82%, 0.26 mmol) as a white solid.  
HPLC tR = 20.1 min (method A). 
 
1
H NMR (500 MHz, CDCl3): δ 8.02 (br s, NH), 7.68 (d, J = 8 Hz, 1H), 7.39 (d, J = 8 
Hz, 1H), 7.25 (dd, J = 8, 8 Hz 1H), 7.17 (dd, J = 8, 8 Hz 1H), 7.08 (s, 1H), 4.90 (t, J = 
7 Hz, 2H), 3.31 (t, J = 7 Hz, 2H), 2.57 (s, 3H). 
 
13
C NMR (125 MHz, CDCl3): δ 216.1, 136.4, 127.5, 122.5, 122.4, 119.7, 119.0, 111.7, 
111.4, 73.9, 24.5, 19.1.  
HRMS-EI m/z: measured 251.0434 ([M]
 +
, calcd. 251.0439 for C12H13NOS2). MS (EI) 
m/z (% relative int.): 251 [M
+
] (3), 143 (100), 130 (14), 115 (11). 
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4.3.2.4 Methyl indolyl-3-methylcarbamodithioate (320)  
 
Reagents and conditions: (i) Et3N, MeNCS, DCM, 76%. 
Methyl isothiocyanate (49 mg, 0.67 mmol) was added to a solution of indolyl-3-
methanethiol (319, 100 mg, 0.613 mmol) and triethylamine (200 μl, 1.47 mmol) in 
DCM (3 ml) and stirred at r.t. for 20 min. After complete conversion of the starting 
material, the reaction mixture was concentrated, loaded on the column of silica gel and 
eluted with EtOAc-Hex (20:80, v/v) to afford the product 320 (110 mg, 0.46 mmol) in 
76% yield.  
HPLC tR = 11.2 (method A). 
 
1
H NMR (500 MHz, CDCl3):  δ 9.20 (br s, NH), 8.01 (br s, NH), 7.63 (d, J = 8 Hz, 
1H), 7.41 (d, J = 8 Hz, 2H), 7.29 (s, J = 2 Hz, 1H), 7.17 (dd, J = 8, 8 Hz, 1H), 7.08 (dd, 
J = 7, 7 Hz, 1H), 4.69 (s, 2H), 3.12 (s, 3H), minor rotamer peaks were found at δ 4.78, 
and 2.93 (ca. 1.7 : 0.3).  
13
C NMR (125 MHz, CDCl3): δ 199.4, 137.8, 128.0, 125.7, 123.3, 120.6, 120.0, 112.9, 
110.8, 34.3, 32.1.  
FTIR (KBr) νmax cm
-1
: 3403, 3323, 2928, 1509, 1455, 1339, 1031, 940, 744.  
UV (HPLC, CH3OH–H2O) λmax (nm): 219, 271.  
HRMS-EI m/z: measured 236.0435 ([M]
 +
, calcd. 236.0442 for C11H12N2S2). MS (EI) 
m/z (% relative int.): 236 [M
+
] (1), 163 (19), 130 (100), 103, (7), 76 (18). 
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4.3.2.5   Methyl 3-(3-indolyl)propyldithiocarbamate (325) 
 
Reagents and conditions: (i) EtOH, H2SO4, 115°C, 96%; (ii) DiBAl-H, toluene, -78 °C, 
90%; (iii) NH2OH.HCl, Na2CO3, EtOH/H2O, 97%; (iv) NaBH4, NiCl2.6H2O, MeOH; 
(v) Pyr, Et3N, CS2, CH3I, 43% (Gaspari, Banerjee et al., 2006). 
 
H2SO4 (4 drops) was added to a solution of indolyl-3-propanoic acid (95, 500 mg, 2.67 
mmol) in EtOH (15 ml) and the reaction mixture was refluxed for 20 h. The reaction 
mixture was then cooled to room temperature; diluted with water (20 ml) and extracted 
in DCM (30 ml). The combined organic extract was washed with 10% Na2CO3 (2 × 20 
ml) followed by water, dried over Na2SO4 and concentrated under reduced pressure. 
The residue was subjected to FCC on silica gel EtOAc-Hex (10:90, v/v) to afford ethyl 
indolyl-3-propanoate (321, 545 mg, 2.51 mmol, 96%) as pale yellow solid (Pedras, 
Minic et al., 2010b). To a solution of ethyl ester 321 (200 mg, 0.926 mmol) in dry 
toluene (2 ml) under argon atmosphere was added DIBAl-H (1.5 M, 800 µl, 1.20 
mmol) at -78 °C and the temperature was gradually raised to -60 °C while stirring. 
After 10 min, the reaction mixture was quenched with 1N HCl (10 ml) and extracted in 
EtOAc (3 x 25 ml).The combined organic layers were dried over Na2SO4 and 
concentrated to afford a residue that was subjected to FCC (SiO2, EtOAc-Hex, 30:70, 
v/v) to afford indole-3-propanaldehyde (322, 160 mg, 90%). Conversion of the 
aldehyde 322 (150 mg, 0.78 mmol) to dithiocarbamate in three consecutive steps as in 
the case of brassinin (17) yielded methyl 3-(3-indolyl)propyldithiocarbamate (325, 88 
mg, 0.33 mmol) as an off-white solid in 42% yield over 3 steps. The analytical data 
matched with published values (Gaspari, Banerjee et al., 2006). 
HPLC tR = 14.7 min (method A). 
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1
H NMR (500 MHz, CDCl3): δ 8.00 (br s, NH, 1H), 7.60 (m, 1H), 7.37 (d, J = 8 Hz, 
1H), 7.23 (dd, J = 7.5, 7.5 Hz, 1H), 7.15 (dd, J = 7.5, 7.5 Hz, 1H), 7.00 (s, 1H), 6.91 (br 
s, NH), 3.80 (q, J = 7 Hz, 2H), 2.86 (t, J = 7 Hz, 2H), 2.54 (s, 3H), 2.1 (m, 2H) and 
signals due to a minor rotamer (ca. 30%) 3.50 (q, J = 7 Hz), 2.68 (s) (Gaspari et al., 
2006).  
13
C NMR (125 MHz, CDCl3): δ 199.7, 136.6, 127.3, 122.3, 121.8, 119.6, 118.9, 115.3, 
111.5, 47.2, 28.3, 22.7, 18.0 and signals due to a minor rotamer at 46.0, 28.9, 18.7.  
FTIR (KBr) νmax cm
-1
:  3408, 3323, 2918, 1504, 1456, 1336, 1094, 940, 744.  
UV (HPLC, CH3OH–H2O) λmax (nm): 200, 220, 272. 
HRMS-EI m/z: measured 264.0752 ([M]
 +
, calcd. 264.0755 for C13H16N2S2). MS (EI) 
m/z (% relative int.): 264 [M
+
] (11), 231 (26), 216 (36), 184 (12), 156 (15), 130 (100). 
 
4.3.2.6 Methyl benzimidazolyldithiocarbamate (327) 
 
Reagents and conditions: (i) NaH, THF, 0 °C; (ii) CS2, CH3I, 72%. 
A solution of benzimidazole (324, 100 mg, 0.85 mmol) in THF (1 ml) was added to a 
stirred suspension of sodium hydride (26 mg, 1.1 mmol)) in THF (1 ml) and stirred at 
r.t for 5 min. Next, CS2 (61 μl, 1.02 mmol) followed by MeI (80 μl, 1.27 mmol) were 
added and the reaction mixture was stirred at r.t. After 20 min, the reaction mixture was 
diluted with ice cold water and extracted with EtOAc (2 × 30 ml). The combined 
organic extract was dried over Na2SO4 and concentrated under reduced pressure to 
yield a residue which was purified by FCC (SiO2; EtOAc-Hex, 20:80; v/v) to afford the 
product methyl benzimidazolyldithiocarbamate (327, 126 mg, 0.61 mmol) as a yellow 
solid in 72% yield.  
HPLC tR = 11.2 min (method A).  
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1
H NMR (500 MHz, CDCl3): δ 8.88 (s, 1H), 8.54 (d, J = 7.5 Hz, 1H), 7.81 (d, J = 8.5 
Hz, 1H), 7.44-7.38 (m, 2H), 2.85 (s, 3H).  
13
C NMR (125 MHz, CDCl3): δ 199.1, 145.5, 141.8, 133.0, 125.9, 125.3, 121.2, 115.8, 
20.1. 
FTIR (KBr) νmax cm
-1
: 3072, 1511, 1446, 1350, 1277, 1221, 1182, 1048, 1018, 825, 
742.  
UV (HPLC, CH3OH–H2O) λmax (nm): 210, 262, 315.  
HRMS-EI m/z: measured 208.0127 ([M]
 +
, calcd. 208.0129 for C9H8N2S2). MS (EI) m/z 
(% relative int.): 208 [M
+
] (100), 161 (64), 134 (27), 91 (100), 63 (8). 
 
4.3.2.7  Methyl 4-biphenyldithiocarbamate (331)  
 
Reagents and conditions: (i) NH2OH.HCl, Na2CO3, EtOH/H2O, 97%; (ii) NaBH4, 
NiCl2.6H2O, MeOH, 91%; (iii) Pyr, Et3N, CS2, CH3I, 72%. 
 
A solution of NH2OH.HCl (757 mg, 10.97 mmol) and Na2CO3 (873 mg, 8.23 mmol) in 
water (4 ml) was added to a solution of 4-biphenylcaboxaldehyde (328, 1000 mg, 5.48 
mmol) in ethanol (10 ml) and refluxed for 30 min. The reaction mixture was 
concentrated to 1/3 volume, diluted with water and extracted in EtOAc (3 × 40 ml). 
The combined organic extract was dried over Na2SO4 and concentrated to afford 4-
biphenylcarboxaldoximes (329, 1049 mg) in 97% yield. NaBH4 (234 mg, 6.18 mmol) 
and NiCl2.6H2O (245 mg, 1.03 mmol) were added to a cooled solution of the oximes 
329 (202 mg, 1.03 mmol) in methanol (8 ml) and the reaction mixture was stirred at r.t. 
After 15 min, the reaction mixture was diluted with 1% NH4OH (30 ml) and filtered. 
The filtrate was extracted with EtOAc (3 × 40 ml) and the organic extract was 
combined, dried over Na2SO4 and concentrated under reduced pressure. The residue 
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was further separated by FCC (SiO2; MeOH/DCM/NH4OH) to afford 4-
biphenylmethanamime (330, 170 mg, 0.93 mmol) in 91% yield. CS2 (68 μl, 1.13 
mmol) followed by MeI (88 μl, 1.40 mmol) were added to a solution of amine 330 (0 
mg, 0.94 mmol) and triethylamine (256 μl, 1.88 mmol) in pyridine (2 ml) and stirred at 
r.t. After 30 min, the reaction mixture was diluted with toluene (2 × 10 ml) and 
concentrated under reduced pressure. The residue was loaded on the column of silica 
gel and eluted with EtOAc-Hex (20:80, v/v) to afford the product 331 (185 mg, 72%, 
0.68 mmol).  
HPLC tR = 23.9 min (method A). 
 
1
H NMR (500 MHz, CDCl3): δ 7.60 (d, J = 8 Hz, 4H), 7.48 (dd, J = 8, 8 Hz, 2H), 
7.42-7.38 (m, 3H), 7.27 (br s, NH), 4.98 (d, J = 5 Hz, 2H), 2.69 (s, 3H). Minor 
rotamers were found at δ 4.66 and 2.72.  
13
C NMR (125 MHz, CDCl3): δ 199.5, 141.3, 140.7, 135.4, 129.1, 128.9, 127.8, 127.7, 
127.3, 51.1, 18.5.  
FTIR (KBr) νmax cm
-1
:  3339, 3224, 2919, 1486, 1328, 1088, 926, 761, 697.  
UV (HPLC, CH3OH–H2O) λmax (nm): 204, 260.  
HRMS-EI m/z: measured 273.0646 ([M]
 +
, calcd. 273.0646 for C15H15NS2). MS (EI) 
m/z (% relative int.): 273 [M
+
] (16), 225 (20), 167 (100), 152 (9). 
  
4.3.2.8  Methyl indolyl-3-propyldithiocarbonate (333)  
 
Reagents and conditions: (i) LiAlH4, THF, 0 °C, 95%; (ii) NaH, THF, 0 °C; (iii) CS2, 
CH3I, 73%. 
 
LAH (116 mg, 3.056 mmol) was added in portions to a cooled solution of ester 321 
(550mg, 2.546 mmol) in dry THF (5 ml) and the reaction mixture was stirred at room 
temperature for 40 min. The reaction mixture was quenched with 1M NaOH solution (5 
ml) and the precipitate was vacuum filtered. The filtrate was extracted with EtOAc (2 x 
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50 ml) and the combined organic extract was dried over Na2SO4, and concentrated 
using a rotary evaporator under reduced pressure. The residue was separated by FCC 
(SiO2; 30% EtOAc/Hex) to afford 3-indolylpropanol (332, 420 mg, 2.40 mmol) as pale 
yellow oil in 95% yield. A solution of 3-(3-indolyl)propanol (332, 30 mg, 0.17 mmol) 
in THF (0.5 ml) was added to a suspension of sodium hydride (6 mg, 0.21 mmol) in 
THF (2 ml) and stirred at r.t for 5 min. Next, CS2 (19 μl, 0.31 mmol) followed by MeI 
(20 μl, 0.31 mmol) were added and the reaction mixture was stirred at r.t. After 20 min, 
the reaction mixture was diluted with ice-cold water and extracted with EtOAc (2 × 40 
ml). The combined organic extract was dried over Na2SO4 and concentrated under 
reduced pressure to yield a residue that was purified by FCC (SiO2; EtOAc-Hex, 20:80, 
v/v) to afford methyl 3-(3-indolyl)propyldithiocarbonate (333, 33 mg, 0.12 mmol) as a 
yellow solid in 72% yield. 
HPLC tR = 21.4 min (method A). 
1
H NMR (500 MHz, CDCl3): δ 7.94 (br s, NH), 7.64 (d, J = 8 Hz, 1H), 7.38 (d, J = 8 
Hz, 1H), 7.25 (dd, J = 7.5, 7.5 Hz, 1H), 7.17 (dd, J = 7.5, 7.5 Hz, 1H), 7.01 (s, 1H), 
4.69 (t, J = 6.5 Hz, 2H), 2.94 (t, J = 7.5 Hz, 2H), 2.60 (s, 3H), 2.25 (m, 2H).  
13
C NMR (125 MHz, CDCl3): δ 216.1, 136.5, 127.4, 122.2, 121.7, 119.4, 118.9, 115.1, 
111.3, 73.8, 28.7, 21.6, 19.1.  
FTIR (KBr) νmax cm
-1
:  3414, 2921, 1456, 1223, 1056, 742.  
UV (HPLC, CH3OH–H2O) λmax (nm): 220, 278.  
HRMS-EI m/z: measured 265.0587 ([M]
 +
, calcd. 265.0595 for C13H15NOS2). MS (EI) 
m/z (% relative int.): 265 [M
+
] (33), 232 (52), 218 (32), 157 (52), 130 (100). 
4.3.2.9   1-Methoxyisobrassinin (342) 
 
Compound 342 was synthesized as previously reported (Pedras, Suchy et al., 2006) and 
as described in section 4.3.1.3.  
HPLC tR = 24.6 min (method A). 
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1
H NMR (500 MHz, CDCl3): δ 7.57 (d, J = 8 Hz, 1H), 7.43 (d, J = 8 Hz, 1H), 7.28 
(dd, J = 8, 8 Hz, 1H), 7.20 (br s, NH), 7.14 (dd, J = 8, 8 Hz, 1H), 6.38 (s, 1 H), 5.14 (d, 
J = 5 Hz, 2H), 4.10 (s, 3H), 2.67 (s, 3H).  
13
C NMR (125 MHz, CDCl3): δ 200.0, 133.0, 131.0, 123.7, 123.1, 121.4, 120.8, 108.5, 
98.9, 65.9, 42.3, 18.5.  
HRMS-EI m/z: measured 266.0543 ([M]
 +
, calcd. 266.0548 for C12H14N2OS2). MS (EI) 
m/z (% relative int.): 266 [M
+
] (9), 235 (100), 218 (23), 160 (54), 129 (82), 91 (43). 
 
4.3.3 Synthesis of metabolites 
4.3.3.1 3-(3-Indolyl)propanol (332) 
 
Synthesized as described earlier (4.3.2.9) in 95% yield. 
HPLC tR = 7.2 min (method A). 
 
1
H NMR (500 MHz, CDCl3): δ 8.10 (br s, NH), 7.65 (d, J = 8 Hz, 1H), 7.36 (d, J = 8 
Hz, 1H), 7.25 (dd, J = 7, 8 Hz, 1H), 7.16 (dd, J = 7, 8 Hz, 1H), 6.96 (s, 1H), 3.74 (t, J = 
6.5 Hz, 2H), 2.88 (t, J = 7.5 Hz, 2H), 2.01 (quint, 2H), 1.81 (br s, OH).  
13
C NMR (125 MHz, CDCl3): δ 136.6, 127.6, 122.1, 121.5, 119.3, 119.0, 116.0, 111.3, 
62.7, 33.1, 21.5.  
HRMS-EI m/z: measured 175.0988 ([M]
 +
, calcd. 175.0991 for C11H13NO). MS (EI) 
m/z (% relative int.): 175 [M
+
] (33), 144 (5), 130 (100), 78 (1). 
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4.3.3.2 Dihydroerucalexin (334)  
 
 
Reagents and conditions: (i) NaBH4, MeOH, 0 °C, 60%. 
 
NaBH4 (1 mg, 0.032 mmol) was added to a solution of erucalexin (29, 15 mg, 0.053 
mmol) in methanol (1 ml) at 0 °C and stirred at the same temperature. After 5 min, the 
reaction mixture was diluted with water (1 ml) and directly loaded onto a reversed 
phase column (C18 silica gel) and eluted with H2O-CH3CN (60:40, v:v)  to afford the 
mixture of diastereomeric products 334 (9 mg, 0.03 mmol, 60% yield) as a white solid 
in 3:1 ratio.       
HPLC tR = 9.2 min (major) and 11.9 min (minor) (method A). 
Major isomer: 
1
H NMR (500 MHz, CD3CN): δ 7.31-7.23 (m, 2H), 7.00 (ddd, J = 8, 8, 
1 Hz, 1H), 6.93 (d, J = 8 Hz, 1H), 4.94 (s, 1H), 4.65 (d, J = 16 Hz, 1H), 4.26 (d, J = 16 
Hz, 1H), 4.09 (br s, OH), 3.86 (s, 3H), 2.51 (s, SMe, 3H).
 
13
C NMR (125 MHz, CDCl3): δ 164.9, 150.7, 130.4, 124.5, 123.9, 112.5, 74.3, 70.2, 
66.8, 65.3, 15.5.  
Minor isomer: 
1
H NMR (500 MHz, CD3CN): δ 7.31-7.23 (m, 2H), 7.00 (ddd, J = 8, 8, 
1 Hz, 1H), 6.93 (d, J = 8 Hz, 1H), 5.24 (s, 1H), 4.49 (d, J = 16.5 Hz, 1H), 4.45 (d, J = 
16.5 Hz, 1H), 4.09 (br s, OH), 3.88 (s, OMe, 3H), 2.51 (s, SMe, 3H). 
 
13
C NMR (125 MHz, CDCl3): δ 163.8, 152.0, 131.1, 130.5, 126.3, 124.1, 113.0, 103.9, 
76.3, 66.7, 15.5.  
FTIR (KBr) νmax cm
-1
:  3317, 2929, 1614, 1570, 1463, 1193, 994, 954, 758.  
UV (HPLC, CH3CN–H2O) λmax (nm): 208, 240, 285.  
HRMS-EI m/z: measured 282.0502 ([M]
 +
, calcd. 282.0497 for C12H14N2O2S2). MS 
(EI) m/z (% relative int.): 282 [M
+
] (12), 250 (51), 191 (100), 177 (68), 149 (22), 132 
(57), 117 (34), 87 (41), 72 (48). 
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4.3.3.3  Synthesis of compounds 340, 344, 346, 348 and 349 
 
General procedure: 
 
Reagents and conditions: (i) Pyr, Ac2O, DCM, 0 °C, 74-90%. 
Acetic anhydride (1.1 eq) was added to a solution of amines 155, 324, 330, 339 or 343 
(1 eq) and pyridine (1.5 eq) in DCM (2 ml) at 0 ⁰C and stirred at r.t. for 10-30 min. 
After complete conversion of the starting material, the reaction mixture was diluted 
with toluene (5 ml) and concentrated using a  rotary evaporator to afford crude 
substituted acetamides which were separated by FCC (SiO2; EtOAc) to afford 
compounds 340, 344, 346, 348 and 349.  
4.3.3.4 Nb-Acetyl-2-indolylmethanamine (340)  
 
Acetylation of indolyl-2-methanamine (339, 30 mg, 0.20 mmol) using the above 
procedure afforded compound 340 (29 mg, 0.15 mmol) in 75% yield.  
HPLC tR = 6.2 min (method A). 
 
1
H NMR (500 MHz, CDCl3): δ 9.05 (br s, NH), 7.57 (d, J = 8 Hz, 1H), 7.33 (d, J = 8 
Hz, 1H), 7.17 (dd, J = 7.5, 7.5 Hz, 1H), 7.09 (dd, J = 7.5, 7.5 Hz, 1H), 6.32 (s, 1H), 
6.18 (br s, NHAc), 4.45 (d, J = 6 Hz, 2H), 2.00 (s, 3H).  
13
C NMR (125 MHz, CDCl3): δ 171.9, 136.6, 127.8, 122.2, 120.5, 119.9, 111.3, 100.7, 
37.6, 23.2.  
FTIR (KBr) νmax cm
-1
: 3392, 3269, 3060, 1651, 1531, 1456, 1423, 1288, 749.  
UV (HPLC, CH3OH–H2O) λmax (nm): 219, 272.  
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HRMS-EI m/z: measured 188.0947 ([M]
 +
, calcd. 188.0950 for C11H12N2O). MS (EI) 
m/z (% relative int.): 188 [M
+
] (100), 145 (46), 130 (40), 118 (51). 
4.3.3.5 Nb-Acetyl-1-methoxy-2- indolylmethanamine (344)  
 
Acetylation of 1-methoxy-2-indolylmethanamine (343, 209 mg, 1.19 mmol) using the 
general procedure afforded compound 344 (223 mg, 1.02 mmol) in 84% yield.  
HPLC tR = 8.9 min (method C). 
 
1
H NMR (500 MHz, CDCl3): δ 7.52 (d, J = 8 Hz, 1H), 7.39 (d, J = 8 Hz, 1H), 7.24 
(dd, J = 8, 8 Hz, 1H), 7.11 (dd, J = 8, 8 Hz, 1H), 6.32 (br s, NHAc), 6.24 (s, 1H), 4.58 
(d, J = 6 Hz, 2 H), 4.04 (s, 3H), 1.98 (s, 3H).  
13
C NMR (125 MHz, CDCl3): δ 170.3, 133.3, 132.7, 123.7, 122.5, 121.0, 120.5, 108.2, 
97.4, 65.5, 34.7, 23.2.  
FTIR (KBr) νmax cm
-1
: 3275, 3060, 2940, 1655, 1541, 1452, 1288, 971, 744.  
UV (HPLC, CH3OH–H2O) λmax (nm): 220, 270.  
HRMS-EI m/z: measured 218.1050 ([M]
 +
, calcd. 218.1055 for C12H14N2O2). MS (EI) 
m/z (% relative int.): 218 [M
+
] (28), 187 (44), 169 (27), 145 (100), 129 (12), 118 (70), 
100 (9), 89 (14). 
4.3.3.6 Nb-Acetyltryptamine (346) 
 
Acetylation of tryptamine (155, 100 mg, 0.62 mmol) using above procedure afforded 
compound 346 (115 mg, 0.57 mmol) in 91% yield (Pedras and Okanga, 2000).  
HPLC tR = 18.3 min (method A). 
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1
H NMR (500 MHz, CDCl3): δ 8.66 (br s, NH), 7.60 (d, J = 8 Hz, 1H), 7.37 (d, J = 8 
Hz, 1H), 7.19 (dd, J = 8, 7.5 Hz, 1H), 7.13 (dd, J = 8, 7.5 Hz, 1H), 7.00 (s, 1H), 5.80 
(br s, NH), 3.58 (q, J = 7 Hz, 2H), 2.97 (t, J = 7 Hz, 2H), 1.91 (s, 3H). 
13
C NMR (125 MHz, CDCl3): δ 170.5, 136.6, 127.4, 122.4, 122.2, 119.5, 118.7, 112.8, 
111.5, 40.1, 25.4, 23.4.  
HRMS-EI m/z: measured 202.1109 ([M]
 +
, calcd. 202.1106 for C12H14N2O). MS (EI) 
m/z (% relative int.): 202 [M
+
] (20), 144 (12), 143 (100), 130 (98). 
4.3.3.7 Nb-Acetyl-3-indolylpropanamine (348)  
 
Acetylation of 3-indolylpropanamine (324, 150 mg, 0.867mmol) using the above 
procedure afforded compound 348 (138 mg, 0.64 mmol) in 74% yield.  
HPLC tR = 21.4 min (method A). 
 
1
H NMR (500 MHz, CDCl3): δ 8.54 (br s, NH), 7.58 (d, J = 8 Hz, 1H), 7.34 (d, J = 8 
Hz, 1H), 7.20 (dd, J = 8, 7 Hz, 1H), 7.12 (dd, J = 8, 7 Hz, 1H), 6.90 (s, 1H), 5.86 (br s, 
NHAc), 3.28 (m, 2H), 2.77 (t, J = 7 Hz, 2H), 1.91 (s, 3H), 1.89 (quint, J = 7 Hz, 2H).  
13
C NMR (125 MHz, CDCl3): δ 170.6, 136.6, 127.4, 121.9, 121.8, 119.1, 118.8, 115.2, 
111.5, 39.7, 29.8, 23.3, 22.7. 
 FTIR (KBr) νmax cm
-1
:  3403, 3283, 2930, 1652, 1550, 1456, 743.  
UV (HPLC, CH3OH–H2O) λmax (nm): 221, 282.   
HRMS-EI m/z: measured 216.1266 ([M]
 +
, calcd. 216.1263 for C13H16N2O). MS (EI) 
m/z (% relative int.): 216 [M
+
] (39), 157 (35), 144 (37), 130 (100). 
4.3.3.8  N-Acetyl-4-biphenylmethanamine (349)  
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Acetylation of 4-biphenylmethanamine (330, 225 mg, 1.24 mmol) using the above 
procedure afforded compound 349 (251 mg, 1.11 mmol) in 90% yield.  
 
HPLC tR = 18.3 min (method A). 
 
1
H NMR (500 MHz, CDCl3): δ 7.64 (d, J = 8 Hz, 2H), 7.61 (d, J = 8 Hz, 2H), 7.46 
(dd, J = 7, 8 Hz, 2H), 7.36 (m, 3H), 6.85 (br s, NH), 4.36 (d, J = 6 Hz, 2H), 1.92 (s, 
3H).  
13
C NMR (125 MHz, CDCl3): δ 171.0, 142.0, 140.9, 140.3, 130.3, 129.3, 128.7, 128.3, 
128.2, 43.6, 23.4.  
FTIR (KBr) νmax cm
-1
:  3292, 3091, 1638, 1554, 1443, 1373, 1294, 1094, 756.  
UV (HPLC, CH3OH–H2O) λmax (nm): 206, 252. 
HRMS-EI m/z: measured 225.1148 ([M]
 +
, calcd. 225.1154 for C15H15NO). MS (EI) 
m/z (% relative int.): 225 [M
+
] (100), 182 (66), 167 (34), 106 (20). 
4.3.3.9   Methyl 3a-hydroxy-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-
1(2H)-yl carbodithioate (345) 
 
Reagents and conditions: (i) Rose Bengal, 5% Pyr/MeOH, hν, 53% (Pedras and 
Okanga, 2000). 
 
Compound 345 was prepared according to a published procedure (Pedras and Okanga, 
2000). Rose bengal (16 mg, 0.016 mmol) was added to a solution of 96 (40 mg, 0.16 
mmol) in 5% Pyr/MeOH (6 ml) in a pyrex tube and the reaction mixture was cooled in 
an icebath. Next, the reaction medium was irradiated with 100 W halogen bulb under 
continuous bubbling of air. After 2 hrs, the reaction mixture was transferred to round 
bottom flask, dimethylsulfide (300 µl) was added and the reaction mixture was stirred 
at r.t. After 1 h, the reaction mixture was diluted with toluene (10 ml) and concentrated 
under reduced pressure. The residue was separated by FCC (SiO2; DCM-Et2O, 1:1, v/v) 
to afford 345 (16 mg, 0.06 mmol) in 53% yield based on recovered starting material. 
HPLC tR = 11.5 min (method A). 
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1
H NMR (500 MHz, CDCl3): δ 7.33 (d, J = 7.5 Hz, 1H), 7.20 (dd, J = 8, 7.5 Hz, 1H), 
6.83 (dd, J = 7.5, 7.5 Hz, 1H), 6.65 (d, J = 8, 7.5 Hz, 1H), 5.76 (s, 1H), 4.14 (m, 1H), 
3.36 (m, 1H), 2.65 (s, 3H), 2.65-2.55 (m, 2H).  
13
C NMR (125 MHz, CDCl3): δ 197.6, 149.2, 131.1, 128.8, 123.7, 119.7, 110.4, 87.3, 
86.4, 50.3, 36.1, 19.5.  
HRMS-EI m/z: measured 266.0544 ([M]
 +
, calcd. 266.0548 for C12H14N2OS2). MS (EI) 
m/z (% relative int.): 266 [M
+
] (100), 251 (8), 219 (19), 186 (42), 160 (41), 133 (56), 91 
(14), 69 (40). 
 
4.4 Brassinin detoxification inhibitors 
4.4.1  Synthesis of quinoline derivatives  
4.4.1.1  2-(2-Thiazolyl)quinoline (350) 
 
Reagents and conditions: (i) ClCO2Et, DCM, 2-(trimethylsilyl)thiazole, r.t., 25%; (ii) o-
chloranil, C6H6, reflux, 52% (Dondoni, Dall’ Occo et al., 1984). 
 
 
Ethylchloroformate (73 mg, 0.77 mmol) was added to a solution of quinoline (396, 100 
mg, 0.77 mmol) in DCM at 0 ºC and the reaction mixture was stirred at r.t. After 30 
min, 2-(trimethylsilyl)thiazole (122 mg, 0.77 mmol) was added and the reaction 
mixture was stirred at r.t. for 3 h. The reaction mixture was concentrated under reduced 
pressure and the residue was separated by FCC (SiO2, DCM/Hex) to afford 2-(2-
thiazolyl)-1(2H)-quinolinecarboxylic acid ethyl ester (397, 55 mg) as a pale yellow 
solid in 25% yield. o-Chloranil (54 mg, 0.22 mmol) was added to a solution of 
compound 397 (55 mg, 0.202 mmol) in benzene (3 ml) and the reaction mixture was 
refluxed at 80 ºC. After 5 h, the reaction mixture was diluted with 5% NaOH (10 ml) 
and extracted with DCM (2 × 30 ml). The combined organic extract was dried over 
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Na2SO4 and concentrated to yield the crude which was separated by FCC (SiO2, 
DCM/Hex) to afford the product 350 (Dondoni, Dall’ Occo et al., 1984) as a white 
solid (23 mg, 0.11 mmol) in 52% yield.  
 
HPLC tR = 15.2 min (method A). 
1
H NMR (500 MHz, CDCl3): δ 8.35 (d, J = 8.5 Hz, 1H), 8.27 (d, J = 8.5 Hz, 1H), 8.15 
(d, J = 8.5 Hz, 1H), 7.99 (d, J = 3 Hz, 1H), 7.85 (d, J = 8 Hz, 1H), 7.75 (ddd, J = 8, 8, 1 
Hz, 1H), 7.57 (ddd, J = 8, 8, 1 Hz, 1H), 7.52 (d, J = 3 Hz, 1H).  
13
C NMR (125 MHz, CDCl3): δ 144.3, 137.3, 131.9, 129.7, 128.8, 127.9, 127.3, 125.9, 
122.2, 118.0, 99.4, 99.3.  
FTIR (KBr) νmax cm
-1
:  3072, 1593, 1504, 1427, 1311, 1116, 1002, 938, 834, 755.  
UV (HPLC, CH3OH–H2O) λmax (nm): 220, 240, 275, 330. 
HRMS-EI m/z: measured 212.0412 ([M]
 +
, calcd. 212.0408 for C12H7N2S). MS (EI) m/z 
(% relative int.): 212 [M
+
] (100), 186 (14), 162 (34), 151 (20), 128 (11), 100 (35). 
4.4.1.2  Synthesis of compounds 351-356 
 
General procedure 
 
Reagents and conditions: (i) Fe/HCl, EtOH; (ii) KOH, C6H5C(O)Me, 42- 83%. 
 
To a solution of o-nitrobenzaldehyde (1 mmol) in EtOH (3 ml) was added iron Fe 
powder (4 mmol) followed by 0.1 N HCl (0.05 mmol) and the reaction mixture was 
refluxed at 95 ºC for 40 min. After complete consumption of the starting material, 
acetophenone (1 mmol) followed by KOH (1.2 mmol) were added and the mixture was 
heated at 95 ºC for 3 h (Li, Ahmed et al., 2007). The reaction mixture was filtered, 
neutralized with 10% HCl (3 ml) and extracted in EtOAc (2 × 30 ml). The combined 
organic extract was dried over Na2SO4 and concentrated under reduced pressure to 
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afford the crude mixture which was separated by FCC (SiO2; DCM/Hex) to afford 351-
356 in 42-83% yields. 
2-Phenylquinoline (351) 
 
Compound 351 was prepared starting from compound 369 (151 mg, 1.00 mmol) 
according to the above procedure in 83% yield (171 mg, 0.83 mmol) (Li, Ahmed et al., 
2007). Analytical data matched with the published values (Movassaghi and Hill, 2006). 
 
HPLC tR = 18.8 min (method A). 
1
H NMR (500 MHz, CDCl3): δ 8.24 (d, J = 8.5 Hz, 1H), 8.18 (m, 3H), 7.89 (d, J = 8.5 
Hz, 1H), 7.84 (d, J = 8 Hz, 1H), 7.74 (dd, J = 7.5, 8 Hz, 1H), 7.54 (dd, J = 7.5, 8 Hz, 
3H), 7.48 (m, 1H).  
13
C NMR (125 MHz, CDCl3): δ 157.6, 148.5, 139.9, 136.9, 129.9, 129.8, 129.5, 129.0, 
127.8, 127.7, 127.4, 126.5, 119.2. 
FTIR (KBr) νmax cm
-1
:  3055, 1617, 1597, 1554, 1490, 1446, 1320, 1284, 829, 765, 691. 
UV (HPLC, CH3OH–H2O) λmax (nm): 210, 259, 322. 
 HRMS-EI m/z: measured 205.0890 ([M]
 +
, calcd. 205.0891 for C15H11N). MS (EI) m/z 
(% relative int.): 205 [M
+
] (100), 176 (5), 149 (5), 102 (14), 76 (6). 
6-Bromo-2-phenylquinoline (352) 
 
3-Bromobenzaldehyde (367, 558 mg, 3.01 mmol) was added drpwise to a cooled 
mixture of HNO3/H2SO4 (0.3ml/3 ml) at 0 ºC and the reaction mixture was stirred at 5 
ºC. After 1 h, the reaction mixture was poured into ice-cold water (20 ml) and the 
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precipitate was filtered. The crude product was purified by FCC (SiO2; 20% 
EtOAc/Hex) to afford compound 368 (470 mg, 2.04 mmol, 68%) as a brown solid 
(Alford and Schofield, 1952). Next, compound 352  was prepared starting from 
compound 368 (59 mg, 0.25 mmol) according to the general procedure described above 
in 64% yield (47 mg, 0.16 mmol). Analytical data matched published values (Huo, 
Gridnev et al., 2010). 
 HPLC tR = 20.5 min (method A). 
1
H NMR (500 MHz, CDCl3): δ 8.20-8.12 (m, 3H), 8.05 (d, J = 9 Hz, 1H), 8.00 (d, J = 2 
Hz, 1H), 7.92 (d, J = 9 Hz, 1H), 7.80 (dd, J = 2, 9 Hz, 1H), 7.55 (dd, J = 7, 7 Hz, 2H), 
7.50 (m, 1H). 
13
C NMR (125 MHz, CDCl3): δ 157.9, 147.1, 139.5, 135.9, 133.3, 131.7, 129.86, 
129.7, 129.1, 128.5, 127.7, 120.3, 120.0. 
FTIR (KBr) νmax cm
-1
:  1595, 1542, 1483, 1278, 887, 875, 830, 786, 758, 695. 
UV (HPLC, CH3OH–H2O) λmax (nm): 220, 257, 325. 
HRMS-EI m/z: measured 284.9987 ([M
+
], calcd. 284.9976 [100%] for C15H10
81
BrN), 
283.0001 ([M
+
], calcd. 282.9997 for C15H10
79
BrN). MS (EI) m/z (% relative int.): 285 
(100), 283 [M
+
] (99), 281 (29), 204 (41), 203 (33), 102 (26). 
 
5-Chloro-2-phenylquinoline (353)  
 
Compound 353 was prepared starting from compound 370 (200 mg, 1.07 mmol) 
according to the above procedure in 84% yield (215 mg, 0.90 mmol).  
HPLC tR = 24.4 min (method A). 
1
H NMR (500 MHz, CDCl3): δ 8.63 (d, J = 9 Hz, 1H), 8.19 (m, 2H), 8.11 (d, J = 8 Hz, 
1H), 7.99 (d, J = 9 Hz, 1H), 7.68-7.59 (m, 2H), 7.56 (m, 2H), 7.50 (dd, J = 7, 7 Hz, 
1H).  
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13
C NMR (125 MHz, CDCl3): δ 158.1, 149.2, 139.2, 133.8, 131.4, 129.9, 129.5, 129.2, 
129.1, 127.8, 126.5, 125.5, 119.9.  
FTIR (KBr) νmax cm
-1
:  3058, 1611, 1593, 1580, 1547, 1486, 1461, 1396, 1316, 1278, 
1201, 1025, 960, 814, 775, 692, 671. 
UV (HPLC, CH3OH–H2O) λmax (nm): 208, 262. 
HRMS-EI m/z: measured 241.0481 ([M]
 +
, calcd. 241.0472 [32%] for C15H10N
37
Cl), 
239.0507 ([M]
 +
, calcd. 239.0502 for C15H10NCl). MS (EI) m/z (% relative int.): 241 
(32), 239 [M
+
] (100), 204 (33), 102 (11).  
6-Chloro-2-phenylquinoline (354) 
 
Compound 354 was prepared starting from compound 371 (200 mg, 1.07 mmol) 
according to the above procedure in 63% yield (161 mg, 0.67 mmol). Analytical data 
matched with the published values (Shi, Rong et al., 2005).  
HPLC tR = 22.2 min (method A). 
1
H NMR (500 MHz, CDCl3): δ 8.20-8.09 (m, 4H), 7.91 (d, J = 9 Hz, 1H), 7.82 (d, J = 2 
Hz, 1H), 7.67 (dd, J = 2, 9 Hz, 1H), 7.55 (t, J = 7.5 Hz, 2H), 7.49 (dd, J = 7, 7.5 Hz, 
1H).  
13
C NMR (125 MHz, CDCl3): δ 157.8, 146.9, 139.4, 136.0, 132.1, 131.6, 130.8, 129.8, 
129.1, 128.0, 127.7, 126.3, 120.0.  
FTIR (KBr) νmax cm
-1
: 3060, 1596, 1548, 1484, 1445, 1320, 1280, 1192, 1130, 1075, 
945, 886, 876, 832, 782, 755, 695. 
UV (HPLC, CH3OH–H2O) λmax (nm): 215, 255, 325. 
HRMS-EI m/z: measured 241.0469 ([M]
 +
, calcd. 241.0472 [33%] for C15H10N
37
Cl), 
239.0496 ([M]
 +
, calcd. 239.0502 for C15H10NCl). MS (EI) m/z (% relative int.): 241 
(33), 239 [M
+
] (100), 204 (33), 102 (9).  
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6-Hydroxy-2-phenylquinoline (355) 
 
Compound 355 was prepared starting from compound 372 (200 mg, 1.19 mmol) 
according to the above procedure in 42% yield (112 mg, 0.51 mmol). Analytical data 
matched with the published values (Melendez Gomez, Kouznetsov et al., 2008).  
HPLC tR = 14.2 min (method A). 
1
H NMR (500 MHz, CDCl3): δ 7.48-7.45 (m, 4H), 7.40 (d, J = 2 Hz , 1H), 7.33 (dd, J = 
2, 2.5 Hz, 1H), 7.31 (dd, J = 2, 2.5 Hz, 1H), 7.28 (dd, J = 2, 2.5 Hz, 1H), 7.24 (d, J = 2 
Hz, 1H), 6.84 (br s, OH).  
13
C NMR (125 MHz, CDCl3): δ 155.5, 153.9, 140.0, 135.5, 131.7, 129.2, 129.0, 128.4, 
127.6, 121.7, 119.7, 109.1.  
FTIR (KBr) νmax cm
-1
: 3500-2500 (br), 1619, 1561, 1452, 1393, 1349, 1228, 1131, 928, 
859, 826, 756. 
UV (HPLC, CH3OH–H2O) λmax (nm): 215, 260, 342. 
HRMS-EI m/z: measured 221.0841 ([M]
 +
, calcd. 221.0841 for C15H11NO). MS (EI) 
m/z (% relative int.): 221 [M
+
] (100), 204 (6), 191 (10), 111 (6).  
6-Methoxy-2-phenylquinoline (356) 
 
Compound 356  was prepared starting from compound 373 (150 mg, 0.82 mmol) 
according to the above procedure in 60% yield (115 mg, 0.49 mmol). Analytical data 
matched published values (Movassaghi and Hill, 2006).   
HPLC tR = 19.3 min (method A). 
   
143 
 
1
H NMR (500 MHz, CDCl3): δ 8.19-8.05 (m, 4H), 7.85 (d, J = 9 Hz , 1H), 7.53 (dd, J = 
7.5, 7 Hz, 1H), 7.45 (dd, J = 7, 7.5 Hz, 1H), 7.40 (dd, J = 9, 3 Hz, 1H), 7.10 (d, J = 3 
Hz, 1H), 3.96 (s, 3H). 
 
13
C NMR (125 MHz, CDCl3): δ 157.9, 155.3, 144.7, 140.1, 135.7, 131.5, 129.2, 129.0, 
128.4, 127.5, 122.5, 119.4, 105.3, 55.7.  
FTIR (KBr) νmax cm
-1
:  3006, 1620, 1597, 1557, 1492, 1340, 1251, 1228, 1163, 1021, 
860, 832, 762. 
UV (HPLC, CH3OH–H2O) λmax (nm): 216, 256, 336. 
HRMS-EI m/z: measured 235.0994 ([M]
 +
, calcd. 235.0997 for C16H13NO). MS (EI) 
m/z (% relative int.): 235 [M
+
] (100), 220 (21), 192 (34). 
 
4.4.1.3 Synthesis of compounds 357-361 
 
General procedure 
 
Reagents and conditions: (i) Fe/HCl, EtOH; (ii) KOH, PhCH2CHO, 39- 80%. 
To a solution of o-nitrobenzaldehyde (1 mmol) in EtOH (3 ml) was added iron powder 
(4 mmol) followed by 0.1 N HCl (0.05 mmol) and the reaction mixture was refluxed at 
95 ºC for 40 min. After consumption of the starting material, phenylacetaldehyde (1 
mmol) followed by KOH (1.2 mmol) were added and the the mixture was heated at 95 
ºC for 3 h (Li et al., 2007). The reaction mixture was filtered, neutralized with 10% 
HCl (3 ml) and extracted with EtOAc (2 × 30 ml). The combined organic extract was 
dried over Na2SO4 and concentrated to yield the crude which was purified by FCC 
(SiO2, DCM/Hex) to afford the products 358-362 in 39-80% yields. 
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3-Phenylquinoline (357) 
 
Compound 357 was prepared starting from compound 369 (200 mg, 1.32 mmol) 
according to the above procedure in 63% yield (172 mg, 0.84 mmol) (Li, Ahmed et al., 
2007). Analytical data matched with the published values. 
HPLC tR = 18.1 min (method A). 
1
H NMR (500 MHz, CDCl3): δ 9.20 (s, 1H), 8.29 (s, 1H), 8.16 (d, J = 8.5 Hz , 1H), 
7.87 (d, J = 8 Hz, 1H), 7.80-7.66 (m, 3H), 7.63-7.50 (m, 3H), 7.43 (dd, J = 7, 7.5 Hz, 
1H).  
13
C NMR (125 MHz, CDCl3): 150.1, 147.5, 138.0, 133.9, 133.3, 129.5, 129.4, 129.2, 
128.2, 128.1, 127.6, 127.1, 127.0.  
FTIR (KBr) νmax cm
-1
:  3057, 1492, 1362, 1340, 1125, 1025, 953, 902, 786, 761, 696. 
UV (HPLC, CH3OH–H2O) λmax (nm): 210, 250, 325. 
HRMS-EI m/z: measured 205.0884 ([M]
 +
, calcd. 205.0891 for C15H11N). MS (EI) m/z 
(% relative int.): 205 [M
+
] (100), 176 (8), 149 (8), 76 (7).  
 
5-Chloro-3-phenylquinoline (358)  
 
Compound 358 was prepared starting from compound 370 (200 mg, 1.07 mmol) 
according to the general procedure in 80% yield (207 mg, 0.87 mmol).
  
HPLC tR = 22.9 min (method A). 
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1
H NMR (500 MHz, CDCl3): δ 9.18 (d, J = 2 Hz , 1H), 8.22 (d, J = 2 Hz , 1H), 8.08 (d, 
J = 9 Hz , 1H), 7.88 (d, J = 2 Hz, 1H), 7.71 (m, 2H), 7.66 (dd, J = 9, 2 Hz, 1H), 7.55 
(m, 2H), 7.47 (dd, J = 7.5, 7.5 Hz, 1H).  
13
C NMR (125 MHz, CDCl3): δ 150.8, 148.1, 137.7, 135.0, 131.7, 130.2, 129.5, 129.2, 
128.7, 128.6, 127.8, 127.3, 126.4. 
 FTIR (KBr) νmax cm
-1
:  3053, 1487, 1456, 1182, 977, 900, 810, 758, 742, 694.  
UV (HPLC, CH3OH–H2O) λmax (nm): 208, 238, 257.  
HRMS-EI m/z: measured 241.0480 ([M]
 +
, calcd. 241.0472 [34%] for C15H10N
37
Cl), 
239.0507 ([M]
 +
, calcd. 239.0502 for C15H10NCl). MS (EI) m/z (% relative int.): 241 
(34), 239 [M
+
] (100), 204 (15), 6 (12). 
6-Chloro-3-phenylquinoline (359) 
 
Compound 359 was prepared starting from compound 371 (200 mg, 1.07 mmol) 
according to the above procedure in 64% yield (163 mg, 0.68 mmol). Analytical data 
matched with the published values (Wang, Xin et al., 2009). 
HPLC tR = 21.1 min (method A). 
 1
H NMR (500 MHz, CDCl3): δ 9.23 (d, J = 2 Hz, 1H), 8.71 (s, 1H), 8.08 (d, J = 7 Hz, 
1H), 7.76 (d, J = 8 Hz, 2H), 7.69-7.61 (m, 2H), 7.56 (dd, J = 7, 8 Hz, 2H), 7.48 (dd, J = 
7, 8 Hz, 1H).  
13
C NMR (125 MHz, CDCl3): δ 150.8, 148.2, 137.7, 135.0, 131.7, 130.2, 129.5, 129.2, 
128.7, 128.6, 127.8, 127.3, 126.4.  
FTIR (KBr) νmax cm
-1
:  3036, 1488, 1452, 1332, 1075, 926, 907, 826, 755, 698. 
UV (HPLC, CH3OH–H2O) λmax (nm): 210, 254, 330. 
HRMS-EI m/z: measured 241.0474 ([M]
 +
, calcd. 241.0472 [34%] for C15H10N
37
Cl), 
239.0501 ([M]
 +
, calcd. 239.0502 for C15H10NCl). MS (EI) m/z (% relative int.): 241 
(34), 239 [M
+
] (100), 204 (14), 176 (11), 88 (6).  
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6-Hydroxy-3-phenylquinoline (360)  
 
Compound 360 was prepared starting from compound 372 (200 mg, 1.19 mmol) 
according to the above procedure in 39% yield (102 mg, 0.46 mmol).  
HPLC tR = 14.0 min (method A). 
1
H NMR (500 MHz, DMSO-d6): δ 10.09 (d, J = 2 Hz , 1H), 8.99 (s, 1H), 8.41 (s, 1H), 
7.89 (d, J = 9 Hz, 1H), 7.84 (d, J = 7.5 Hz, 2H), 7.53 (dd, J = 7.5, 7.5 Hz, 2H), 7.44 
(dd, J = 7.5, 7.5 Hz, 1H), 7.31 (dd, J = 2, 9 Hz, 1H), 7.23 (d, J = 2 Hz , 1H).  
13
C NMR (125 MHz, DMSO-d6): δ 155.9, 146.1, 142.2, 137.4, 132.8, 131.1, 130.1, 
129.2, 128.0, 127.1, 122.0, 108.7.  
FTIR (KBr) νmax cm
-1
: 2952, 1620, 1496, 1457, 1376, 1246, 1217, 1166, 950, 898, 763, 
701.  
UV (HPLC, CH3OH–H2O) λmax (nm): 206, 255, 342. 
HRMS-EI m/z: measured 221.0838 ([M]
 +
, calcd. 221.0841 for C15H11NO). MS (EI) 
m/z (% relative int.): 221 [M
+
] (100), 192 (7), 165 (11), 139 (5).  
6-Methoxy-3-phenylquinoline (361) 
 
Compound 361 was prepared starting from compound 373 (178 mg, 0.98 mmol) 
according to the above procedure in 53% yield (123 mg, 0.52 mmol). Analytical data 
matched with the published values (Monrad and Madsen, 2011). 
HPLC tR = 18.6 min (method A). 
   
147 
 
1
H NMR (500 MHz, CDCl3): δ 9.03 (s, 1H), 8.21 (s, 1H), 8.04 (d, J = 9 Hz, 1H), 7.71 
(d, J = 7.5 Hz, 2H), 7.53 (dd, J =7.5, 7.5 Hz, 2H), 7.44 (dd, 7.5, 7.5 Hz, 1H), 7.38 (dd, 
7.5, 1.5 Hz, 1H), 7.14 (s, 1H), 3.96 (s, 3H).  
13
C NMR (125 MHz, CDCl3): δ 158.3, 147.6, 143.7, 138.3, 134.3, 132.3, 130.8, 129.3, 
129.2, 128.2, 127.6, 122.4, 105.5, 55.8.  
FTIR (KBr) νmax cm
-1
:  3002, 2834, 1620, 1496, 1463, 1374, 1351, 1244, 1213, 1164, 
1029, 902, 831, 763, 697. 
UV (HPLC, CH3OH–H2O) λmax (nm): 207, 255, 340.  
HRMS-EI m/z: measured 235.1000 ([M]
 +
, calcd. 235.0997 for C16H13NO). MS (EI) 
m/z (% relative int.): 235 [M
+
] (100), 205 (7), 193 (10), 192 (63), 165 (15), 139 (6), 115 
(5).  
4.4.2 Synthesis of isoquinoline derivatives   
4.4.2.1    1-(2-Thiazolyl)isoquinoline (362) 
 
Reagents and conditions: (i) ClCO2Et, DCM, 2-(trimethylsilyl)thiazole, r.t., 54%; (ii) o-
chloranil, C6H6, reflux, 70%. 
 
To a solution of isoquinoline (379, 100 mg, 0.77 mmol) in DCM was added 
ethylchloroformate (73 mg, 0.77 mmol) at 0 ºC and the reaction mixture was stirred for 
30 min. Next, 2-(trimethylsilyl)thiazole (122 mg, 0.77 mmol) was added and the 
reaction mixture was stirred at r.t. for 3 h. Concentration of the reaction mixture 
followed by FCC separation (SiO2, DCM/Hex) of the residue afforded 1-(2-thiazolyl)-
1(2H)-isoquinolinecarboxylic acid ethyl ester 380 (113 mg, 0.39 mmol) as a pale 
yellow solid in 54% yield. To a solution of compound 380 (110 mg, 0.404 mmol) in 
benzene (5 ml) o-chloranil (108 mg, 0.44 mmol) was added and the reaction mixture 
was refluxed for 5 h. The reaction mixture was diluted with 5% NaOH (10 ml) and 
extracted with DCM (2 × 30 ml). Combined organic extract was dried over Na2SO4 and 
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concentrated to yield the crude which was separated by FCC (SiO2, DCM/Hex) to 
afford the product 362 (60 mg, 0.28 mmol) as a white solid in 70% yield (Dondoni, 
Dall’ Occo et al., 1984). 
HPLC tR = 14.7 ± 0.5 min (method A). 
1
H NMR (500 MHz, CDCl3): δ 9.50 (m, 1H), 8.57 (d, J = 5.5 Hz, 1H), 8.07 (d, J = 3 
Hz, 1H), 7.88 (m, 1H), 7.74 (m, 3H), 7.52 (d, J = 3 Hz, 1H).  
13
C NMR (125 MHz, CDCl3): δ 1.0, 149.7, 144.2, 141.9, 137.5, 130.6, 128.8, 128.0, 
127.1, 125.7, 122.4, 122.2. 
FTIR (KBr) νmax cm
-1
:  3050, 1579, 1550, 1496, 1425, 1350, 1312, 1270, 1236, 1097, 
946, 878, 828, 747. 
UV (HPLC, CH3OH–H2O) λmax (nm): 230, 295, 343. 
HRMS-EI m/z: measured 212.0413 ([M]
 +
, calcd. 212.0408 for C12H8N2S). MS (EI) m/z 
(% relative int.): 212 [M
+
] (100), 186 (10), 155 (9), 128 (14), 101 (11).   
4.4.2.2  Synthesis of compounds 363 and 364 
General procedure 
 
 
Reagents and conditions: (i) Aminoacetaldehyde dimethyl acetal, toluene, reflux 
(Dean-Stark); (ii) P2O5, H2SO4, 160 °C, 15-20% (Czako, Kurti et al., 2009); (iii) 
ClCO2Et, DCM, 2-trimethylsilylthiazole, r.t.; (iv) o-chloranil, toluene, reflux, 15-32%. 
 
 
Aminoacetaldehyde dimethyl acetal (3.0 eq) was added to a solution of 
bromobenzaldehydes 367 and 374 (1 eq) in toluene (30 ml) and refluxed (using a Dean-
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Stark apparatus) at 120 ºC. After consumption of the starting material (2 h), the 
reaction mixture was evaporated under reduced pressure to afford the crude acetals 375 
and 376. A cooled viscous solution of the acetals 375 and 376 in conc. H2SO4 (2 ml) 
was added to a cooled solution of P2O5 in conc. H2SO4 (0.5 ml) and the reaction 
mixture was heated to 160 ºC. After 30 min, reaction mixture was cooled to r.t. and 
neutralized with 10 N NaOH and extracted in EtOAc (3 × 40 ml). Combined organic 
extract was dried over anhydrous Na2SO4 and concentrated under reduced pressure to 
afford the crude product, which was purified by FCC to yield 6-bromoisoquinoline 
(377, 30 mg, 0.14 mmol) in 14% yield and 7-bromoisoquinoline (378, 99 mg, 0.47 
mmol) in 22% yield  (Jiang, Duckett et al., 2007). 
 
Ethylchloroformate (1 eq) was added to a solution of isoquinolines 377-379 (1 eq) in 
DCM at 0 ºC and the reaction mixture was stirred for 30 min. Next, 2-
(trimethylsilyl)thiazole (1 eq) was added and the reaction mixture was stirred at r.t. for 
3 h. Concentration of the reaction mixture followed by FCC separation (SiO2, 
DCM/Hex) of the residue afforded 1-(2-thiazolyl)-1(2H)-isoquinolinecarboxylic acid 
ethyl esters 380-382 (113 mg, 0.39 mmol). Further, solution of compounds 380-382 (1 
eq) in benzene (5 ml) o-chloranil (1 eq) was added and the reaction mixture was 
refluxed for 5 h. The reaction mixture was diluted with 5% NaOH (10 ml) and 
extracted with DCM (2 × 30 ml). Combined organic extract was dried over Na2SO4 and 
concentrated to yield the crude which was separated by FCC (SiO2, DCM/Hex) to 
afford the products 362-364 (Dondoni, Dall’ Occo et al., 1984). 
6-Bromo-1-(2-thiazolyl)isoquinoline (363) 
 
6-Bromoisoquinoline (377, 30 mg, 0.14 mmol) was synthesized starting from 4-
bromobenzaldehyde (374, 200 mg, 1.08 mmol) in 14% yield. Further, compound 363 
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was synthesized starting from 6-bromoisoquinoline (377, 100 mg, 0.48 mmol) in 15% 
yield over two steps (21 mg, 0.07 mmol). 
HPLC tR = 22.4 min (method A). 
1
H NMR (500 MHz, CDCl3): δ 9.77 (d, J = 9 Hz, 1H), 8.58 (d, J = 5.5 Hz, 1H), 8.06 
(m, 2H), 7.79 (dd, J = 2, 9 Hz, 1H), 7.61 (d, J = 5.5 Hz, 1H), 7.53 (d, J = 3 Hz, 1H).  
13
C NMR (125 MHz, CDCl3): δ 0.6, 149.9, 144.4, 143.0, 138.7, 132.3, 130.1, 129.1, 
125.7, 124.0, 122.5, 121.2. 
FTIR (KBr) νmax cm
-1
:  2924, 2852, 1782, 1608, 1546, 1426, 1246, 1183, 947, 880, 810. 
UV (HPLC, CH3OH–H2O) λmax (nm): 240, 345. 
HRMS-EI m/z: measured 291.9494 ([M]
 +
, calcd. 291.9493 [100%] for C12H7N2S
81
Br), 
289.9519 ([M]
 +
, calcd. 289.9513 for C12H7N2S
81
Br). MS (EI) m/z (% relative int.): 292 
[M
+
] (100), 290 (95), 264 (7), 248 (53), 211 (22), 153 (9), 127 (12), 100 (34), 58 (15).  
 
7-Bromo-1-(2-thiazolyl)isoquinoline (364) 
 
 
7-Bromoisoquinoline (378, 99 mg, 0.47 mmol) was synthesized starting from 
compound 367 in 22% yield (Jiang, Duckett et al., 2007). Further, compound 364 was 
synthesized starting from 7-bromoisoquinoline (378, 100 mg, 0.48 mmol) in 24% yield 
over two steps (35 mg, 0.12 mmol).   
HPLC tR = 21.0 min (method A). 
1
H NMR (500 MHz, CDCl3): δ 10.12 (s, 1H), 8.58 (d, J = 5.5 Hz, 1H), 8.08 (d, J = 3 
Hz, 1H), 7.80 (dd, J = 9, 2 Hz, 1H), 7.73 (d, J = 9 Hz, 1H), 7.67 (d, J = 5.5 Hz, 1H), 
7.53 (d, J = 3 Hz, 1H).  
13
C NMR (125 MHz, CDCl3): δ 0.3, 148.6, 144.5, 142.3, 136.0, 134.2, 130.5, 128.6, 
126.3, 123.1, 122.5, 122.1. 
FTIR (KBr) νmax cm
-1
:  3089, 1781, 1573, 1544, 1491, 1425, 1247, 1103, 947, 850, 813, 
732. 
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UV (HPLC, CH3OH–H2O) λmax (nm): 240, 302, 350. 
HRMS-EI m/z: measured 291.9483 ([M]
 +
, calcd. 291.9493 [100%] for C12H7N2S
81
Br), 
289.9512 ([M]
 +
, calcd. 289.9513 for C12H7N2SBr). MS (EI) m/z (% relative int.): 292 
(100), 290 [M
+
] (99), 264 (6), 211 (32), 185 (5), 162 (15), 153 (15), 127 (13), 100 (24), 
58 (15).  
 
4.4.2.3   1-Phenylisoquinoline (365) 
 
Reagents and conditions: (i) H2O2, AcOH, 80 °C, (Barber, Dickinson et al., 2004); (ii) 
POCl3, CHCl3, 80 °C (Alcock, Wirth et al., 1993); (iii) I2, THF; (iv) PhMgCl, Fe, THF. 
 
A solution of H2O2 (2.5 ml) and acetic acid (5 ml) was heated to 80 ºC. After 1 hr, 
isoquinoline (379, 200 mg, 1.55 mmol) was added to the reaction mixture and heated at 
the same temperature for 16 h. The reaction mixture was diluted with water (10 ml) and 
concentrated using a rotary evaporator to 1/3
rd
 volume; extracted with EtOAc (3 × 30 
ml). Combined organic extract was dried over Na2SO4 and concentrated under reduced 
pressure to afford the crude isoquinoline-N-oxide (398) (Barber, Dickinson et al., 
2004). POCl3 (119 µl, 1.27 mmol) was added dropwise to a solution of N-oxide CP064 
(88 mg, 0.60 mmol) in CHCl3 and refluxed at 80 ºC. After 3 hrs, reaction mixture was 
cooled to r.t., and diluted with ice cold water (10 ml), basified with 33% NH4OH (1 ml) 
and extracted with EtOAc (3 × 30 ml). The combined organic extract was dried over 
Na2SO4 and concentrated under reduced pressure to afford 1-chloroisoquinoline (383, 
38 mg, 0.23 mmol) in 42% yield (Alcock, Wirth et al., 1993). Iodine (18 mg, 0.073 
mmol) was added to a solution of compound 383 (12 mg, 0.073 mmol) in THF (2 ml) 
and stirred at r.t. After 30 min, Fe powder (16  mg, 0.294 mmol) followed by PhMgCl 
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(2 M in THF, 43 µl, 0.087 mmol) were added and stirred at r.t. for 6 h. After complete 
consumption of the starting material by TLC, the reaction mixture was diluted with ice-
cold water (20 ml) and extracted EtOAc (3 × 30 ml). The combined organic extract was 
dried over Na2SO4 and concentrated under reduced pressure to afford 1-
phenylisoquinoline (365, 10 mg, 0.05 mmol) in 67% yield. Analytical data matched 
with the published values (Larivee, Mousseau et al., 2008).          
HPLC tR = 16.2 min (method A). 
1
H NMR (500 MHz, CDCl3): δ 8.63 (d, J = 5.5 Hz, 1H), 8.12 (d, J = 8.5 Hz, 1H), 7.90 
(d, J = 8.5 Hz, 1H), 7.71 (m, 3H), 7.67 (d, J = 5.5 Hz, 1H), 7.51 (m, 4H).  
13
C NMR (125 MHz, CDCl3): δ 161.0, 142.5, 139.9, 137.1, 130.2, 130.1, 128.8, 128.6, 
127.8, 127.4, 127.2, 127.0, 1201.1.   
FTIR (KBr) νmax cm
-1
:  3053, 1695, 1556, 1444, 1385, 973, 825, 763, 699. 
UV (HPLC, CH3OH–H2O) λmax (nm): 229, 276, 324. 
HRMS-EI m/z: measured 205.0880 ([M]
 +
, calcd. 205.0891 for C15H11N). MS (EI) m/z 
(% relative int.): 205 [M
+
] (48), 204 (100), 176 (6), 102 (9), 69 (6).  
 
4.4.2.4  7-Bromo-1-phenylisoquinoline (366)  
 
Reagents and conditions: (i) I2, THF; (ii) PhMgCl, Fe, THF. 
 
Repetition of the above procedure starting from compound 384 (40 mg, 0.16 mmol) 
instead of compound 383 yielded compound 366 (21 mg, 0.07 mmol) in 47% yield.    
HPLC tR = 23.4 min (method A). 
1
H NMR (500 MHz, CDCl3): δ 8.64 (d, J = 6 Hz, 1H), 8.07 (d, J = 2 Hz, 1H), 7.99 (d, J 
= 9 Hz, 1H), 7.68 (dd, J = 2, 7.5 Hz, 2H), 7.62 (dd, J = 2, 9 Hz, 1H), 7.58-7.53 (m, 4H). 
 
13
C NMR (125 MHz, CDCl3): δ 161.2, 143.6, 139.3, 138.2, 130.9, 130.1, 129.7, 129.3, 
129.1, 128.7, 125.3, 125.1, 119.0.  
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FTIR (KBr) νmax cm
-1
: 3061, 3033, 2923, 1480, 1429, 1261, 1091, 1042, 1008, 903, 
800, 728, 697. 
UV (HPLC, CH3OH–H2O) λmax (nm): 220, 258, 328. 
HRMS-EI m/z: measured 284.9969 ([M]
 +
, calcd. 284.9976 [10%] for C15H10N
81
Br), 
282.9985 ([M]
 +
, calcd. 282.9997 for C15H10NBr). MS (EI) m/z (% relative int.): 285 
(10), 283 [M
+
] (10), 237 (26), 204 (13), 184 (41), 149 (19), 108 (6), 102 (5), 98 (26), 
91 (100), 84 (27), 65 (25).  
 
4.5 Antifungal activity 
 
The antifungal activity of compounds was determined using a mycelial radial growth 
bioassay. Isolates of L. maculans (isolates BJ-125/ UAMH-9410) were grown on V8 
agar plates for 14 days at 23ºC under constant light. Sterile tissue culture plates (6-well, 
33 mm diameter) were used in all bioassays. Solutions of each compound in ACN / 
DMSO were added to PDA (1% ACN / DMSO in final volume) to prepare the plates 
(0.50, 0.20 and 0.10 mM). Control plates were prepared to contain 1% ACN / DMSO 
in PDA. Plates containing test and control agar (2 ml per well) were inoculated with 
mycelium plugs [4 mm, cut from 7-day-old V8 plates of L. maculans (isolates BJ-125/ 
UAMH-9410] placed upside down on the center of each plate and incubated under 
constant light for 5 days (Pedras and Jha, 2006). Mycelial growth in each well was 
measured and % inhibition values were calculated as previously reported (Pedras and 
Jha, 2006). All bioassay experiments were carried out in triplicate, at least two times. 
 
4.6 Metabolism studies 
 
Metabolism studies of compounds in fungal cultures were carried out as previously 
reported (Pedras and Suchy, 2006). Erlenmeyer flasks (250 ml) each containing 100 ml 
minimal media were employed. Media was inoculated with spores of L. maculans 
(isolate BJ-125, 10
6
/ml) and incubated at 23 ºC on a shaker at 120 rpm under constant 
light. After two days, phytoalexins, related compounds or potential inhibitors of 
brassinin detoxification (in ACN/DMSO, final conc 0.10 mM) were added to the 
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cultures as well as uninoculated media (control).  Samples (2 ml or 5 ml) were 
withdrawn immediately and at intervals between 6-72 h after incubation; and were 
either frozen or immediately extracted with EtOAc (2  5 ml). The organic extracts 
were concentrated; dissolved in ACN/MeOH (1 ml) and analyzed by HPLC. 
 
4.7 Screening of potential inhibitors of brassinin 
detoxification 
 
Erlenmeyer flasks (125 ml) each containing 50 ml minimal media were employed. 
Media was inoculated with spores of L. maculans (isolate BJ-125, 10
4
/ml) and 
incubated at 23 ºC on a shaker at 120 rpm under constant light. After five days, mycelia 
were filtered, resuspended in water (50 ml) and further incubated under same 
conditions.  After 72 h, potential inhibitors (final concentration 0.10 mM) in 
ACN/DMSO, followed by brassinin (17, 0.10 mM) in ACN were added to three flasks 
(triplicates). Only brassinin (17, 0.10 mM) in ACN was added to three flasks (control). 
Samples (2 ml) were withdrawn immediately and after 6, 15, 24, 48 and 72 h of 
incubation; and were either frozen or immediately extracted with EtOAc (2  5 ml). 
The organic extracts were concentrated, dissolved in ACN (1 ml) and analyzed by 
HPLC. 
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Appendix 
 
A1A Structures of cruciferous phytoalexins 
 
 
Figure A. 1 Phytoalexins from Brassicaceae: brassinin (A1); 1-methoxybrassinin (A2); 
4-methoxybrassinin (A3); brassitin (A4);1-methoxybrassitin (A5); 1-methoxybrassenin 
A (A6); 1-methoxybrassenin B (A7); wasalexins, A (A8) and B (A9); biswasalexins, A 
(A10) and B (A11); spirobrassinin (A12); 1-methoxyspirobrassinin (A13); 1-
methoxyspirobrassinol (A14); 1-methoxyspirobrassinol methyl ether (A15); erucalexin 
   
II 
 
(A16); dioxibrassinin (A17); cyclobrassinin (A18); cyclobrassinin sulfoxide (A19); 4-
methoxycyclobrassinin (A20); sinalbin A (A21); sinalbin B (A22); dehydro-4-
methoxycyclobrassinin (A23); cyclobrassinone (A24); rutalexin (A25); brussalexin 
(A26); isalexin (A27); caulilexin B (A28); brassicanal B (A29); brassicanal A (A30); 
brassicanal C (A31); brassicanate A (A32); methyl 1-methoxyindole-3-carboxylate 
(A33); caulilexin A (A34); caulilexin C (A35); indolyl-3-acetonitrile (A36) arvelexin 
(A37); rapalexins, A (A38) and B (A39); camalexin (A40); 1-methylcamalexin (A41); 
6-methoxycamalexin (A42); brassilexin (A43); sinalexin (A44) (Pedras, Yaya et al., 
2011b). 
 
 
 
A1B Structures of phytoalexin-related compounds not 
metabolized by pathogenic fungi  
 
 
Figure A. 2 Structures of brassinin analogs resistant to fungal metabolism: compounds 
not metabolized by Leptosphaeria maculans (virulent on canola) A45-A61 
 
(Pedras and 
Jha, 2006; Pedras, Jha et al., 2007b); compounds not metabolized by Leptosphaeria 
biglobosa (virulent on mustard) A45-A57 (Pedras, Gadagi et al., 2007a; Pedras, Minic 
et al., 2009b); compounds not metabolized by Sclerotinia sclerotiorum A62-A65 
(Pedras and Hossain, 2007). 
 
 
   
III 
 
 
 
Figure A. 3 Structures of camalexin analogs resistant to fungal metabolism: 
compounds not metabolized by Leptosphaeria maculans (virulent on canola) A66-A73 
(Pedras, Minic et al., 2009c); compounds not metabolized by Leptosphaeria biglobosa 
(virulent on mustard) A72 and A73 (Pedras, Gadagi et al., 2007a); compounds not 
metabolized by Sclerotinia sclerotiorum A73-A78 (Pedras and Hossain, 2007). 
 
 
 
 
Figure A. 4 Structures of brassilexin analogs resistant to fungal metabolism by 
Leptosphaeria maculans (virulent on canola) A79-A87 (Pedras and Suchy, 2006). 
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A1C Summary of metabolism of phytoalexins and 
analogs 
 
 
Table A. 1 Antifungal activity of phytoalexin analogs and their biotransformation 
products in cruciferous fungal pathogens L. m [Leptosphaeria maculans (virulent on 
canola)], L. mL2 [L. maculans (virulent on mustard)], L. b (Leptosphaeria biglobosa); 
S. s (Sclerotinia sclerotiorum), R. s (Rhizoctinia solani), A. b (Alternaria brassicicola) 
and B. c (Botrytis cineria). c.i. = complete inhibition; n.i. = no inhibition. 
 
Compound/ % growth inhibition at 
0.50 mM (Fungal species) 
Product / Fungal species (Ref)   
 
Brassinin/ 55% (L. m); 38% (L. m 
L2); 39% (A. b); 100% (B. c); c.i. (S. 
s). 
 
Indolyl-3-carboxaldehyde/ L. m (Pedras and 
Taylor, 1993); 
 
Indolyl-3-methanamine/L. mL2
 
(Pedras, 
Gadagi et al., 2007a); 
A. b  (Pedras, Chumala et al., 2009a);  
B. c (Pedras, Hossain et al., 2011a); 
 
1--D-glucopyranosylbrassinin/ S. s  (Pedras, 
Ahiahonu et al., 2004a) 
 
1-Methylbrassinin  
 
1-Methyl-indolyl-3-carboxaldehyde/L. m
   
(Pedras, Jha et al., 2007b). 
 
Brassitin  
Indolyl-3-carboxaldehyde/L. m
 
(Pedras, Jha et 
al., 2007b) 
   
V 
 
Compound/ % growth inhibition at 
0.50 mM (Fungal species) 
Product / Fungal species (Ref)   
 
Indolyl-3-propanamide/ 48% (L. m). 
 
Indolyl-3-propionic acid/ L. m
 
(Pedras and 
Jha, 2006). 
 
Methyl indolyl-3-propanamide/ n.i. 
(L. m
 a
). 
Indolyl-3-propionic acid/ L. m
 
(Pedras and 
Jha, 2006). 
 
Methyl indolyl-3-propionate/ 48% 
(L. m
 a
); n.i. (L. m
 b
).  
Indolyl-3-propionic acid/  L. m
 
(Pedras and 
Jha, 2006); L. mL2 (Pedras, Gadagi et al., 
2007a). 
 
N-(Indol-3-ylmethyl)-N′-
methylthiourea/ 73% (L. m). 
Indolyl-3-carboxaldehyde/L. m (Pedras and 
Jha, 2006). 
 
Methyl tryptaminedithiocarbamate/ 
c.i. (L. m); 95% (L. mL2); c.i. (S. s). 
 
 
Nb-Acetyltryptamine/ L. m
 
(Pedras and 
Okanga, 2000); L. mL2 (Pedras, Gadagi et al., 
2007a; Pedras and Okanga 2000). 
 
 
Methyl 1-(-D-
glucopyranosyl)tryptaminedithiocarbamate/ S. 
s (Pedras, Ahiahonu et al., 2004a) 
 
Methyl 1-methyltryptamine 
dithiocarbamate/ c.i. (S. s). 
 
 
Methyl 7-(O--D-glucopyranosyl)-1-
methyltryptaminedithiocarbamate/ S. s   
(Pedras, Ahiahonu et al., 2004a; Pearson., 
Ph.D. thesis, 2004). 
   
VI 
 
Compound/ % growth inhibition at 
0.50 mM (Fungal species) 
Product / Fungal species (Ref)   
 
Tryptophol dithiocarbonate/ 41% (L. 
m); 41% (L. mL2); 
  
Tryptophol/ L. m
 a
 (Pedras and Jha, 2006); L. 
m
 b
 (Pedras, Gadagi et al., 2007a)  
 
 
Methyl N-(1-
naphthalenylmethyl)dithiocarbamate
/ 44% (L. m)/ 80% (S. s). 
 
1-Naphthoic acid/ L. m (Pedras and Jha, 
2006); 
Undetermined products/ S. s (Pedras, 
Ahiahonu et al., 2004a). 
 
Methyl N-(2-
naphthalenylmethyl)dithiocarbamate
/ 40% (L. m); 80% (S. s). 
 
2-Naphthoic acid/ L. m
 
(Pedras and Jha, 
2006). 
 
 
Methyl 6-oxy-(O--D-glucopyranosyl)-N-(2-
naphthalenylmethyl)dithiocarbamate/S. s 
(Pedras, Ahiahonu et al., 2004a). 
 
Methyl N-benzyldithiocarbamate/ 
c.i. (L. m). 
 
Benzoic acid/ L. m
 
(Pedras and Jha, 2006). 
 
Methyl N-(4-
chlorobenzyl)dithiocarbamate. 
 
4-Chlorobenzoic acid/L. m (Pedras, Khan et 
al., 1997); L. b (Pedras, Khan et al., 1997). 
 
Methyl N-(4- 
hydroxybenzyl)dithiocarbamate. 
Undetermined polar metabolites/ L. m 
(Pedras, Khan et al., 1997); L. b (Pedras, 
Khan et al., 1997). 
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Compound/ % growth inhibition at 
0.50 mM (Fungal species) 
Product / Fungal species (Ref)   
 
Methyl N-(2,4-
dichlorobenzyl)dithiocarbamate. 
 
N-(2,4-dichlorobenzyl)acetamide/ L. m  
(Pedras, Khan et al., 1997); L. b (Pedras, 
Khan et al., 1997). 
 
 
Methyl phenyldithiocarbazate/ c.i. 
(L. m).  
 
S-methyl-3-phenylthiocarbazate /L. m (Pedras 
and Jha, 2006). 
 
Methy (thianaphthen-3-  
yl)methyldithiocarbamate/ 89% (S. 
s). 
 
 
Methyl (7-oxy-O--D-
glucopyranosylthianaphthen-3-yl)methyl-
dithiocarbamate/S. s (Pedras and Hossain, 
2007). 
 
 
Methyl (thianaphthen-3-yl-1-S-
oxide)methyldithiocarbamate/S. s (Pedras and 
Hossain, 2007). 
 
Isobrassinin/ c.i. at 0.30 mM (S. s). 
 
Methyl (1--D-glucopyranosyl-3-
hydroxylindol-2-yl)methyldi-thiocarbamate/ 
S. s (Pedras and Hossain, 2007). 
 
Dihydrowasalexin/ 63% (L. m); 34% 
(L. mL2). 
 
1-Methoxy-3-methylindol-2-one/ L. m
 
(Pedras 
and Suchý, 2006); L. mL2 (Pedras and Suchý, 
2006). 
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Compound/ % growth inhibition at 
0.50 mM (Fungal species) 
Product / Fungal species (Ref)   
 
 
Camalexin/ c.i. (L. m, L. b, L. mL2, 
A. b, S. s, R. s, B. c) 
No metabolism/ L. m (Pedras, Khan et al., 
1998); 
No metabolism/ L. b (Pedras, Khan et al., 
1998); 
No metabolism/ L. mL2 (Pedras, Gadagi et 
al., 2007a); 
No metabolism/ A. brassicae (Pedras, Khan et 
al., 1998); 
 
 
6-oxy-(O--D-glucopyranosyl)camalexin/ S. s 
(Pedras and Ahiahonu, 2002) 
 
 
5-Hydroxycamalexin/ R. s (Pedras and Khan, 
1997) 
 
Indolyl-3-thiocarboxamide/ B. c (Pedras, 
Hossain et al., 2011a). 
 
5-Methylcamalexin/ c.i. at 0.25 mM 
(R. s). 
 
5-Hydroxymethylcamalexin/ R. s (Pedras and 
Liu, 2004). 
 
6-Fluorocamalexin/ 70% (S. s).  
 
6-Fluoro-(1--D-glucopyranosyl)brassinin/ S. 
s (Pedras and Ahiahonu, 2002). 
   
IX 
 
Compound/ % growth inhibition at 
0.50 mM (Fungal species) 
Product / Fungal species (Ref)   
 
6-Fluoro-1-methylcamalexin/ c.i. (S. 
s). 
 
 
6-Fluoro-1-methyl-7-(O-β-d-
glucopyranosyl)camalexin/ S. s (Pedras and 
Ahiahonu, 2002). 
 
1-Methylcamalexin/ c.i. at 0.25 mM 
(R. s). 
 
1-Methylindolyl-3-carbonitrile/ R. s (Pedras 
and Liu, 2004). 
 
3-Phenylindole/ c.i. at 0.10 mM (S. 
s); C.I. (L. m
 a
). 
 
1--D-glucopyranosyl-3-phenylindole/ S. s 
(Pedras and Hossain, 2007). 
 
Brassilexin/ c.i. [L. m, L. mL2, S. s, 
B. c]  
1--D-glucopyranosylbrassilexin/ S. s (Pedras 
and Hossain, 2006); 
 
3-Aminomethyleneindole-2-thione/ 
L. m (Pedras and Suchy, 2005);  
L. mL2 (Pedras and Snitynsky, 2010); 
B. c (Pedras, Hossain et al., 2011a). 
   
X 
 
Compound/ % growth inhibition at 
0.50 mM (Fungal species) 
Product / Fungal species (Ref)   
 
1-Methylbrassilexin/ c.i. (L. m); c.i. 
at 0.30 mM (S. s). 
 
3-Aminomethylene-1-methoxyindole-2-
thione/ L. m
 
(Pedras and Suchy, 2005). 
 
 
1-Methyl-(oxy-O--D-
glucopyranosyl)brassilexin/  S. s (Pedras and 
Hossain, 2006). 
 
 
 
1-Acetylbrassilexin 
 
3-Aminomethylene-1-methylindole-2-thione/ 
L. m
 
(Pedras and Suchy, 2005). 
 
Isothiazolo[5,4-b]thianaphthene/ c.i. 
(L. m) 
Undetermined product/  L. m
 
(Pedras and 
Suchy, 2006). 
 
4-Phenylisothiazole/ 69% (L. m) 
Undetermined product/  L. m
 
(Pedras and 
Suchy, 2006). 
 
4-(2-Chlorophenyl)isothiazole/ 79% 
(L. m) 
Undetermined product/  L. m
 
(Pedras and 
Suchy, 2006). 
 
4-(2-Tolyl)isothiazole/ 65% (L. m) 
Undetermined product/  L. m
 
(Pedras and 
Suchy, 2006). 
 
4-(2-Nitrophenyl)isothiazole/ 67% 
(L. m) 
Undetermined product/  L. m
 
(Pedras and 
Suchy, 2006). 
 
4-(2-Hydroxyphenyl)isothiazole/ c.i. 
(L. m) 
Undetermined product/  L. m
 
(Pedras and 
Suchy, 2006). 
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A1D Summary of inhibition of BOLm 
 
 
Table A. 2 Inhibition of BOLm and antifungal activities against Leptosphaeria 
maculans of tested compounds (Pedras et al., 2009; Pedras et al., 2010). c.i. = complete 
inhibition; n.i. = no inhibition. 
 
  Compound % Inhibition of 
BOLm 
Antifungal activity at 
0.10 mM/ Ref 
0.10 mM    0.30 mM     
 
Camalexin  
30 ± 4 53 ± 4 35 ± 5/ (Pedras, Minic 
et al., 2009c). 
 
Thiabendazole  
16 ± 3 25 ± 7 23 ± 3/ (Pedras, Jha et 
al., 2005). 
 
5-Fluorocamalexin  
47 ± 5 63 ± 2 76 ± 7/ (Pedras, Minic 
et al., 2009c). 
 
6-Fluorocamalexin  
29 ± 10 46 ± 2 29 ± 9/ (Pedras, Minic 
et al., 2009c). 
 
5-Methoxycamalexin  
51 ± 4 72 ± 1 60 ± 7/ (Pedras, Minic 
et al., 2009c). 
 
6-Methoxycamalexin  
41 ± 6 63 ± 5 70 ± 4/ (Pedras, Minic 
et al., 2009c). 
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  Compound % Inhibition of 
BOLm 
Antifungal activity at 
0.10 mM/ Ref 
0.10 mM    0.30 mM     
 
Brassilexin  
8 ± 2 16 ± 2 8 ± 1/ (Pedras and Jha, 
2005) 
 
5-Fluorobrassilexin  
7 ± 4 14 ± 6 24 ± 19/ (Pedras and 
Jha, 2005) 
 
6-Fluorobrassilexin  
22 ± 3 40 ± 5 64 ± 1/ (Pedras and 
Jha, 2005) 
 
5-Chlorobrassilexin  
21 ± 6 40 ± 2 n.i./ (Pedras and Jha, 
2005) 
 
6-Chlorobrassilexin  
56 ± 5 66 ± 7 69 ± 6/ (Pedras and 
Jha, 2005) 
 
5-Bromobrassilexin  
30 ± 5 45 ± 2 60 ± 10/ (Pedras and 
Jha, 2005) 
 
6-Bromobrassilexin  
42 ± 4 63 ± 4 c.i./ (Pedras and Jha, 
2005) 
 
5-Methoxybrassilexin  
5 ± 1 18 ± 4 14 ± 1/ (Pedras and 
Jha, 2005) 
 
6-Methoxybrassilexin  
15 ± 2 38 ± 4 n.i./ (Pedras and Jha, 
2005) 
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  Compound % Inhibition of 
BOLm 
Antifungal activity at 
0.10 mM/ Ref 
0.10 mM    0.30 mM     
 
Sinalexin  
n.d. n.d. 24 ± 7/ (Pedras and 
Jha, 2005) 
 
Wasalexins  
8 ± 5 14 ± 4 36 ± 5/ (Pedras and 
Suchý, 2006) 
 
Dihydrowasalexin  
n.d. n.d. 41 ± 8/ (Pedras and 
Suchý, 2006) 
 
N´-Methylbrassinin  
n.d. - 74 ± 2/ (Pedras and 
Jha, 2006). 
 
N-(Indol-3-ylmethyl)-N´-
methylurea  
n.d. - n.d./ (Pedras and Jha, 
2006) 
 
N-(Indol-3-ylmethyl)-N-methyl- 
N´-ethylurea  
n.d. - n.d./ (Pedras and Jha, 
2006)  
 
N-(Indol-3-ylmethyl)-N-methyl- 
N´-propylurea  
n.d. - n.d./ (Pedras and Jha, 
2006)  
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  Compound % Inhibition of 
BOLm 
Antifungal activity at 
0.10 mM/ Ref 
0.10 mM    0.30 mM     
 
N-(Indol-3-ylmethyl)-N-methyl- 
N´-phenylurea  
n.d. - 30 ± 3/ (Pedras and 
Jha, 2006) 
 
Indol-3-ylmethylurea  
n.d. - n.d./ (Pedras and Jha, 
2006)  
 
N-(Indol-3-ylmethyl)-N´-
ethylurea  
n.d. - 21 ± 5/ (Pedras and 
Jha, 2006) 
 
N-(Indol-3-ylmethyl)-N´-
propylurea  
n.d. - 43 ± 5/ (Pedras and 
Jha, 2006) 
 
N-(Indol-3-ylmethyl)-N´-
phenylurea  
n.d. - 22 ± 3/ (Pedras and 
Jha, 2006) 
 
Methyl 2´-methylindol-3-
ylmethylcarbamate  
n.d. - n.d./ (Pedras and Jha, 
2006)  
 
Indol-3-ylmethylthiourea  
n.d. - n.d./ (Pedras and Jha, 
2006)  
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  Compound % Inhibition of 
BOLm 
Antifungal activity at 
0.10 mM/ Ref 
0.10 mM    0.30 mM     
 
N-(Indol-3-ylmethyl)-N´-
propylthiourea  
n.d. - n.d./ (Pedras and Jha, 
2006) 
 
N-(Indol-3-ylmethyl)-N´-
phenylthiourea  
n.d. - 64 ± 3/ (Pedras and 
Jha, 2006) 
 
N-(Indol-3-ylmethyl)-N-methyl- 
N´-phenylthiourea  
n.d. - 73 ± 3/ (Pedras and 
Jha, 2006) 
 
N-(Indol-3-
ylmethyl)methanesulfonamide  
n.d. - 22 ± 3/ (Pedras and 
Jha, 2006) 
 
N-(Indol-3-ylmethyl)-N-methyl 
methanesulfonamide  
n.d. - n.d./ (Pedras and Jha, 
2006)  
 
Indol-3-ylmethylsulfamide  
n.d. - n.d./ (Pedras and Jha, 
2006)  
 
N-(Indol-3-ylmethyl)-N–
n.d. - n.d./ (Pedras and Jha, 
2006) 
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  Compound % Inhibition of 
BOLm 
Antifungal activity at 
0.10 mM/ Ref 
0.10 mM    0.30 mM     
methylsulfamide  
 
Indolyl-3-propanamide  
n.d. - n.d./ (Pedras and Jha, 
2006)  
 
N´-Methyl-indolyl-3-
propanamide  
n.d. - n.d./ (Pedras and Jha, 
2006) 
 
3-Indolylmethylpropargylamine  
n.d. - - 
 
Methyl 
tryptaminedithiocarbamate  
n.d. - n.d./ (Pedras and 
Okanga, 2000) 
 
Tryptophol dithiocarbonate  
n.d. - 20 ± 7/ (Pedras and 
Jha, 2006) 
 
Naphthalen-2-ylmethylurea  
n.d. - 81 ± 3/ (Pedras and 
Jha, 2006) 
 
N-Methyl-N-(naphthalen-2-
ylmethyl)urea  
n.d. - 24 ± 2/ (Pedras and 
Jha, 2006) 
 
n.d. - 18 ± 4/ (Pedras and 
Jha, 2006) 
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  Compound % Inhibition of 
BOLm 
Antifungal activity at 
0.10 mM/ Ref 
0.10 mM    0.30 mM     
N´-Ethyl-N-methyl-N-
(naphthalen-2-ylmethyl)urea  
 
N-(Naphthalen-2-ylmethyl)- N´-
propylurea  
n.d. - 24 ± 3/ (Pedras and 
Jha, 2006) 
 
N´-Phenyl-N-(naphthalen-2-
ylmethyl)urea  
n.d. - 58 ± 2/ (Pedras and 
Jha, 2006) 
 
N´-Ethyl-N-(naphthalen-2-
ylmethyl)urea  
n.d. - 23 ± 3/ (Pedras and 
Jha, 2006) 
 
Naphthalen-2-
ylmethanesulfonamide  
n.d. - n.d./ (Pedras and Jha, 
2006) 
 
N-Methyl-N-(naphthalen-2-
ylmethyl)methanesulfonamide  
n.d. - n.d./ (Pedras and Jha, 
2006) 
 
Naphthalen-2-
ylmethylsulfamide  
n.d. - n.d. (Pedras and Jha, 
2006)  
 
N -(Naphthalen-2-ylmethyl)- 
N´-propylthiourea  
n.d. - n.d./ (Pedras and Jha, 
2006) 
 
N -Methyl-N-(naphthalen-2-
ylmethyl)- N´-propylthiourea  
n.d. - n.d./ (Pedras and Jha, 
2006) 
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  Compound % Inhibition of 
BOLm 
Antifungal activity at 
0.10 mM/ Ref 
0.10 mM    0.30 mM     
 
N -(Naphthalen-2-ylmethyl)- 
N´-phenylthiourea  
n.d. - n.d./ (Pedras and Jha, 
2006) 
 
N -Methyl-N-(naphthalen-2-
ylmethyl)- N´-phenylthiourea  
n.d. - n.d. (Pedras and Jha, 
2006)  
 
Methylnaphthalen-2-
ylmethyldithiocarbamate  
n.d. - n.d./ (Pedras and Jha, 
2006) 
 
Naphthalen-1-ylmethylurea  
n.d. - n.d./ (Pedras and Jha, 
2006) 
 
N-Methyl-N-(naphthalen-1-
ylmethyl)urea  
n.d. - 28 ± 2/ (Pedras and 
Jha, 2006) 
 
N´-Ethyl-N-(naphthalen-1-
ylmethyl)urea  
n.d. - n.d./ (Pedras and Jha, 
2006) 
 
N -(Naphthalen-1-ylmethyl)- 
N´-propylurea  
n.d. - n.d./ (Pedras and Jha, 
2006) 
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  Compound % Inhibition of 
BOLm 
Antifungal activity at 
0.10 mM/ Ref 
0.10 mM    0.30 mM     
 
N -(Naphthalen-1-ylmethyl)- 
N´-phenylurea  
n.d. - n.d./ (Pedras and Jha, 
2006) 
 
N´-Ethyl-N-methyl- N -
(naphthalen-1-ylmethyl)urea  
n.d. - n.d./ (Pedras and Jha, 
2006) 
 
N-Methyl-N-(naphthalen-1-
ylmethyl)- N´-propylurea  
n.d. - n.d./ (Pedras and Jha, 
2006) 
 
N-Methyl-N-(naphthalen-1-
ylmethyl)- N´-phenylurea  
n.d. - n.d./ (Pedras and Jha, 
2006)  
 
N -(Naphthalen-1-ylmethyl)- 
N´-propylthiourea  
n.d. - n.d./ (Pedras and Jha, 
2006) 
 
N-Methyl-N-(naphthalen-1-
ylmethyl)- N´-propylthiourea  
n.d. - n.d./ (Pedras and Jha, 
2006)  
 
n.d. - n.d./ (Pedras and Jha, 
2006) 
   
XX 
 
  Compound % Inhibition of 
BOLm 
Antifungal activity at 
0.10 mM/ Ref 
0.10 mM    0.30 mM     
N-Methyl-N-(naphthalen-1-
ylmethyl)- N´-phenylthiourea  
 
N -(Naphthalen-1-
ylmethyl)methanesulfonamide  
n.d. - n.d./ (Pedras and Jha, 
2006) 
 
N-Methyl-N-(naphthalen-1-
ylmethyl)methanesulfonamide  
n.d. - n.d./ (Pedras and Jha, 
2006) 
 
Naphthalen-1-
ylmethylsulfamide  
n.d. - n.d./ (Pedras and Jha, 
2006)  
 
N-Methyl-N-(naphthalen-1-
ylmethyl)sulfamide  
n.d. - n.d./ (Pedras and Jha, 
2006) 
 
Methyl N-
benzyldithiocarbamate  
n.d. - n.d./ (Pedras and Jha, 
2006) 
 
Methyl-3-phenyldithiocarbazate  
n.d. - 32 ± 2/ (Pedras and 
Jha, 2006) 
 
Methyl-3-benzyldithiocarbazate  
n.d. - - 
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  Compound % Inhibition of 
BOLm 
Antifungal activity at 
0.10 mM/ Ref 
0.10 mM    0.30 mM     
 
Methyl-3-phenylthiocarbazate  
n.d. - - 
 
MethylN-(α,α´-
dimethylbenzyl)dithiocarbamat
e  
n.d. - - 
 
MethylN-(α,α´-dimethylbenzyl) 
carbamate 
n.d. - - 
 
Benzylthiourea  
n.d. - - 
 
Tolnafthate  
n.d. - - 
 
2-Bromothiazole  
n.d. - - 
 
Rutalexin  
n.d. - Not soluble/ (Pedras, 
Montaut et al., 2004b). 
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